Document:

EX-10.9

 Exhibit 10.9 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS 

BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE 

REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. 

CONFIDENTIAL 

AMENDED AND RESTATED 

LICENSE AND COLLABORATION AGREEMENT 

between 
 AVENTIS INC.

 and 
 DICE
MOLECULES SV, LLC 
 Dated as of December 17, 2015 

Amended and Restated August 16, 2017 
  

 CONFIDENTIAL 

AMENDED AND RESTATED 

LICENSE AND COLLABORATION AGREEMENT 

This Amended and Restated License and Collaboration Agreement (the “Agreement”) is made and entered into effective as of
December 17, 2015 (the “Effective Date”) by and between DiCE Molecules SV, LLC, a Delaware limited liability company (“DiCE”), and Aventis Inc., a corporation organized and existing under the laws of
Pennsylvania, having offices at 55 Corporate Drive in Bridgewater, New Jersey 08807 (“Sanofi”). DiCE and Sanofi are sometimes referred to herein individually as a “Party” and collectively as the
“Parties.” 
 RECITALS 

WHEREAS, DiCE owns and controls certain intellectual property rights with respect to
DNA-programmed directed chemical evolution that is useful for the identification of Active Compounds; 

WHEREAS, DiCE and Sanofi wish to enter into a collaboration together whereby DiCE shall generate Collaboration Compounds for Sanofi;

 WHEREAS, DiCE wishes to grant to Sanofi, and Sanofi wishes to take, an exclusive license to certain of DiCE’s intellectual
property rights to develop and commercialize Collaboration Compounds and Collaboration Products in the Territory in the Field, in each case in accordance with the terms and conditions set forth below; and 

WHEREAS, DiCE and Sanofi have agreed to amend certain terms of this Agreement, and amend and restate the Agreement as of
August 16, 2017 (the “Amendment Date”), as set forth herein. 
 NOW, THEREFORE, in consideration of the
premises and the mutual promises and conditions set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS 

Unless otherwise specifically provided herein, the following terms shall have the following meanings: 

1.1    “Accounting Standards” means, with respect to a Party or its Affiliates or its or their
sublicensees, GAAP, International Financial Reporting Standards or such other similar national standards as such Party, its Affiliate or their (Sub)licensee uses for its financial reporting obligations, in each case, consistently applied. 

 1.2    “Active Compound” means, on a Sanofi Target-by-Sanofi Target basis, any Library Compound that the JSC determines meets the applicable Active Compound Criteria. 

1.3    “Active Compound Criteria” means on a Sanofi Target-by-Sanofi Target basis, the criteria set forth in the applicable Target Plan for establishing whether a Library Compound is an Active Compound. These criteria may include [*]. 

1.4    “Active Sanofi Target” means a Sanofi Target for which DiCE is actively conducting
activities in connection with the Research Program. [*]. 
 1.5    “Affiliate” means, with
respect to a Party or other Person, any Person that, directly or indirectly, through one (1) or more intermediaries, controls, is controlled by or is under common control with such Party or other Person. For purposes of this definition,
“control” and, with correlative meanings, the terms “controlled by” and “under common control with” means: (i) the possession, directly or indirectly, of the power to direct the management or policies of a business
entity, whether through the ownership of voting securities, by contract relating to voting rights or corporate governance or otherwise; or (ii) the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or
other ownership interest of a business entity (or, with respect to a limited partnership or other similar entity, its general partner or controlling entity). 

1.6    “Agreement” has the meaning set forth in the preamble hereto. 

1.7    “Agreement Term” has the meaning set forth in Section 12.1.1. 

1.8    “Anti-Corruption Laws” means the U.S. Foreign Corrupt Practices Act, as amended, the UK
Bribery Act 2010, as amended and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism. 

1.9    “Applicable Law” means applicable laws, rules and regulations, including any rules,
regulations, guidelines or other requirements of the Regulatory Authorities, that may be in effect from time to time, including any applicable regulations and guidance of the FDA and European Union (and national implementations thereof) that
constitute good laboratory practices, good manufacturing practices, good pharmacovigilance practices and good clinical practices. 

1.10    “Arbitration Notice” has the meaning set forth in Section 13.1. 

1.11    “Arbitrator” has the meaning set forth in Section 13.2. 

1.12    “Board of Directors” has the meaning set forth in the definition of “Change of
Control.” 

  
 -2- 

 1.13    “Business Day” means a day other than a
Saturday or Sunday or a day on which banking institutions in New York, New York or in Paris (France) are permitted or required to be closed. 

1.14    “Calendar Quarter” means each successive period of three (3) calendar months
commencing on January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1,
April 1, July 1 or October 1 after the Effective Date and the last Calendar Quarter shall end on the last day of the Agreement Term. 

1.15    “Calendar Year” means each successive period of twelve (12) calendar months
commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year
of the Agreement Term shall commence on January 1 of the year in which the Agreement Term ends and end on the last day of the Term. 

1.16    “Change of Control,” with respect to a Party, shall be deemed to have occurred if any of
the following occurs after the Effective Date: 
 1.16.1    as a result of any transaction or series of related
transactions any “person” or “group” (as such terms are defined below) (i) becomes the “beneficial owner” (as defined below, except that a “person” or “group” shall be deemed to have
“beneficial ownership” of all shares of capital stock or other equity interests if such person or group has the right to acquire, whether such right is exercisable immediately or only after the passage of time), directly or indirectly, of
shares of capital stock or other interests (including partnership interests) of such Party then outstanding and normally entitled (without regard to the occurrence of any contingency) to vote in the election of the directors, managers or similar
supervisory positions (“Voting Stock”) of such Party representing fifty percent (50%) or more of the total voting power of all outstanding classes of Voting Stock of such Party or (ii) acquires the power, directly or
indirectly, to elect a majority of the members of the Party’s board of directors or similar governing body (“Board of Directors”); 

1.16.2    such Party enters into a merger, consolidation or similar transaction with another Person (whether or not
such Party is the surviving entity) and as a result of such merger, consolidation or similar transaction (i) the members of the Board of Directors of such Party immediately prior to such transaction constitute less than a majority of the
members of the Board of Directors of such Party or such surviving Person immediately following such transaction or (ii) the Persons that beneficially owned, directly or indirectly, the shares of Voting Stock of such Party immediately prior to
such transaction cease to beneficially own, directly or indirectly, shares of Voting Stock of the surviving Person representing at least a majority of the total voting power of all outstanding classes of Voting Stock of the surviving Person; or 

1.16.3    such Party sells or transfers to any Third Party, in one or more related transactions, properties or
assets representing all or substantially all of such Party’s consolidated total assets to which this Agreement relates. 
 For the purpose of this
definition of Change of Control: (i) “person” and “group” have the meanings given such terms under Section 13(d) and 14(d) of the United States Securities 

  
 -3- 

 
Exchange Act of 1934 and the term “group” includes any group acting for the purpose of acquiring, holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the aforesaid Act; (ii) a “beneficial owner” shall be determined in accordance with Rule 13d-3 under the aforesaid Act; and (iii) the
terms “beneficially owned” and “beneficially own” shall have meanings correlative to that of “beneficial owner.” 

1.17    “Collaboration Compound” shall mean any (i) Active Compound, or (ii) Derivative
Compound that (a) is within the scope of any Program Patent, or (b) utilizes, incorporates or is discovered with the use of (X) any Program Know How and/or (Y) any information contained in any SAR Dataset that has been licensed
to Sanofi. 
 1.18    “Collaboration Product” means any pharmaceutical product, in final form,
that is comprised of or contains a Collaboration Compound, alone or in combination with one (1) or more additional active ingredients, in each case, in any and all forms, presentations, delivery systems, dosages and formulations, for sale by
prescription, over-the-counter or any other method. 

1.19    “Combination Product” means (i) any pharmaceutical preparation in final form
containing a Collaboration Compound in combination with one (1) or more additional active ingredients (that are not generic compounds) or (ii) any package containing a Collaboration Product combined with another product, where the other
product or device is separately approved or sold as a medical product and the package is sold as one (1) SKU, in each case of clauses (i) and (ii), sold either as a fixed dose/unit or as separate doses/units in a single package. 

1.20    “Commercialization” means any and all activities directed to the preparation for sale of,
offering for sale of or sale of a Collaboration Product, including activities related to marketing, promoting, distributing and importing such Collaboration Product, and interacting with Regulatory Authorities regarding any of the foregoing. When
used as a verb, “to Commercialize” and “Commercializing” means to engage in Commercialization and “Commercialized” has a corresponding meaning. 

1.21    “Commercially Reasonable Efforts” shall mean: 

1.21.1    [*] 

1.21.2    [*] 

1.21.3    “Commercially Reasonable” shall have a corresponding meaning. 

1.22    “Confidential Information” has the meaning set forth in Section 9.1. 

1.23    “Control” means, with respect to any Information and Inventions, Regulatory Documentation,
material, Patent or other intellectual property right, and possession of the right, whether directly or indirectly and whether by ownership, license or otherwise (other than by operation of the license and sublicense in Section 4.2 and 4.3), to
grant a license, sublicense or other right to or under such Information and Inventions, Patent or other intellectual property right as provided for herein without violating the terms of any agreement with any Third Party. 

  
 -4- 

 1.24    “Derivative Compound” shall mean any
chemical compound, except a Library Compound, that demonstrates activity against any Sanofi Target and is derived from one or more Library Compound(s) within the SAR Dataset for such Sanofi Target, by DiCE, Sanofi, or by a Third Party under
authority from Sanofi. A chemical compound having activity against any Sanofi Target shall be deemed to have been “derived from” a Library Compound if such chemical compound: 

(i)    is actually synthesized in a chemical synthesis program based on one or more Library Compound(s)within the SAR
Dataset for such Sanofi Target, as documented by laboratory notebooks or other competent proof; or 
 (ii)    is
actually synthesized based on structure-activity data relating to one or more Library Compound(s) or Derivative Compound(s) within the SAR Dataset for such Sanofi Target, as documented by laboratory notebooks or other competent proof. 

1.25    “Development” means all activities related to
pre-clinical and other non-clinical testing, test method development and stability testing, toxicology, formulation, process development, manufacturing scale-up, qualification and validation, quality assurance/quality control, clinical studies, including Manufacturing in support thereof, statistical analysis and report writing, the preparation and submission of
Drug Approval Applications, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a Regulatory Authority as a condition or in support of obtaining or
maintaining a Regulatory Approval. When used as a verb, “Develop” means to engage in Development. 

1.26    “DiCE Know-How” means all Information and
Inventions which are Controlled by DiCE or any of its Affiliates as of the Effective Date or at any time prior to the end of the Agreement Term, related to any Collaboration Compounds or Collaboration Product or the Exploitation of any of the
foregoing and that are useful for such Exploitation, but excluding any DPDCE Know-How and DiCE’s interest in any Joint Program Know-How (as defined in
Section 8.1.2(ii)). 
 1.27    “DiCE Patents” means all of the Patents Controlled by
DiCE or any of its Affiliates as of the Effective Date or at any time prior to the end of the Agreement Term that claim or cover or are otherwise necessary to commercialize any Collaboration Compound or Collaboration Product, but excluding any DPDCE
Patents. The DiCE Patents existing as of the Effective Date are set forth in Schedule 1.27, attached hereto. 

1.28    “DiCE Technology” means DiCE Patents and DiCE Know How. 

1.29    “Dispute” has the meaning set forth in Section 13.1. 

1.30    “Distributor” means any Person(s) appointed by Sanofi or any of its Affiliates or its or
their Sublicensees to distribute, market and sell Collaboration Product(s), with or without packaging rights, in one or more countries in the Territory, in circumstances where the Person purchases its requirements of Collaboration Product(s) from
Sanofi or its Affiliates or its or their Sublicensees but does not otherwise make any upfront, royalty or other payment (separate from a payment for supply of Collaboration Product) to Sanofi or its Affiliates or its or their Sublicensees with
respect to Collaboration Product(s). 

  
 -5- 

 1.31    “Dollars” or “$” means
United States Dollars. 
 1.32    “DPDCE Know How” means all Information and Inventions
Controlled by DiCE relating to the practice of DNA-programmed directed chemical evolution, including all methods, instrumentation and materials. 

1.33    “DPDCE Patents” means all Patents Controlled by DiCE relating to the practice of DNA-programmed directed chemical evolution, including all methods, instrumentation and materials. The DPDCE Patents existing as of the Effective Date are set forth in Part A of Schedule 1.27, attached hereto.

 1.34    “DPDCE Technology” means the DPDCE Patents and DPDCE
Know-How. 
 1.35    “Drug Approval Application” means a
New Drug Application or Supplemental New Drug Application as defined in the FFDCA or any corresponding foreign application in the Territory, including, with respect to the European Union, a Marketing Authorization Application filed with the EMA
pursuant to the centralized approval procedure or with the applicable Regulatory Authority of a country in Europe with respect to the mutual recognition or any other national approval. 

1.36    “Effective Date” has the meaning set forth in the preamble hereto. 

1.37    “EMA” means the European Medicines Agency and any successor agency thereto. 

1.38    “ES (Early Selection) Target” means any Sanofi Target that is designated as an ES Target
pursuant to Section 2.4.5. 
 1.39    “ET (Early Termination) Target” means any Sanofi
Target that is designated as an ET Target pursuant to Section 2.4.3(i). 
 1.40    “European
Union” or “EU” means the economic, scientific and political organization of member states as it may be constituted from time to time, which as of the Effective Date consists of Austria, Belgium, Bulgaria, Croatia, Czech
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom of Great Britain and
Northern Ireland and that certain portion of Cyprus included in such organization. 

1.41    “Exploit” means to make, have made, import, use, sell or offer for sale, including to
research, Develop, Commercialize, register, Manufacture, have Manufactured, hold or keep (whether for disposal or otherwise), have used, export, transport, distribute, promote, market or have sold or otherwise dispose of a compound, product or
process, including to make a Collaboration Compound for use in Collaboration Products. “Exploitation” means the act of Exploiting a compound, product or process. 

  
 -6- 

 1.42    “FDA” means the United States Food and
Drug Administration, and any successor agency thereto. 
 1.43    “FFDCA” means the United
States Federal Food, Drug, and Cosmetic Act, as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto). 

1.44    “Field” means all human and veterinary health care applications including, but not limited
to, research, prognosis and diagnosis, therapeutics, prophylaxis, and monitoring with respect to any indication. 

1.45    “First Commercial Sale” means, with respect to any Collaboration Product, [*]. 

1.46    “GAAP” means United States generally accepted accounting principles. 

1.47    “Generic Product” means, with respect to a particular Collaboration Product, any
pharmaceutical or biological product that (i) is distributed by a Person other than Sanofi or its Affiliates under a Drug Approval Application approved by a Regulatory Authority in reliance, in whole or in part, on the prior approval (or on
safety or efficacy data submitted in support of the prior approval) of such Collaboration Product, including any product authorized for sale (a) in the U.S. pursuant to Section 505(b)(2) or Section 505(j) of the Act (21 U.S.C.
355(b)(2) and 21 U.S.C. 355(j), respectively), (b) in the EU pursuant to a provision of Articles 10, 10a or 10b of Parliament and Council Directive 2001/83/EC as amended (including an application under Article 6.1 of Parliament and Council
Regulation (EC) No 726/2004 that relies for its content on any such provision) or (c) in any other country or jurisdiction pursuant to all equivalents of such provisions or (ii) is otherwise substitutable under Applicable Law for such
Collaboration Product when dispensed without the intervention of a physician or other health care provider with prescribing authority. 

1.48    “Government Official” means (i) any Person employed by or acting on behalf of a
government, government-controlled agency or entity or public international organization, (ii) any political party, party official or candidate, (iii) any Person who holds or performs the duties of an appointment, office or position created
by custom or convention or (iv) any Person who holds himself out to be the authorized intermediary of any of the foregoing. 

1.49    “Hatch-Waxman Act” means the U.S. “Drug Price Competition and Patent Term Restoration
Act” of 1984, as set forth at 21 U.S.C. §355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV). 

1.50    “IFRS” shall mean International Financial Reporting Standards as issued by the
International Accounting Standards Board (IASB) and as adopted by the European Union. 

1.51    “IND” means (i) an investigational new drug application filed with the FDA for
authorization to commence clinical studies and its equivalent in other countries or regulatory jurisdictions and (ii) all supplements and amendments that may be filed with respect to the foregoing. 

1.52    “Indemnification Claim Notice” has the meaning set forth in Section 11.3.1. 

  
 -7- 

 1.53    “Indemnified Party” has the meaning set
forth in Section 11.3.1. 
 1.54    “Indication” [*]. 

1.55    “Information and Inventions” means all inventions, discoveries, technical, scientific and
other know-how and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance,
designs, drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other material, including: biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, pre-clinical, clinical, safety, manufacturing and quality control data and information, including study designs and protocols, assays and biological methodology, in each case (whether or not confidential,
proprietary, patented or patentable) in written, electronic or any other form now known or hereafter developed. For clarity, tangible materials shall not be included within the Information and Inventions. 

1.56    “Inventor Personnel” has the meaning set forth in Section 10.2.9. 

1.57    “Invoiced Sales” has the meaning set forth in the definition of “Net
Sales”. 
 1.58    “Joint Steering Committee” or “JSC” has the meaning
set forth in Section 3.1. 
 1.59    RESERVED 

1.60    “Legal Dispute” has the meaning set forth in Section 3.3.7. 

1.61    “Library” shall mean any chemical compound library prepared by or on behalf of DiCE.
Libraries shall be comprised of two (2) types, as follows: 
 1.61.1    “Screening Library”
shall mean a chemical compound library, other than a Focused Library, comprising at least 108 distinct target structures, based on specific agreed scaffold(s) and synthons, prepared by DiCE for
use in DiCE internal and external programs, including the Research Program. 
 1.61.2    “Focused
Library” shall mean any chemical compound library designed and prepared by DiCE in connection with and specifically for screening in the Research Program based on (i) one or more Active Compounds, including without limitation, SAR data
for a given Target, and/or (ii) Confidential Information of either Party regarding structures that have been determined to have activity with respect to a particular Sanofi Target), and/or (iii) information in the public domain. For
clarity, it is understood and agreed that information used to design a Focused Library may be derived from various sources including but not limited to, results obtained during Stage 1 of the Research Program. 

1.62    “Library Compound” means a compound contained in one or more of the Libraries generated by
DiCE. 
 1.63    “Losses” has the meaning set forth in Section 11.1. 

  
 -8- 

 1.64    “Major Market” means each of [*]. 

1.65    “Manufacture” and “Manufacturing” means all activities related to the
production, manufacture, processing, filling, finishing, packaging, labeling, shipping and holding of any Collaboration Compound, any Collaboration Product or any intermediate thereof, including process development, process qualification and
validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance and
quality control, and chemistry, manufacturing and controls. 
 1.66    “Net Sales” means, with
respect to a Collaboration Product for any period, the gross amount billed or invoiced by Sanofi, its Affiliates or its or their Sublicensees for the sale of a Collaboration Product to Third Parties (including Distributors) (the “Invoiced
Sales”), less deductions for: 
 1.66.1    [*] 

1.66.2    [*] 

1.66.3    [*] 

1.66.4    [*] 

1.66.5    [*] 

1.66.6    [*] 

1.66.7    [*] 

1.66.8    [*] 
 [*].

 [*]. 
 [*]. 

In all cases, Net Sales shall be calculated in accordance with applicable Accounting Standards, consistently applied. 

1.67    “Party” and “Parties” have the meaning set forth in the preamble hereto.

 1.68    “Patents” means: (i) all national, regional and international patents and patent
applications, including provisional patent applications; (ii) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including
divisionals, continuations, continuations-in-part, provisionals, converted provisionals and continued prosecution applications; (iii) any and all patents that have
issued or in the future issue from the foregoing patent applications ((i) and (ii)), 

  
 -9- 

 
including utility models, petty patents, innovation patents and design patents and certificates of invention; (iv) any and all extensions or restorations by existing or future extension or
restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications
((i), (ii) and (iii)); and (v) any similar rights, including so-called pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or patent of
additions to any of such foregoing patent applications and patents. 
 1.69    “Person” means an
individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity
or organization, including a government or political subdivision, department or agency of a government. 

1.70    “Phase I Clinical Trial” means a human clinical study of a biopharmaceutical product, the
principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a) (as amended or any replacement thereof), or a similar clinical study prescribed by the Regulatory Authority
in a country other than the United States. 
 1.71    “Phase II Clinical Trial” means a human
clinical study of a biopharmaceutical product, the principal purpose of which is a determination of safety and efficacy in the target patient population, as described in 21 C.F.R. 312.21(b) (as amended or any replacement thereof), or a similar
clinical study prescribed by the Regulatory Authority in a country other than the United States. 

1.72    “Phase III Clinical Trial” means a human clinical study of a biopharmaceutical product,
the design of which is acknowledged by the FDA to be sufficient for such clinical study to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any replacement thereof), or a similar human clinical study prescribed by the Regulatory
Authority in a country other than the United States, the design of which is acknowledged by such Regulatory Authority to be sufficient for such clinical study to satisfy the requirements of a pivotal efficacy and safety clinical study,
provided that if a Phase II Clinical Study has not previously been completed with respect to such product, then a clinical study shall not be deemed a “Phase III Clinical Study” until the design of such clinical study is
acknowledged in writing by a Regulatory Authority (either prospectively or following completion of the clinical study) to be sufficient for such clinical study to be included as a pivotal efficacy and safety clinical study in an application for
Regulatory Approval filed with the applicable Regulatory Authority in the applicable country or jurisdiction. 

1.73    “Pre-Candidate” means an Active Compound for which
(a) Sanofi has elected to advance into exploratory repeat dose pre-clinical in vivo toxicology, and (b) such studies are commenced in at least one species. 

1.74    “PPI Status” means for a particular Sanofi Target that the Active Compound(s) for such
Sanofi Target are expected to (a) inhibit the binding of a peptidic ligand to the applicable Sanofi Target by either an allosteric or orthostatic mechanism, or (b) promote binding of the applicable Sanofi Target to another protein target,
resulting in reduced function. By way of 

  
 -10- 

 
example but without limitation, an example of clause (b) above would be an Active Compound that bound to an E3 ligase with a consequent ubiquination of the protein target and reduced
half-life. 
 1.75    “Product Labeling” means, with respect to a Collaboration Product in a
country in the Territory, (i) the Regulatory Authority-approved full prescribing information for such Collaboration Product for such country, including any required patient information and (ii) all
labels and other written, printed or graphic matter upon a container, wrapper or any package insert utilized with or for such Collaboration Product in such country. 

1.76    “Product Trademarks” means the Trademark(s) used or to be used by Sanofi or its Affiliates
or its or their Sublicensees for the Commercialization of any Collaboration Product in the Territory and any registrations thereof or any pending applications relating thereto in the Territory (excluding, in any event, any trademarks, service marks,
names or logos that include any corporate name or logo of the Parties or their Affiliates or its or their Sublicensees). 

1.77    “Program Know-How” means any [*]. 

1.78    “Program Patent” means any [*]. 

1.79    “Program Technology” means Program Patents and Program
Know-How. 
 1.80    “Program Transfer” has the meaning
in Section 12.5.1. 
 1.81    “Regulatory Approval” means, with respect to a country in the
Territory, any and all approvals (including Drug Approval Applications), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell or market a Collaboration Product in such country, including,
where applicable, (i) pricing or reimbursement approval in such country, (ii) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization
related thereto) and (iii) labeling approval. 
 1.82    “Regulatory Authority” means any
applicable supra-national, federal, national, regional, state, provincial or local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the
Exploitation of Collaboration Compound or Collaboration Products in the Territory, including the FDA in the United States and the EMA in the European Union. 

1.83    “Regulatory Documentation” means: all (i) applications (including all INDs and Drug
Approval Applications), registrations, licenses, authorizations and approvals (including Regulatory Approvals); (ii) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports
relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all Adverse Event files and complaint files; and (iii) clinical and other data, including Study Data, contained or relied
upon in any of the foregoing; in each case ((i), (ii) and (iii)) relating to the Collaboration Compound or a Collaboration Product. 

1.84    “Regulatory Exclusivity Period” means, with respect to each Collaboration Product in any
country in the Territory, a period of exclusivity (other than Patent exclusivity) 

  
 -11- 

 
granted or afforded by Applicable Law or by a Regulatory Authority in such country that confers exclusive marketing rights with respect to such Collaboration Product in such country or that
confers data or similar exclusivity such that Third Parties or the applicable Regulatory Authority(-ies) in such country are prohibited from relying on data used to obtain Regulatory Approval for the
Collaboration Product in applying for or granting Regulatory Approval to Third Party products. 

1.85    “Research Plan” has the meaning set forth in Section 2.2.2. 

1.86    “Research Program” has the meaning set forth in Section 2.2.1. 

1.87    “Research Program Term” has the meaning set forth in Section 2.2.5. 

1.88    “Royalty Term” has the meaning set forth in Section 6.5.1(i). 

1.89    “S1 Criteria” means, with respect to a particular Sanofi Target, the applicable criteria
set forth in the applicable Target Plan. 
 1.90    “S2 Criteria” means, with respect to a
particular Sanofi Target, the applicable criteria set forth in the applicable Target Plan. 
 1.91    “S3
Criteria” means, with respect to a particular Sanofi Target, the applicable criteria set forth in the applicable Target Plan. 

1.92    “S1 Determination” [*]. 

1.93    “S2 Determination” [*]. 

1.94    “S3 Determination” [*]. 

1.95    “Sanofi” has the meaning set forth in the preamble hereto. 

1.96    “Sanofi Know-How” means all Information and
Inventions Controlled by Sanofi or any of its Affiliates during the Term that is (a) developed by Sanofi or any of its Affiliates under this Agreement after the Effective Date and during the Agreement Term and (b) related to the
Collaboration Compounds or useful for the Exploitation of Collaboration Products, but excluding any Joint Program Know-How and any Know-How related to any device, device
technology or active pharmaceutical ingredients other than the Collaboration Compounds. 

1.97    “Sanofi Patents” means all Patents Controlled by Sanofi or any of its Affiliates or
Sublicensees during the Term, that (a) cover inventions which are made or conceived by Sanofi or any of its Affiliates or its or their Sublicensees under this Agreement after the Effective Date and during the Agreement Term and (b) are
related to one or more Collaboration Compounds, but excluding any Joint Program Patents and any Patents related to any device, device technology or active pharmaceutical ingredients other than the Collaboration Compounds. 

1.98    “Sanofi Target” means the molecular targets proposed by Sanofi pursuant to
Section 2.4 and agreed by the JSC that shall be screened in the Research Program to identify one 

  
 -12- 

 
or more Active Compounds. A Sanofi Target may be an Active Sanofi Target or an ES Target (i.e., a former Active Sanofi Target that Sanofi has selected pursuant to Section 2.4.5), or an ET
Target. 
 1.99    “Sanofi Technology” means the Sanofi Know How and Sanofi Patents. 

1.100    “Senior Executives” means, with respect to DiCE, its Chief Executive Officer and with
respect to Sanofi, its Vice President, Global Head of Small Molecule Drug Discovery. 
 1.101    “Small
Molecule Status” or “SM Status” means for a particular Sanofi Target that the Active Compound(s) are not expected to have PPI Status. 

1.102    [*]. 

1.103    “Stanford License” shall mean [*]. 

1.104    “Status” means, for a particular Sanofi Target, for purposes of Section 6.4, whether
the Collaboration Compound(s) and/or Collaboration Product(s) with regard to such Sanofi Target shall be treated as having (i) Small Molecule Status or (ii) PPI Status, in each case, as set forth in the applicable Target Plan. For clarity,
Status shall be determined in advance and stated in the applicable Target Plan, and such determination shall apply regardless of the actual mechanism of action of any Active Compound. 

1.105    “Structure-Activity-Relationship (SAR) Dataset” means, [*]. 

1.106    “Study Data” means any and all data generated by or on behalf of Sanofi in any pre-clinical study or any clinical trial of any Collaboration Product. 

1.107    “Sublicensee” means a Person, other than an Affiliate or a Distributor that is granted a
sublicense by Sanofi or its Affiliate under the grants in Section 4.2, as provided in Section 4.3. 

1.108    “Target Plan” means, with respect to a particular Sanofi Target, the written plan agreed
by the JSC [*]. 
 1.109    “Terminated Product” means a Collaboration Product with respect to
which this Agreement is terminated in its entirety or in one or more Terminated Territory(-ies) pursuant to Article 12. In the case of a termination of this Agreement in its entirety, all Collaboration
Products shall be considered Terminated Products. 
 1.110    “Terminated Territory” means the
country(ies) with respect to which this Agreement is terminated pursuant to Article 12 or, if this Agreement is terminated in its entirety, the entire Territory. 

1.111    “Territory” means the entire world, other than the Terminated Territory. 

  
 -13- 

 1.112    “Third Party” means any Person other
than DiCE, Sanofi and their respective Affiliates. 
 1.113    “Third Party Acquirer” has the
meaning set forth in Section 14.3.2. 
 1.114    “Third Party Infringement Claim” has the
meaning set forth in Section 8.5. 
 1.115    “Third Party Right” has the meaning set forth
in Section 8.6. 
 1.116    “Trademark” means any word, name, symbol, color, shape,
designation or any combination thereof, including any trademark, service mark, trade name, brand name, sub-brand name, trade dress, product configuration, program name, delivery form name, certification mark,
collective mark, logo, tagline, slogan, design or business symbol, that functions as an identifier of source or origin, whether or not registered and all statutory and common law rights therein and all registrations and applications therefor,
together with all goodwill associated with, or symbolized by, any of the foregoing. 

1.117    “Transferred Materials” has the meaning set forth in Section 2.6. 

1.118    “United States” or “U.S.” means the United States of America and its
territories and possessions (including the District of Columbia and Puerto Rico). 
 1.119    “Valid
Claim” means with respect to any DiCE Patent, Sanofi Patent or Program Patent, a claim of (a) any issued and unexpired Patent or (b) a pending application for a Patent that has not been pending for more than seven (7) years
from its earliest priority date existing in the country in the Territory in which the Collaboration Product is manufactured, used or sold to a Third Party, in each case, which claim covers the applicable Collaboration Product or its Manufacture,
use, offer for sale, sale or importation, in each case the validity, enforceability or patentability of which has not been revoked, found or held unenforceable, invalid or unpatentable by a court, governmental agency, national or regional patent
office or other appropriate body having competent jurisdiction in a decision for which no appeal can or has been taken, and which has not been affected or rendered unenforceable through disclaimer, irretrievable lapse, abandonment or dedication to
the public. 
 1.120    “VAT” has the meaning set forth in Section 7.4. 

1.121    “Voting Stock” has the meaning set forth in the definition of “Change of
Control.” 
 ARTICLE 2 

RESEARCH PROGRAM 

2.1    Overall Objectives. The objective of the Research Program is to identify, in [*] (or more if agreed
by the JSC) Screening Libraries made by DiCE with the use of its DPDCE Technology, compounds that specifically bind to each Sanofi Target, with desired properties in agreed assays, to generate compounds and related structure-activity relationship
(SAR) information that can be used by Sanofi to develop and commercialize Collaboration Products for use in the Field. 

  
 -14- 

 2.2    Research Program. 

2.2.1    General. Each Party shall use Commercially Reasonable Efforts to undertake and perform agreed
activities to achieve the foregoing objectives, as set forth in the Research Plan (the “Research Program”). DiCE shall be responsible for preparing and screening Libraries against the Sanofi Targets. Sanofi may, as agreed by the
JSC, participate in the design of Screening Libraries, and shall have the right to participate in the design of Focused Libraries. 

2.2.2    Research Plan. The Parties shall perform the Research Program in accordance with a written research
plan (the “Research Plan”), the specific Target Plans, and the terms and conditions of this Agreement. The Research Plan shall include a description of the specific activities to be performed by the Parties in support of the
Research Program and projected timelines and budget for completion of such activities. Following the Amendment Date, the Research Plan will consist of such research activities relating to the Sanofi Targets as DiCE, in its discretion, elects to
perform, together with such other research plans and activities as are mutually agreed to by the Parties in writing and approved by the JSC. The Parties may, through the JSC, modify and update the then existing Research Plan from time to time. 

2.2.3    Sanofi Targets; Target Plans. With respect to each Sanofi Target, the JSC may (but is not required)
to elect to agree on a Target Plan for the applicable Sanofi Target. The JSC shall have the authority to modify any such Target Plan(s), in accordance with Section 3.3.6. 

2.2.4    Research Program Expenses. DiCE shall be fully responsible for all costs and expenses (both
internal and external) it incurs conducting the Research Program; provided, however, that DiCE shall not be obligated to spend any amounts on the conduct of the Research Program that exceed the amounts budgeted for such activities in the
then-current Research Plan. 
 2.2.5    Research Program Term. The Research Program shall commence on the
Effective Date and, unless terminated earlier as provided in Article 12, shall continue until the date that is [*] years after the Effective Date (the “Research Program Term”). The Research Program Term for a particular Sanofi
Target will be extended for consecutive [*] year periods if [*] ARTICLE 5 [*]. If at the expiration of the Research Program Term for a Sanofi Target [*] has not occurred and DiCE is no longer conducting research activities with respect to such
Sanofi Target, then such Sanofi Target shall cease to be a Sanofi Target thereafter. 
 2.3    Libraries. 

2.3.1    Screening Libraries. DiCE shall make available at least [*] Screening Libraries for screening in
the Research Program. [*]. With respect to Active Sanofi Targets, the JSC shall determine which Screening Library [*] shall be used to screen against such Sanofi Target(s). In accordance with the applicable Target Plans agreed by the JSC, DiCE shall
screen at least one Screening Library against each Active Sanofi Target for a minimum of [*] rounds (unless otherwise agreed by the JSC, or with regard to the applicable Sanofi Target, Sanofi selects it as an

  
 -15- 

 
ES Target, or the JSC designates it as an ET Target). For purposes of this section “screen” shall mean the sequential selection rounds of DPDCE using the Screening Library or Focused
Libraries with each Active Sanofi Target and its controls (ligands, etc) to determine if a positive selection [*] has occurred and suggesting the presence of Active Compounds in the Library. The Parties acknowledge that if screens on Active Sanofi
Targets fail to identify Active Compounds then new Screening Libraries may be made, subject to the final decision of the JSC. 

2.3.2    Focused Libraries. Based on results obtained with the Screening Libraries, the JSC shall determine,
on a Sanofi-Target-by-Sanofi Target basis, if [*] Focused Libraries should be prepared by DiCE based on compounds in a Screening Library identified as specific
for the applicable Sanofi Target and other agreed information. The size and composition of each Focused Library shall vary, but a minimum size and composition shall be decided by the JSC. 

2.3.3    Library Exclusivity. During the Agreement Term, DiCE shall disclose to Sanofi, but not disclose to
any Third Party, the results of the screening of any Sanofi Target against any Library hereunder. Sanofi agrees that DiCE shall be free, at its sole discretion, to screen any Library against any target that is not a Sanofi Target during the Research
Program Term or thereafter, on its own behalf or for any Third Parties; provided, in each case, that (a) before any such screening using a Library occurs for a Third Party, DiCE shall have executed a written agreement with such Third
Party that retains for DiCE the right to screen such Library against the Sanofi Target(s), and (b) DiCE continues to provide sufficient human, financial and physical resources required to support the screening of Libraries against each Active
Sanofi Target, on a Sanofi Target-by-Sanofi Target basis, in accordance with the Research Plan and the applicable Target Plan. 

2.3.4    Library Operations. 

(i)    Construction. Sanofi understands and agrees that a particular Focused Library subject to this Agreement may,
for reasons of technical efficiency, be made concurrently with one or more other Libraries (i.e., a Screening Library or one or more other Focused Library, so long as DiCE is able to distinguish (i.e., bioinformatically, via tags) the compounds
within a particular Focused Library and distinguish these from other concurrently made Library Compounds. Focused Libraries made in such a manner shall be treated in the same way as Focused Libraries made individually (i.e., one at a time).

 (ii)    Screening. During the Research Program Term, DiCE may, at its discretion, screen at least [*]
Screening Libraries, and any Focused Libraries prepared by DiCE in accordance with Section 2.3.2, against the Active Sanofi Targets, in each case as may be set forth in the applicable Research Plan and applicable Target Plans. For clarity, it
is understood and agreed that the JSC shall determine whether any particular Active Sanofi Target shall be screened against more than one Screening Library. Sanofi understands and agrees that a particular Focused Library subject to this Agreement
may, for reasons of technical efficiency, be screened concurrently with one or more other Libraries (e.g., a Screening Library or one or more other Focused Library) which may or may not be subject to this Agreement, so long as DiCE is able to
distinguish (e.g., bioinformatically, via tags, etc.) the compounds within a particular Focused Library and distinguish these from other Library Compounds. In any such case, DiCE shall not be obligated to report to Sanofi any screening results
relating to any Library Compound that is not subject to this Agreement (i.e., that is not included within (a) a Screening Library selected for use under this Agreement, or (b) a Focused Library) and no such Library Compound shall be an
Active Compound (regardless of whether such Library Compound has any activity against any Sanofi Target). 

  
 -16- 

 2.3.5    Other Libraries. With the agreement of the
Parties, DiCE may (but shall not be obligated to) screen one or more Libraries made by DiCE outside the Research Program with regard to one or more Sanofi Targets, on the terms set forth herein. 

2.3.6    Physical Ownership. DiCE shall retain title to and ownership of the tangible property embodied in
all Libraries. It is understood that Sanofi shall have, ownership of certain intellectual property rights pursuant to Section 8.1, and certain license rights under Sections 4.1 and 4.2. 

2.3.7    SAR Datasets. DiCE shall be the [*] of all information in the SAR Datasets, provided Sanofi shall
[*] of any intellectual property proprietary to Sanofi that Sanofi disclosed to DiCE that is embodied in any such SAR Dataset(s). 

2.4    Sanofi Targets. 

2.4.1    General.    It is expected that [*] Active Sanofi Targets will be selected for
the Research Program on or before [*], and [*] additional Active Sanofi Targets will be selected for the Research Program on or before [*], in accordance with Section 2.4.2. Pursuant to Section 2.4.5, certain Active Sanofi Targets may, at
Sanofi’s election, become ES Targets. Unless substituted, terminated pursuant to Section 12.3, or otherwise agreed in writing by the Parties, each Sanofi Target (including without limitation any ES Target and any ET Target) shall remain a
Sanofi Target during [*]. 
 2.4.2    New Active Target Selection. Sanofi may propose to the JSC that a
molecular target become an Active Sanofi Target hereunder. All Active Sanofi Targets shall be proposed by Sanofi, but acceptance as an Active Sanofi Target is subject to [*]. Promptly after a target becomes an Active Sanofi Target pursuant to this
Section 2.4.2, the JSC may elect to agree upon a Target Plan for such Active Sanofi Target and update the Research Plan accordingly.

2.4.3    Active Target Substitution. If Research Program activities have commenced for a particular Active
Sanofi Target and Sanofi wishes to substitute such Active Sanofi Target with another molecular target, it may propose such a substitution in accordance with the terms of this Section 2.4.3. 

(i)    If following the achievement of [*] and DiCE’s generation and panning of a Focused Library with respect to a
particular Sanofi Target, the JSC agrees that continued activities with respect to a particular Active Sanofi Target are not worthwhile, it shall designate that target as a ET Target. In such case, such ET Target shall continue to be a Sanofi Target
(but not an Active Sanofi Target) and Sanofi shall pay [*].  
 (ii)    If Sanofi desires to substitute an Active
Sanofi Target, then Sanofi shall provide DiCE with a written notice (the “Request Notice”), which Request Notice shall identify the current Active Sanofi Target to be substituted, state as applicable whether such Active Sanofi
Target will become an ES Target, and identify the proposed new molecular target (the “Proposed Target”). [*] then the 

  
 -17- 

 
Proposed Target will become an Active Sanofi Target. Promptly after a Proposed Target becomes an Active Sanofi Target pursuant to this Section 2.4.3, the JSC may elect to agree upon a Target
Plan for such new Active Sanofi Target and update the Research Plan accordingly. 
 2.4.4    Consequences of
Substitution. Any former Active Sanofi Target which has been substituted subject to Section 2.4.3 shall (unless it becomes an ES Target or an ET Target) no longer be a Sanofi Target. Subject to Section 2.4.6 and Article 9, DiCE shall
be free to conduct any activities with any former Sanofi Target(s) as it deems appropriate. 
 2.4.5    ES
Target Selection. The Parties acknowledge that the SAR Dataset for any Active Sanofi Target may contain sufficient information to allow Sanofi to advance the development of Collaboration Compounds and Collaboration Products for such Active
Sanofi Target without advancement by DiCE to the [*]. Accordingly, Sanofi shall have the right to elect, by written notice to DiCE and subject to the terms in this Section 2.4, to designate any Active Sanofi Target that has achieved [*] as an
ES Target (whereupon such Sanofi Target shall cease to be an “Active Sanofi Target” and shall become an “ES Target” hereunder). In each such case, such ES Target shall be treated as if DiCE had achieved the [*] for such Sanofi
Target, for purposes of determining the milestones payable pursuant to Section 6.4.2 and royalties payable pursuant to Section 6.5. 

2.4.6    Target Exclusivity. 

(i)    Sanofi Targets. With respect to a particular Sanofi Target, DiCE shall not enter into an agreement with a
Third Party regarding, or screen on its own account or for a Third Party against, such Sanofi Target. Notwithstanding the foregoing, if: [*]. 

(ii)    RESERVED 

(iii)    Targets other than Sanofi Targets. Except as expressly set forth herein or as agreed by the Parties,
during and after the Research Program Term, DiCE shall be free to conduct any activities outside the Research Program with any targets that are not then Sanofi Targets (e.g., screening for any target not covered by the exclusivity provisions above).
If the Parties agree in writing that Sanofi will provide in-kind services to DiCE in connection with DiCE’s activities outside the Research Program with respect to the identification of compounds [*]
subject to this Section 2.4.4(iii). 
 2.5    Compound Designation. 

2.5.1    Active Compound(s). At any time during the Research Program that either Party believes that an
Active Compound has been identified with regard to any Sanofi Target, it shall notify the JSC, with a written summary of the basis for its view. At its next meeting, or such earlier time as the Parties may agree, the JSC shall either
(a) confirm that the identified compound is an Active Compound, or (b) that the identified compound is not an Active Compound, in which case the specific reason for any failure to meet the applicable Active Compound Criteria shall be
summarized in writing. The Parties agree that any compound that is an Active Compound shall be Collaboration Compound for all purposes of this Agreement. 

  
 -18- 

 2.5.2    S1/S2/S3 Criteria. At any time during the
Research Program that either Party believes that for any particular Sanofi Target, [*]. At its next meeting, or such earlier time as the Parties may agree, the JSC shall [*]. 

In addition, if at any time during the Research Program, DiCE determines that the data and results regarding compounds active against a particular Sanofi
Target are sufficient to allow Sanofi to [*] then DiCE shall notify the JSC and if the JSC concurs with DiCE’s determination then: 

(i)     DiCE shall notify Sanofi in writing; 

(ii)    Sanofi shall have [*] from the date of DiCE’s notice to notify DiCE that it wishes to obtain a license to the
SAR Dataset for such Sanofi Target, or to convene a meeting of the Sanofi [*] to [*]; and 
 (iii)     if during such
[*] day period Sanofi does not notify DiCE that it wishes to obtain a license to the SAR Dataset or convene a meeting of the Sanofi [*], as applicable, then [*]. 

2.6    Transfer of Materials. With written approval of the JSC, DiCE may transfer one or more Active
Compounds to Sanofi, in quantities agreed by the JSC for the purposes set forth in the Research Plan (“Transferred Materials”). For clarity, in no event shall DiCE shall be obligated to transfer any Screening Library to Sanofi.
Sanofi shall use the Transferred Materials solely for research activities expressly approved in advance in writing by the JSC or in practicing its rights granted under this Agreement. 

2.7    Limited Use. Except in connection with the practice of the rights expressly granted to Sanofi with
regard to Collaboration Compound(s) and Collaboration Products pursuant to this Agreement, Sanofi shall not, without the express prior written consent of DiCE: (i) transfer any DiCE Technology to any Third Party; (ii) use any data and
information obtained from the activities conducted using any Collaboration Compound for any other purpose; (iii) permit any Third Party to obtain or use any data containing or comprising any DiCE Technology for any purpose; or (iv) use, or
attempt to use, any data or information containing or comprising any DiCE Technology, including without limitation, structural motifs, to reverse engineer, reconstruct, synthesize or otherwise modify or copy any Collaboration Compound. 

2.8    Sanofi Resources. Sanofi shall, at its own cost and expense (not to exceed [*] in any one Calendar
Year during the Research Program Term) provide in-kind resources for the conduct of the Research Program, if and as agreed by the JSC. Such resources may include the [*] Controlled by Sanofi or its Affiliates.

 2.9    Third Party Intellectual Property. 

2.9.1    DiCE Responsibility. DiCE shall be responsible for acquiring any Third Party license and the
payment of any amounts due to Third Parties [*] for intellectual property necessary for the practice of the DPDCE Technology, during and in the course of the Research Program, [*]. 

2.9.2    Sanofi Responsibility. [*]. 

  
 -19- 

 2.9.3    Infringement Claims. [*]. 

2.10    Records. DiCE and Sanofi shall each maintain records of the activities conducted by it in the
Research Program (or cause such records to be maintained) in sufficient detail and in good scientific manner as shall properly reflect all work done and results achieved in the performance of the Research Program. Subject to Section 2.11, each
Party shall allow the other to have reasonable access to all data generated by or on behalf of such Party with respect to each Collaboration Compound in connection with the Research Program. Upon reasonable request by Sanofi, DiCE shall provide
Sanofi with additional data, results and other information with respect to the work performed by DiCE in the performance of the Research Program. However, it is understood that DiCE shall have no obligation to disclose to Sanofi any methods of
practicing any DPDCE Technology. 
 2.11    Information Sharing. The results of all work performed by DiCE
and its Affiliates and contractors as part of the Research Program shall be promptly disclosed to Sanofi in a reasonable manner as such results are obtained; provided, however, that (a) DiCE shall have no obligation to disclose to Sanofi
(i) developments relating to the DPDCE Technology except as described in the last sentence of this Section 2.11, or (ii) any information relating to any SAR Dataset [*], and (b) DiCE shall not disclose to Sanofi the structure of
any Library Compound active against a particular Sanofi Target [*]. DiCE shall provide reports and analyses at each JSC meeting, and more frequently on reasonable request by the JSC, detailing the current status of the Research Program. DiCE shall,
through the JSC, inform Sanofi of any new material developments regarding the capabilities or issues with the use of its DPDCE technology learned from its practice outside of the Research Program. For purposes of clarity, DiCE shall not be obliged
to share with Sanofi any information which is specific to any DiCE proprietary programs or programs that DiCE is pursuing with a third party). 

2.12    Research Efforts; Resources, Scientific Manner. DiCE shall conduct the Research Program as it
determines in its sole discretion. DiCE shall maintain laboratories, offices, administrative support and all other facilities at its own expense and risk necessary to carry out its responsibilities under the Research Plan. DiCE agrees to make its
employees reasonably available at their respective places of employment to consult with Sanofi personnel on issues arising during the performance of the Research Program. DiCE shall contribute its relevant
know-how and experience necessary to carry out the Research Program. The Research Program shall be conducted by DiCE in good scientific manner, and in compliance with applicable legal requirements, to attempt
to achieve efficiently and expeditiously the objectives of the Research Program. 
 ARTICLE 3 

COLLABORATION MANAGEMENT 

3.1    Joint Steering Committee. Within [*] after the Effective Date, the Parties shall establish a joint
steering committee (the “Joint Steering Committee” or “JSC”), which shall consist of [*] of each Party, each with the requisite experience and seniority to enable such person to make decisions on behalf of
the applicable Party with respect to the issues falling within the jurisdiction of the JSC. The initial Sanofi JSC members shall be [*] and the initial DiCE JSC members shall be [*]. From time to time, each Party may substitute one or more of its
representatives to the JSC on written notice to the other Party. 

  
 -20- 

 3.2    Responsibilities and Authority. The JSC shall: 

3.2.1    monitor the progress of the Research Program and address any issues arising with respect to the conduct of
the Research Program; 
 3.2.2    review and approve amendments and modifications to the Research Plan and any
Target Plan; 
 3.2.3    delegate any of its responsibilities to a subcommittee to oversee and review the
subcommittees in the performance of their respective activities; 
 3.2.4    approve each Sanofi Target that will
be screened in the Research Plan pursuant to Section 2.4, and determine if any Active Sanofi Target shall be an ET Target pursuant to Section 2.4.3 ; 

3.2.5    establish for each Sanofi Target prior to the commencement of screening of any Library against such Sanofi
Target, a Target Plan, detailing without limitation, [*], the Status of such Sanofi Target [*]; 

3.2.6    determine for each Sanofi Target, whether the Active Compound Criteria have been met by [*] Library
Compounds; 
 3.2.7    determine for each Sanofi Target, whether an Active Compound(s) has satisfied [*]; and

 3.2.8    perform such other functions as are set forth in this Agreement, or as the Parties may mutually agree
in writing (except where in conflict with any provision of this Agreement). 
 3.3    General. 

3.3.1    Meetings. During the Research Program Term, the JSC shall meet to discharge its responsibilities
[*], but may meet more frequently as the JSC may agree. The JSC must have a quorum to make decisions, which shall require at least one JSC member from each Party to participate. The JSC shall meet at locations that are mutually agreed upon by the
Parties. Each Party shall pay its own expenses associated with attendance at JSC meetings. 

3.3.2    Process. The chairperson of the respective committee shall be responsible for calling meetings on
no less [*] notice unless exigent circumstances require shorter notice. Each Party shall make all proposals for agenda items at least [*] in advance of the applicable meeting and shall provide all appropriate information with respect to such
proposed items at least [*] in advance of the applicable meeting; provided that under exigent circumstances requiring input by the respective committee, a Party may provide its agenda items to the other Party within a shorter period of time
in advance of the meeting or may propose that there not be a specific agenda for a particular meeting, so long as the other Party consents to such later addition of such agenda items or the absence of a specific agenda for such meeting (which
consent shall not be unreasonably withheld, conditioned or delayed). 

  
 -21- 

 3.3.3    Procedural Rules. The JSC shall have the right to
adopt such standing rules as shall be necessary for its work, to the extent that such rules are not inconsistent with this Agreement. Representatives of the Parties on each committee may attend a meeting either in person or by telephone, video
conference or similar means in which each participant can hear what is said by and be heard by, the other participants. Representation by proxy shall be allowed. Alliance Managers or other employees or consultants of a Party who are not
representatives of the Parties on the committee may attend meetings; provided, however, that such attendees (i) shall not vote or otherwise participate in the decision-making process of the committee and (ii) are bound by
obligations of confidentiality and non-disclosure at least as protective of the other Party as those set forth in Article 9. 

3.3.4    Minutes. The chairperson of the respective committee shall prepare and circulate for review and
approval of the Parties minutes of each meeting within [*] after the meeting. The Parties shall agree on the minutes of each meeting and sign such minutes promptly, but in no event later than the next meeting of the respective committee. 

3.3.5    Subcommittees. The JSC shall have the right to establish such other subcommittees with
representation from each Party as the JSC deems appropriate to address specific issues relating to Collaboration Compounds or Collaboration Products (e.g., Patent Committee, etc.).    If a subcommittee cannot, or does not, reach
a unanimous decision on an issue within [*], then the dispute shall be referred to the JSC for resolution and a special meeting of the JSC may be called for such purpose. 

3.3.6    Decision-Making. In general, decisions of the JSC shall require unanimous decision of the JSC
representatives present at a meeting, with each Party having a single vote irrespective of the number of representatives of such Party in attendance or by a written resolution signed by at least one (1) representative appointed by each Party.
Notwithstanding the above, [*]. If the JSC does not, reach a unanimous decision on an issue within the jurisdiction and authority of the JSC for which unanimity is required, within [*], then the result will be that no decision has been
reached. 
 3.3.7    Limitations on Authority. Without limitation to the foregoing, the Parties hereby
agree that the following matters are outside the jurisdiction and authority of the JSC and any other committee: (i) amendment, modification or waiver of compliance with this Agreement, (which may only be amended or modified as provided in
Section 14.6 or compliance with which may only be waived as provided in Section 14.11) and (ii) matters explicitly reserved to the consent, approval, agreement or other decision-making authority of either or both Parties in this
Agreement and (iii) Disputes with respect to the application, breach, termination, interpretation or construction of this Agreement (a “Legal Dispute”). 

3.3.8    Alliance Managers. Promptly after the Effective Date, by notice to the other Party, each Party
shall appoint a person(s) who shall oversee contact between the Parties and facilitate the effective exchange of information between the Parties for all matters hereunder and shall have such other responsibilities as the Parties may agree in writing
after the Effective Date, 

  
 -22- 

 
which person(s) may be replaced at any time by notice in writing to the other Party (the “Alliance Managers”). The Alliance Managers shall work together to manage and facilitate
the effective communication between the Parties under this Agreement, including the resolution (in accordance with the terms of this Agreement) of issues between the Parties that arise in connection with this Agreement. 

ARTICLE 4 
 GRANT OF RIGHTS

 4.1    Research Program Licenses. 

4.1.1    DiCE. Subject to the terms and conditions of this Agreement, DiCE hereby grants to Sanofi a [*]
without any right to grant sublicenses (except to Sanofi Affiliates) under the DiCE Technology and DiCE’s interest in the Program Technology solely to perform Sanofi’s obligations in connection with the Research Program; provided
that the foregoing license does not include any license or right to practice any DPDCE Technology. 

4.1.2    Sanofi. Subject to the terms and conditions of this Agreement, Sanofi hereby grants to DiCE a [*]
without any right to grant sublicenses, under the Sanofi Technology and Sanofi’s interest in the Program Technology solely to perform DiCE’s obligations in connection with the Research Program. 

4.2    Grants to Sanofi. 

4.2.1    Exclusive License. Subject to the terms and conditions of this Agreement, DiCE hereby grants to
Sanofi an exclusive (including with regard to DiCE and its Affiliates), license with the right to grant sublicenses in accordance with Section 4.3, under the DiCE Technology and DiCE’s interest in Program Technology, to Develop,
Manufacture and Exploit the Collaboration Compounds and Collaboration Products for any and all uses in the Field in the Territory. 

4.2.2    SAR Dataset License. On a Sanofi
Target-by-Sanofi Target basis, effective upon payment by Sanofi of the milestone payment due pursuant to Section 6.4.1 for achievement of [*] milestone with respect
to the applicable Sanofi Target hereunder, DiCE shall and hereby does grant to Sanofi an exclusive, non-sublicensable (except to Sanofi Affiliates), non-transferable
license to the SAR Dataset for such Sanofi Target to exploit such SAR Dataset solely to identify Collaboration Compounds for use in the Field. Regardless of any SAR Dataset license or other license granted to Sanofi, DiCE shall have the right to
disclose to any Third Party information regarding (i) the class of targets (e.g., protein-protein interface, kinase, E3 ligase, serine protease, etc.) studied in the Research Program, and (ii) blinded results achieved in the Research
Program, for purposes of demonstrating the application of the DPDCE technologies; in each case subject to the restrictions set forth in Article 9. 

4.3    Right to Grant Sublicenses. Sanofi shall have the right to grant sublicenses to its Affiliates and
Third Parties, through multiple tiers of sublicensees, under the licenses and rights of reference granted in Section 4.2. Sanofi shall provide DiCE with at least the following information with respect to each potential Sublicensee: [*]. 

  
 -23- 

 4.4    Retained Rights. Notwithstanding Section 4.2.1
above, DiCE shall retain the right to make, have made and use any and all Library Compounds that are not Active Compounds to develop, improve and validate its DPDCE Technology and for screening any target that is not a Sanofi Target. 

4.5    License to DiCE.    Subject to the terms and conditions of this Agreement, Sanofi
hereby grants to DiCE, and DiCE hereby accepts, a [*] under Sanofi’s interest in the Sanofi Technology and Program Technology use the DPDCE Technologies to create and use chemical libraries and identify chemical compounds of interest, on its
behalf and on behalf of Third Parties. 
 4.6    Third Party Rights. 

4.6.1    Overlapping Rights. Sanofi acknowledges that DiCE is in the business of preparing and screening
diverse chemical libraries to Third Parties in the pharmaceutical, agriculture and other industries, and that DiCE may grant such Third Parties rights after the Effective Date to acquire licenses for compounds derived from such libraries similar to
Sanofi’s rights under this Article 4. Notwithstanding the licenses granted Sanofi above, it is possible that a Third Party may acquire rights from DiCE with respect to one or more compounds within the scope of a patent of which DiCE is a
sole or joint owner; accordingly, DiCE’s grant of rights to Sanofi in this Article 4 is limited to the extent that (i) a Third Party (either alone or jointly with DiCE) has filed a patent application with respect to such a compound prior
to the filing by Sanofi (either alone or jointly with DiCE) of a patent application with respect to such a compound, or (ii) DiCE has previously granted a Third Party a license or other rights with respect to such a compound, and subject to any
such grant of rights to a Third Party. Notwithstanding the foregoing, during the Agreement Term as long as the applicable Sanofi Target remains a Sanofi Target and Sanofi’s rights thereto under this Agreement have not terminated, DiCE shall not
grant to any Third Party any rights to Develop, Manufacture and/or Exploit Collaboration Compounds or Collaboration Products with regard to the applicable Sanofi Target in the Field in the Territory. 

4.6.2    No Liability. It is understood and agreed that, even if DiCE complies with its obligations under
this Agreement, compounds provided to Third Parties in the course of DiCE’s other business activities may result in Third Party patent applications and Patents, including patent applications and patents owned by such Third Parties, or owned
jointly by DiCE and such Third Parties, which could conflict with patent applications and/or Patents owned by Sanofi, or jointly owned by Sanofi and DiCE hereunder. DiCE shall use reasonable efforts to avoid such conflict, but Sanofi acknowledges
that DiCE has no control over patents applications filed by Third Parties. 
 4.7    Confirmatory Patent
License. DiCE shall, if requested to do so by Sanofi, [*], immediately enter into confirmatory license agreements in such form as may be reasonably requested by Sanofi for purposes of recording the licenses granted under this Agreement with such
patent offices in the Territory as Sanofi considers appropriate. Until the execution of any such confirmatory licenses, so far as may be legally possible, DiCE and Sanofi shall have the same rights in respect of the DiCE Patents and be under the
same obligations to each other in all respects as if the said confirmatory licenses had been executed. 

  
 -24- 

 4.8    Discussion of Enabling License. Commencing on the
[*] anniversary of the Effective Date, during the Research Program Term, Sanofi shall have a [*] under the DPDCE Patents and Dice Know-how for the [*] by Sanofi (or agreed Sanofi Affiliates) against agreed
targets. The terms of any such license must be agreed by the Parties and would reflect the agreed value of any such license. 

4.9    No Implied Licenses. No rights or licenses are granted or shall be deemed granted under this
Agreement with respect to any intellectual property owned by a Party, other than those rights and licenses expressly and specifically provided under this Agreement. The Parties agree that neither Party is granted any implied rights to or under any
of the other Party’s current or future patents, trade secrets, copyrights, moral rights, trade or service marks, trade dress, or any other intellectual property rights. Specifically, but without limitation, it is understood and agreed that no
license is granted in this Agreement to Sanofi to use or practice any DPDCE Technology, and Sanofi hereby covenants and agrees that it and its Affiliates shall not, during the Agreement Term, knowingly practice any DiCE Patent Rights or DiCE Know-How. 
 ARTICLE 5 

DEVELOPMENT AND COMMERCIALIZATION 

5.1    In General. As between the Parties, Sanofi (itself or through its Affiliates or its or their
Sublicensees), [*] shall have the sole right to Develop and Commercialize Collaboration Products to which Sanofi retains rights under this Agreement. 

5.2    Development. Except as provided in Sections 12.5.1, as between the Parties, Sanofi shall have the
sole right and responsibility, [*] for all aspects of the Development of Collaboration Products. Sanofi shall be the sole owner of, with all rights, title and interest in, all Study Data generated by it. 

5.3    Diligence. Sanofi shall use Commercially Reasonable Efforts to Commercialize [*] for each Sanofi
Target in [*] following receipt of Regulatory Approval in the applicable country. 
 5.4    Reports.
During the Agreement Term, after the end of the Research Program, Sanofi shall provide DiCE with [*] written reports within [*] of the applicable anniversary of the Effective Date providing at least the following information with respect to each
Collaboration Product: [*]. The reports as described in this Section 5.4 shall contain sufficient information to allow DiCE to monitor Sanofi’s compliance with this Agreement including without limitation Sanofi’s obligations with
respect to payments set forth in Article 6. Until first commercial introduction of each royalty-bearing product incorporating a Collaboration Compound on behalf of Sanofi hereunder, Sanofi shall keep DiCE apprised of the status of the pre-clinical, clinical and commercial development of such product by [*] providing DiCE with a written report detailing such activities with respect to each such Collaboration Product during the Agreement Term. All
reports and information provided under this Section 5.4 shall be deemed Confidential Information of Sanofi. 

5.5    Regulatory Activities. 

  
 -25- 

 5.5.1    Regulatory Approvals. 

(i)    All Regulatory Documentation (including all Regulatory Approvals) relating to the Collaboration Compounds or
Collaboration Products obtained by Sanofi after the Effective Date shall be owned by, be the sole property of, and held in the name of, Sanofi; 

(ii)    Sanofi shall have the sole right and responsibility [*] to file all Drug Approval Applications and make all other
filings with the Regulatory Authorities to seek all Regulatory Approvals for Collaboration Products in the Territory, as well as to conduct all meetings, correspondence and communications with Regulatory Authorities regarding such matters. 

(iii)    Sanofi shall use Commercially Reasonable Efforts to seek and obtain Regulatory Approval for the Collaboration
Products for each Sanofi Target in [*]. 
 5.5.2    Recalls, Suspensions or Withdrawals. In the event that
any government agency or authority issues or requests a recall or takes similar action in connection with the Collaboration Compounds or the Collaboration Products, or in the event Sanofi determines that an event, incident or circumstance has
occurred that may result in the need for a recall or market withdrawal, the Party notified of or desiring such recall or market withdrawal shall as promptly as reasonably practical under the circumstances advise the other Party thereof. As between
the Parties, Sanofi shall have the right to make the final determination whether to voluntarily implement any such recall, market suspension or market withdrawal in the Territory. If a recall, market suspension or market withdrawal is mandated by a
Regulatory Authority in the Territory, as between the Parties, Sanofi shall initiate such a recall, market suspension or market withdrawal in compliance with Applicable Law. For all recalls, market suspensions or market withdrawals undertaken
pursuant to this Section 5.5.2, as between the Parties, Sanofi shall be solely responsible for the execution and DiCE shall reasonably cooperate in all such efforts. Sanofi shall be responsible for all costs of any such recall, market
suspension or market withdrawal. 
 5.5.3    Global Safety Dataset. Sanofi shall establish, hold and
maintain (at Sanofi’s cost and expense) the global safety database for Collaboration Products. 

5.6    Booking of Sales; Distribution. As between the Parties, Sanofi shall have the sole right to invoice
and book sales, establish all terms of sale (including pricing and discounts) and warehouse and distribute the Collaboration Products in the Territory and perform or cause to be performed all related services. As between the Parties, Sanofi shall
handle all returns, order processing, invoicing, collection, distribution and inventory management with respect to the Collaboration Products in the Territory. 

5.7    No Products Other than Collaboration Products. Except as otherwise agreed in writing or specifically
provided in the terms of this Agreement, neither Sanofi nor its Affiliates nor Sublicensees shall commercialize any Collaboration Compound, other than as a Collaboration Product in accordance with this Agreement. 

ARTICLE 6 
 PAYMENTS TO DICE

  
 -26- 

 6.1    Initial Payment. In partial consideration of the
rights granted by DiCE to Sanofi hereunder, Sanofi shall pay DiCE a non-creditable and non-refundable initial payment of eight million Dollars ($8,000,000). On or after
the Effective Date, DiCE shall invoice Sanofi for such initial payment amount and Sanofi shall pay such invoice on [*]. 

6.2    RESERVED 

6.3    RESERVED 

6.4    Milestone Payments. 

6.4.1    [*] 

(i)    [*]. With respect to each Sanofi Target, on a Sanofi Target-by-Sanofi Target basis, [*]. 
  

					
	6.4.2	 	6.4.4[*]	 	
	6.4.3 Milestone	 	6.4.5[*]	 	6.4.6[*]
	6.4.7[*]	 	6.4.8[*]	 	6.4.9[*]
	6.4.10[*]	 	6.4.11[*]	 	6.4.12[*]
	6.4.13[*]	 	6.4.14[*]	 	6.4.15[*]
	6.4.16[*]	 	6.4.17[*]	 	6.4.18[*]

 6.5    [*]. 

6.6    [*]. 

[*]. 

(i)    [*] Milestone Payments. In partial consideration of the rights granted by DiCE to Sanofi hereunder, Sanofi
shall pay DiCE each of the following one-time only milestone payments upon DiCE’s [*]: 
  

			
	 [*] Milestone
	  	 Milestone Payment

	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]

 6.6.2    [*]. 

  
 -27- 

 (i)    [*]. 

6.6.3    [*]. 

6.6.4    Development & Regulatory Milestone Payments. In partial consideration of the
rights granted by DiCE to Sanofi hereunder, with respect to each Sanofi Target, on a Sanofi Target-by-Sanofi Target basis, Sanofi shall pay to DiCE each of the following
one-time only milestone payments upon the first achievement by a Collaboration Compound or Collaboration Product for such Sanofi Target of the corresponding milestone described below. Except with respect to ES
Targets, for which the [*] shall be deemed achieved for all Collaboration Compounds for such Sanofi Target for the purpose of this Section 6.4.2, the milestone payment amount shall depend upon (i) whether the applicable Sanofi Target is an
ET target, (ii) whether [*] was made with respect to the applicable Collaboration Compound, and (iii) whether the applicable milestone is achieved with respect to a Collaboration Compound for a Sanofi Target that has [*], as set forth
below. 
  

							
	Milestone	  	Milestone Payment
		  	
        [*]     
   
	  	
        [*]     
   
	  	
        [*]     
   

	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]

 6.6.5    Milestone Payment Process. Sanofi shall provide prompt written
notice to DiCE of the achievement of each applicable milestone pursuant to this Section 6.4. Upon receipt of such notice, DiCE shall provide an invoice to Sanofi, and payment shall be due within [*] after receipt by Sanofi of such invoice. For
clarity, in the event any particular milestone described in this Section 6.4 is achieved more than once for a particular Sanofi Target, no additional milestone payments shall be due for the second or subsequent achievement of such milestone for
such Sanofi Target. 
 6.6.6    Backup Collaboration Compounds. The accrual of [*] set forth in
Section 6.4.1(i) and the milestone payments set forth in Section 6.4.2 above shall be made with respect to the first Collaboration Compound or corresponding Collaboration Product active against a particular Sanofi Target that achieves the
corresponding milestone event, as the case may be; 

  
 -28- 

 
provided that, [*] pursuant to Section 6.4.1(i), or received a milestone payment pursuant to Section 6.4.2, with respect to the achievement of any milestone event set forth in
Section 6.4.1(i) or Section 6.4.2 by a Collaboration Compound or Collaboration Product active against a particular Sanofi Target, then [*] and no milestone payment shall be due upon the accomplishment of that same milestone with respect to
the next Collaboration Compound or Collaboration Product hereunder active against the same Sanofi Target. 

6.6.7    Termination. If (a) Sanofi provides a notice of termination of this Agreement pursuant to
Section 12.3 (or termination of country(ies) or region(s) or any Collaboration Products), or (b) DiCE provides notice of termination pursuant to Section 12.4, in each case, prior to the achievement of any milestone, then Sanofi shall
have no obligation to make any further milestone payment under Section 6.4 with respect to such Terminated Territory or such Terminated Product from and after the date of such notice (except if such milestone was achieved before the date of
such notice); provided, that, if this Agreement is not actually terminated following such notice, then any milestone payments associated with the achievement of a milestone with respect to such country or jurisdiction after such date of
notice shall be due within [*] after the date on which it was determined by the Parties in writing that this Agreement would not terminate. 

  
 -29- 

 6.7    Royalties. 

6.7.1    Royalty Rates. In partial consideration for the rights granted to Sanofi hereunder, on a
Collaboration Product-by-Collaboration Product basis, Sanofi shall pay to DiCE royalties on annual worldwide Net Sales of Collaboration Products by Sanofi and its
Affiliates and Sublicensees, in accordance with this Section 6.5. The applicable royalty rate shall depend upon [*], as set forth below. 
  

							
	[*]	  	[*]
	Portion of annual Net Sales	  	Royalty Rate	  	Portion of annual Net Sales	  	Royalty Rate
	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]	  	[*]
	[*]	  	[*]	  		  	

 (i)    Royalty Term. Royalties shall be due to DiCE on a country-by-country and Collaboration Product-by Collaboration Product basis until the later of (a) the first date on which there
is no Valid Claim of any DiCE Patent and/or Sanofi Patent covering the manufacture, use, import or sale of such Collaboration Product in such country, and (b) the expiration of any Regulatory Exclusivity Period for such Collaboration Product in
such country (the “Royalty Term”). Sanofi shall have no obligation to pay any royalty with respect to Net Sales of any Collaboration Product in any country after the Royalty Term for such Collaboration Product in such country has
expired. 
 (ii)    Single Royalty; Non-royalty Sales. No royalty shall
be payable under this Section 6.5 with respect to sales of Collaboration Products among Sanofi, its Affiliates and Sublicensees for resale; rather royalties on such Collaboration Products shall be due on the [*]. In no event shall more than one
royalty be due hereunder with respect to any Collaboration Product unit even if covered by more than one patent included in the Licensed Technology. 

6.7.2    Royalty Reductions. Notwithstanding Section 6.5.1 above: 

(i)    Third Party Royalties. Sanofi shall be responsible for the payment of any amounts due Third Parties for the
acquisition or license of intellectual property rights necessary for the manufacture, use or Commercialization of Collaboration Products, provided that, Sanofi may, on a Collaboration Product-by-Collaboration Product and country-by-country basis, deduct [*] of such amounts

  
 -30- 

 
paid to Third Parties for such intellectual property rights necessary for the manufacture, use or commercialization of the applicable Collaboration Product in the applicable country from royalty
payments due to DiCE with respect to the applicable Collaboration Product in the applicable country (“Third Party Payments”). DiCE shall be responsible for any amounts due to Stanford for the Development, Manufacture or
Commercialization of Collaboration Products. 
 (ii)    Generic Competition. If, during the applicable Royalty
Term for a particular Collaboration Product in a particular country, a Generic Product is launched and Sanofi’s Net Sales in any Calendar Quarter following such launch decrease by [*] as compared to the amount of Net Sales booked by Sanofi for
that Collaboration Product in that country during the Calendar Quarter immediately preceding the first launch of a Generic Product, then the royalties due to DiCE pursuant to Section 6.5.1 shall be reduced by [*] from what would otherwise have
been due under Section 6.5.1 for as long as Sanofi’s Net Sales in any Calendar Quarter following launch of such Generic Product remain between [*] less than the amount of Net Sales booked by Sanofi for that Collaboration Product in that
country during the Calendar Quarter immediately preceding the first launch of a Generic Product. Sanofi’s royalty payment obligations shall cease for a particular Collaboration Product in a particular country if a Generic Product is launched in
such country and Sanofi’s Net Sales in any Calendar Quarter following such launch decrease by [*] as compared to the amount of Net Sales booked by Sanofi for that Collaboration Product in that country during the Calendar Quarter immediately
preceding the first launch of a Generic Product in such country. 
 (iii)    Compulsory Licenses. If a court or a
governmental agency of competent jurisdiction requires Sanofi or any of its Affiliates or its or their Sublicensees to grant a compulsory license to a Third Party permitting such Third Party to make and sell a Collaboration Product in a country in
the Territory, then the royalties otherwise due to DiCE pursuant to Section 6.5.1 for Net Sales made by compulsory licensees shall, subject to Section 6.5.3, in lieu of the royalties that would otherwise apply, be the greater of (a) [*] of
the amount received by Sanofi from such licensee, and (b) the applicable royalties that would otherwise be payable hereunder. 

(iv)    No Valid Claim. With respect to royalties payable on Net Sales in a particular country, during any period
within the applicable Royalty Term when there is no DiCE Patent and/or Sanofi Patent in such country that contains a Valid Claim that covers the manufacture, use, import or sale of such Collaboration Product in such country, the otherwise applicable
royalty rate with respect to such Collaboration Product in such country shall be reduced by [*]. 

6.7.3    Minimum Royalty. With regard to any Collaboration Product, except if no royalties are due to DiCE
with regard to sales of such Collaboration Product in a particular country pursuant to the last sentence of Section 6.5.2(ii), regardless of any royalty reductions available to under Section 6.4.2, in no event shall the amount paid by
Sanofi to DiCE with regard to royalties for a particular Collaboration Product in a particular country be less than [*] of the royalty payments that would have been due to DiCE with regard to the applicable Collaboration Product under
Section 6.5.1 
 6.7.4    Royalty Reports. Sanofi shall calculate all amounts payable to DiCE
pursuant to Article 6 at the end of each Calendar Quarter, which amounts shall be converted to Dollars, in accordance with Section 7.2. Sanofi shall provide to DiCE written notice of such amounts within [*] after the end of each Calendar
Quarter, which such report shall include a 

  
 -31- 

 
statement for each Collaboration Product for each country of the Territory during the applicable Calendar Quarter, including at least the following information: (a) gross sales revenues, to
the extent available, and Net Sales; (b) the royalties due to DiCE, which shall have accrued hereunder in respect to the applicable Net Sales, and calculations showing how such royalties were determined, including the royalty rates applied to
calculate the royalties due; (c) the amount of taxes, if any, withheld to comply with applicable law; (d) the exchange rates used in determining the royalty payments due DiCE; and (e) any royalty offsets or other adjustments (e.g.,
for any Combination Product as provided for in Section 1.65) applied in calculating the amounts due to DiCE, and (e) stepwise calculations showing the royalties due to DiCE for the applicable Collaboration Product after any such offset or
adjustments. Each such report shall be accompanied by the applicable payment of royalties due to DiCE for such Calendar Quarter pursuant to Article 6. In the event that Sanofi begins to maintain information with respect to any products
(including, without limitation, any Collaboration Products regarding gross sales of such product(s), in addition to the information above, Sanofi shall include in such reports such information, and all calculations showing the determination of Net
Sales based on such gross sales. 
 ARTICLE 7     

GENERAL FINANCIAL MATTERS 

7.1    Mode of Payment. All payments to DiCE under this Agreement shall be made by deposit of Dollars by
wire transfer in immediately available funds in the requisite amount to such bank account as DiCE may from time to time designate by notice to Sanofi. 

7.2    Currency Conversion. For the purpose of calculating any sums due under, or otherwise reimbursable
pursuant to, this Agreement (including the calculation of Net Sales expressed in currencies other than Dollars), Sanofi shall convert any amount expressed in a foreign currency into Dollar equivalents based on the selling exchange rate using its
Affiliate’s or Sublicensee’s standard conversion methodology in accordance with applicable Accounting Standards, consistently applied. 

7.3    Interest on Late Payments. If any payment due to DiCE under this Agreement is not paid when due, then
Sanofi shall pay interest thereon (before and after any judgment) at an annual rate equal to [*], such interest to run from the date on which payment of such sum became due until payment thereof in full together with such interest. The obligation to
pay interest for late payments shall not limit DiCE’s ability to seek any other remedy for any failure to timely pay any amount due to DiCE under this Agreement. 

7.4    Taxes. DiCE shall be solely responsible for paying any and all taxes, including value added tax
(“VAT”), levied on account of, or measured in whole or in part by reference to, the milestones, royalties and other amounts payable by Sanofi to DiCE pursuant to this Agreement (each, a “Payment”), except for any
withholding taxes required to be deducted from Payments and remitted by Sanofi by Applicable Law. Notwithstanding the foregoing, if DiCE is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, applicable
withholding tax, it may deliver to Sanofi or the appropriate governmental authority (with the assistance of Sanofi to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the
applicable rate of withholding or to relieve Sanofi of its obligation to withhold such tax and Sanofi shall apply the reduced rate 

  
 -32- 

 
of withholding or dispense with withholding, as the case may be. If, in accordance with the foregoing, Sanofi withholds any amount, it shall pay to DiCE the balance when due, make timely payment
to the proper taxing authority of the withheld amount and send to DiCE proof of such payment within [*] following such payment. 

7.5    Financial Records. Sanofi shall and shall cause its Affiliates and its and their (sub)licensees to,
keep complete and accurate financial books and records pertaining to Net Sales of Collaboration Products, in each case, to the extent required to calculate and verify all amounts payable hereunder. Each Party shall, and shall cause its Affiliates
and its and their (sub)licensees to, retain such books and records until [*] after the end of the period to which such books and records pertain. 

7.6    Audit Procedures. 

7.6.1    At the request of DiCE, Sanofi shall, and shall cause its Affiliates and its and their Sublicensees to,
permit an independent auditor designated by DiCE and reasonably acceptable to the audited Party, at reasonable times and upon reasonable notice, to audit the books and records maintained pursuant to Section 7.5 to ensure the accuracy of all
reports and payments made hereunder. 
 7.6.2    Such examinations for any entity may not (i) be conducted
for any Calendar Quarter more than [*] after the end of such quarter, (ii) be conducted more than [*] (unless a previous audit during such [*] revealed an underpayment (or with respect to any reimbursement, an overpayment) with respect to such
period) or (iii) be repeated for [*]. 
 7.6.3    Upon completion of the audit, the auditor shall provide a
report to both Parties, which report shall be limited to a description of any failure to comply with the terms of this Agreement and the amount of the financial discrepancy. 

7.6.4    The cost of this audit shall be borne by DiCE, unless the audit reveals an underpayment by or
over-reporting of applicable costs or an under-reporting of applicable revenues by the audited Party, in either case of more than [*] from the reported amounts for the period under audit, in which case Sanofi shall bear the cost of the audit.
Subject to the dispute resolution provisions set forth in Article 13, if such audit concludes that (a) Sanofi underpaid royalties, then Sanofi shall pay the additional amounts due, with interest from the date originally due as provided in
Section 7.3, (b) Sanofi overpaid royalties, then the amount of the overpayment shall be credited against any future royalties due to DiCE, with interest from the date originally due as provided in Section 3.1, in each case of a
payment due under this Section 7.6, within [*] after the date on which the audit report is delivered to the Parties. 

7.6.5    The receiving Party shall treat all information subject to review under this Article 7 in accordance
with the confidentiality provisions of Article 9 and the Parties shall cause the auditor to enter into a reasonably acceptable confidentiality agreement with Sanofi obligating such firm to retain all such financial information in confidence
pursuant to such confidentiality agreement. 

  
 -33- 

 7.7    Monetization. Sanofi acknowledges that DiCE may
wish to monetize the payment stream(s) it is entitled to receive under this Agreement with respect to any Collaboration Product with one or more Third Parties (each a “Monetization Entity”), and that DiCE shall have the right to do
so. In connection with any such monetization, DiCE shall have the right to disclose, under terms of confidentiality, to any Monetization Entity with respect to the applicable Collaboration Product: (i) the terms of this Agreement, and
(ii) the reports and records provided by Sanofi pursuant to Sections 5.4 and 6.5.4 with respect to the applicable Collaboration Products. In addition, DiCE may assign to any such Monetization Entity its rights with respect to one or more
Collaboration Products (i) to receive financial reports (as provided in Section 6.5.4), (ii) to receive payments (as provided in Section 6.7) with respect to the applicable Collaboration Products, (iii) to audit Sanofi’s
books with respect to the applicable Collaboration Products and records in each case, related to or the applicable milestone payments and/or royalty payments with respect to the applicable Collaboration Product, and (iv) commence legal
proceedings against Sanofi in the event of any failure by Sanofi to timely pay any amount due hereunder to recover such amount due (with interest) and damages (but not terminate this Agreement). Sanofi agrees to cooperate, at DiCE’s request, in
discussions with any potential or actual Monetization Entity and to use reasonable efforts to facilitate any such monetization transaction by DiCE. 

ARTICLE 8 
 INTELLECTUAL
PROPERTY 
 8.1    Ownership. 

8.1.1    Pre-existing Technology. Each Party shall retain ownership
and control of any intellectual property and materials Controlled by it (a) prior to the Effective Date, or (b) developed, made or otherwise acquired outside the scope of the Research Program. 

8.1.2    Ownership of Intellectual Property Made in Research Program. 

(i)    General. Except with respect to any developments relating to DPDCE Technology (which DiCE shall have no
obligation to disclose to Sanofi), should any new Invention arise from activities of either Party solely or both Parties jointly under this Agreement, regardless of whether such invention is patentable, each Party shall promptly provide the other
Party with a fully detailed description of such Invention so that both Parties can meet and consult with each other regarding such Invention. Subject to the licenses and other rights granted herein, as between the Parties, each Party shall own all
right, title and interest in and to any and all: (i) Information and Inventions that are conceived, discovered, developed or otherwise made by or on behalf of such Party or its Affiliates under or in connection with this Agreement, whether or
not patented or patentable, and (ii) Patents and other intellectual property rights with respect thereto. For clarity, Information, Inventions and related intellectual property rights developed by DiCE in connection with the Research program
shall not be treated as developed or otherwise made on behalf of Sanofi for purposes of the foregoing sentence. Notwithstanding the foregoing, (a) DiCE shall be the sole owner of any and all DPDCE Technology, regardless of which Party made,
conceived or reduced to practice such DPDCE Technology, made or otherwise developed in connection with the Research Program or thereafter, and (b) Sanofi shall be the sole owner of all right, title and interest in and to Collaboration Compounds
and Collaboration Products regardless of which party made, conceived or reduced to practice such Collaboration Compounds and Collaboration Products made or otherwise developed in connection with the Research Program or thereafter. 

  
 -34- 

 (ii)    Ownership of Joint Program Technology. Subject to the
licenses and other rights granted herein and the last sentence of Section 8.1.2(i), as between the Parties, the Parties shall each own an equal, undivided interest in any and all: (i) Information and Inventions that are conceived,
discovered, developed or otherwise made jointly by or on behalf of DiCE or its Affiliates, on the one hand and Sanofi or its Affiliates, on the other hand, under or in connection with this Agreement, whether or not patented or patentable (the
“Joint Program Know-How”); and (ii) Patents (the “Joint Program Patents”) and other intellectual property rights with respect to the Information and Inventions described
in clause (i) (together with Joint Program Know-How and Joint Program Patents, the “Joint Program Intellectual Property Rights”). Each Party shall promptly disclose to the other Party in
writing and shall cause its Affiliates, and its and their licensees and sublicensees to so disclose, the development, making, conception or reduction to practice of any Joint Intellectual Property Rights. Subject to the licenses and other rights
granted hereunder, except as otherwise prohibited hereunder, each Party shall have the right to Exploit the Joint Intellectual Property Rights without the consent of the other Party or a duty of accounting to the other Party. 

8.1.3    United States Law. The determination of whether any Information and Inventions are conceived,
discovered, developed or otherwise made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other intellectual property rights) as set forth in this Article 8, shall, for purposes of this Agreement, be made in
accordance with Applicable Law in the United States as such law exists as of the Effective Date irrespective of where or when such conception, discovery, development or making occurs. For clarity, inventorship and rights of ownership of all Patents
shall be determined in accordance with U.S. patent law. 
 8.1.4    Assignment; Assignment Obligation. To
the extent necessary to give effect to the terms of this Sections 8.1, each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, such right, title and interest in and
to any Information and Inventions, as well as any intellectual property rights with respect thereto, as is necessary to fully effect the allocation of ownership set forth in such Sections. Each Party shall cause all Persons who perform activities
for such Party under or in connection with this Agreement or who conceive, discover, develop or otherwise make any Information and Inventions by or on behalf of either Party or its Affiliates under or in connection with this Agreement to be under an
obligation to assign (or, if such Party is unable to cause such Person to agree to such assignment obligation despite such Party’s using commercially reasonable efforts to negotiate such assignment obligation, provide a license under) their
rights in any Information and Inventions resulting therefrom to such Party, except where Applicable Law requires otherwise and except in the case of governmental,
not-for-profit and public institutions that have standard policies against such an assignment (in which case a suitable license, or right to obtain such a license, shall
be obtained). 
 8.2    Maintenance and Prosecution of Patents. 

8.2.1    Patent Prosecution and Maintenance. 

  
 -35- 

 (i)    Sanofi Patents. Sanofi shall have the first right, but not
the obligation, using counsel of its own choice, to prepare, file, prosecute and maintain the Sanofi Patents worldwide in countries of its choice and to be responsible for any related interference,
re-issuance, re-examination and opposition proceedings. Sanofi shall be responsible for all costs and expenses incurred in connection with such prosecution and
maintenance of the Sanofi Patents. For clarity, Sanofi may file as Sanofi Patents, patent applications claiming: geniuses of Active Compounds and related Derivative Compounds, including any salt, hydrate, solvate, free acid form or free base form,
crystalline polymorph, amorphous form, racemic or optically active zwitterion form of an Active Compound. 

(ii)    DiCE Patents. DiCE shall have the first right, but not the obligation, using counsel of its own choice, to
prepare, file, prosecute and maintain the DiCE Patents and DPDCE Patents worldwide in countries of its choice, and to be responsible for any related interference, re-issuance,
re-examination and opposition proceedings. DiCE shall be responsible for all costs and expenses incurred in connection with such prosecution and maintenance of such Patents. 

(iii)    Joint Program Patents. As between the Parties, unless otherwise agreed in writing, Sanofi shall have the
first right, but not the obligation, using counsel reasonably acceptable to DiCE and retained by both Sanofi and DiCE, to prepare, file, prosecute and maintain the Joint Program Patents in agreed countries and to be responsible for any related
interference, re-issuance, re-examination and opposition proceedings. Subject to the following, each of DiCE and Sanofi shall be responsible for [*], of all reasonable out-of-pocket costs and expenses incurred in connection with such activities with regard to Joint Program Patents. With regard to any such expenses, DiCE shall reimburse
Sanofi on a Calendar Quarter basis to achieve the foregoing allocation of such costs and expenses with respect to the Joint Program Patents.  

(iv)    However, if either Party does not wish to seek patent protection with respect to any Joint Program Know How in a
particular country it shall notify the other Party hereto. If only one Party wishes to seek patent protection with respect to such Joint Invention in such country or countries, it may file, prosecute and maintain patent applications and patents with
respect thereto, at its own expense. 
 (v)    If at any time the Party responsible for the patent activities described
in this Section 8.2.1 (the “Responsible Party”) does not wish to file or wishes to discontinue the prosecution or maintenance of any patent application or patent within the Joint Program Patents filed in any country, on a country-by-country basis, it shall promptly give notice of such intention to the other Party. The latter shall have the right, but not the obligation, to assume responsibility
for the prosecution of any such Patents) in the applicable country, at its own expense, by giving notice to the Responsible Party of such intention within [*]. 

(vi)    Cooperation. The non-prosecuting Party shall, and shall cause its
Affiliates to, assist and cooperate with the prosecuting Party, as the prosecuting Party may reasonably request from time to time, in the preparation, filing, prosecution and maintenance of the DiCE Patents, Sanofi Patents and Joint Program Patents
in the Territory under this Agreement, including that the non-prosecuting Party shall, and shall ensure that its Affiliates, (i) offer its comments, if any, promptly, (ii) provide access to relevant
documents and other evidence and make its employees available at reasonable business hours and (iii) provide the prosecuting Party, upon its request, with copies of any patentability search reports generated by its patent counsel with respect
to the DiCE Patents, Sanofi Patents or Joint Program Patents, including relevant Third Party patents and patent applications (provided that neither Party 

  
 -36- 

 
shall be required to provide legally privileged information with respect to such intellectual property unless and until procedures reasonably acceptable to such Party are in place to protect such
privilege); provided, further, that (except with respect to the Joint Program Patents) the prosecuting Party shall reimburse the non-prosecuting Party for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith. 

8.2.2    Patent Term Extension and Supplementary Protection Certificate. As between the Parties, Sanofi
shall have the sole right to make decisions regarding, and to apply for, patent term extensions worldwide, including the United States with respect to extensions pursuant to 35 U.S.C. §156 et. seq. and in other jurisdictions pursuant to
supplementary protection certificates, and in all jurisdictions with respect to any other extensions that are now or become available in the future, wherever applicable, for the Sanofi Patents and any DiCE Patents, in each case including whether or
not to do so. DiCE shall provide prompt and reasonable assistance, as requested by Sanofi, including by taking such action as patent holder as is required under any Applicable Law to obtain such extension or supplementary protection certificate.

 8.2.3    Patent Listings. As between the Parties, Sanofi shall have the sole right to make all filings
with Regulatory Authorities in the Territory with respect to the Sanofi Patents and any DiCE Patents claiming any Collaboration Product, including as required or allowed (i) in the United States, in the FDA’s Orange Book and (ii) in
the European Union, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents. 

8.3    Enforcement of Patents. 

8.3.1    Notice. [*]. 

8.3.2    Enforcement of Joint Program Patents and DiCE Patents. [*]. 

8.3.3    Enforcement of Sanofi Patents. [*]. 

8.3.4    Cooperation. [*]. 

8.3.5    Recovery. [*]. 

8.4    Invalidity or Unenforceability Defenses or Actions. [*]. 

8.5    Infringement Claims by Third Parties. [*]. 

8.6    Third Party Rights. [*]. 

8.7    Trademarks and Domain Names. 

8.7.1    Product Trademarks. Sanofi shall have the sole right to select, register, prosecute, maintain and
enforce the Product Trademarks using counsel of its own choice. All costs and expenses of registering, prosecuting, maintaining and enforcing the Product Trademarks shall be borne solely by Sanofi. 

8.7.2    Domain Names. Sanofi may, in exercising its rights under the licenses granted to it hereunder,
register and use domain names used or intended for use in connection with the Commercialization of the Collaboration Compounds and Collaboration Products in the Field in the Territory (the “Domain Names”). As between the Parties,
the Domain Names shall be exclusively owned and operated by Sanofi, and Sanofi shall have the sole right to protect, maintain, enforce and defend the Domain Names, except as otherwise agreed by Sanofi in writing. 

  
 -37- 

 ARTICLE 9 

CONFIDENTIALITY AND NON-DISCLOSURE 

9.1    Confidentiality Obligations. At all times during the Term and for a period of [*] following
termination or expiration hereof in its entirety, each Party shall and shall cause its officers, directors, employees and agents to, keep confidential and not publish or otherwise disclose to a Third Party and not use, directly or indirectly, for
any purpose, any Confidential Information furnished or otherwise made known to it, directly or indirectly, by the other Party, except to the extent such disclosure or use is expressly permitted by the terms of this Agreement. “Confidential
Information” means any technical, business or other information provided by or on behalf of one Party to the other Party in connection with this Agreement, whether prior to, on or after the Effective Date, including the terms of this
Agreement, information relating to the Collaboration Compound or any Collaboration Product, any Development or Commercialization of the Collaboration Compound or any Collaboration Product, any know-how with
respect thereto developed by or on behalf of the disclosing Party or its Affiliates or, in the case of Sanofi, its or their Sublicensees (including Sanofi Know-How and DiCE
Know-How, as applicable) or the scientific, regulatory or business affairs or other activities of either Party. Notwithstanding the foregoing, Joint Know-How and the
terms of this Agreement shall be deemed to be the Confidential Information of both Parties (and both Parties shall be deemed to be the receiving Party and the disclosing Party with respect thereto). Notwithstanding the foregoing, the confidentiality
and non-use obligations under this Section 9.1 with respect to any Confidential Information shall not include any information that: 

9.1.1    is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like
through no breach of this Agreement by the receiving Party; 
 9.1.2    can be demonstrated by documentation or
other competent proof to have been in the receiving Party’s possession prior to disclosure by the disclosing Party without any obligation of confidentiality with respect to such information; provided that the foregoing exception shall
not apply with respect to Confidential Information constituting Joint Know-How or otherwise described in Section 9.1; 

9.1.3    is subsequently received by the receiving Party from a Third Party who is not bound by any obligation of
confidentiality with respect to such information; 
 9.1.4    has been published by a Third Party or otherwise
enters the public domain through no fault of the receiving Party in breach of this Agreement; or 
 9.1.5    can
be demonstrated by documentation or other competent evidence to have been independently developed by or for the receiving Party without reference to the disclosing Party’s Confidential Information. 

Specific aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of the receiving Party merely
because the Confidential Information is embraced by more general information in the public domain or in the possession of the receiving Party. Further, any combination of Confidential Information shall not be considered in the public domain or in
the possession of the receiving Party merely because 

  
 -38- 

 
individual elements of such Confidential Information are in the public domain or in the possession of the receiving Party unless the combination and its principles are in the public domain or in
the possession of the receiving Party. 
 9.2    Permitted Disclosures. Each Party may disclose
Confidential Information to the extent that such disclosure is made in response to a valid order of a court of competent jurisdiction or other supra-national, federal, national, regional, state, provincial or local governmental or regulatory body of
competent jurisdiction or if such disclosure is otherwise required by law, including in order to comply with applicable securities laws or regulations or the rules or regulations of any stock exchange on which securities of the Party making such
disclosure are traded; provided, however, that the receiving Party shall, if practicable, first have notified the disclosing Party of such requirement so that the disclosing Party may seek to quash such order or to obtain a protective
order or confidential treatment with respect to such disclosure; and provided, further, that the Confidential Information disclosed in response to such court or governmental order or other legal requirement shall be limited to that
information which is legally required to be disclosed in response to such court or governmental order. In addition, DiCE may disclose (i) to its investors, and (ii) to any actual or potential Monetization Entity, the information described
in Section 7.7. 
 9.3    Use of Name. Except as expressly provided herein, neither Party shall
mention or otherwise use the name, logo or Trademark of the other Party or any of its Affiliates or any of its or their Sublicensees (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional material or
other form of publicity without the prior written approval of such other Party in each instance. The restrictions imposed by this Section 9.3 shall not prohibit (i) Sanofi from making any disclosure identifying DiCE to the extent required
in connection with its exercise of its rights or obligations under this Agreement, (ii) either Party from making any disclosure identifying the other Party that is required by Applicable Law or the rules of a stock exchange on which the
securities of the disclosing Party are listed (or to which an application for listing has been submitted) or (iii) either Party from making any disclosure identifying the other Party that has then previously been made in accordance with the
terms of this Agreement provided that such disclosure remains accurate as of such time and provided the frequency and form of such disclosure are reasonable. Each Party shall be allowed to disclose in a patent application it prepares and
files pursuant to this Agreement the names of the Parties to this Agreement, or to amend a pending application it is prosecuting pursuant to this Agreement to state the names of the Parties to this Agreement. 

9.4    Public Announcements. Neither Party shall issue any public announcement, press release or other
public disclosure regarding this Agreement or its subject matter without the other Party’s prior written consent, except for any such disclosure that is required by Applicable Law or the rules of a stock exchange on which the securities of the
disclosing Party are listed (or to which an application for listing has been submitted). In the event a Party is required by Applicable Law or the rules of a stock exchange on which its securities are listed (or to which an application for listing
has been submitted) to make such a public disclosure, such Party shall submit the proposed disclosure in writing to the other Party as far in advance as reasonably practicable (and in no event less than [*] prior to the anticipated date of
disclosure) so as to provide a reasonable opportunity to comment thereon. Notwithstanding the foregoing, Sanofi and its Affiliates and its and their Sublicensees shall have the right to publicly disclose research,

  
 -39- 

 
development and commercial information (including with respect to regulatory matters) regarding the Collaboration Compound and Collaboration Products; provided such disclosure is subject
to the provisions of Article 9 with respect to DiCE’s Confidential Information. Neither Party shall be required to seek the permission of the other Party to repeat any information regarding the terms of this Agreement or any amendment hereto
that has already been publicly disclosed by such Party or by the other Party, in accordance with this Section 9.4, provided that such information remains accurate as of such time and provided the frequency and form of such disclosure are
reasonable. 
 9.5    Publications. 

9.5.1    The Parties recognize the desirability of publishing and publicly disclosing the results of and
information regarding, activities under this Agreement. Accordingly, Sanofi shall be free to publicly disclose the results of and information regarding, activities under this Agreement, subject to prior review by DiCE of any disclosure of DiCE
Confidential Information for issues of patentability and protection of such Confidential Information, in a manner consistent with Applicable Law and industry practices, as provided in this Section 9.5. Accordingly, prior to publishing or
disclosing any DiCE Confidential Information relating to any Sanofi Target, Sanofi shall provide DiCE with drafts of proposed abstracts, manuscripts or summaries of presentations that cover such Confidential Information. DiCE shall respond promptly
through its designated representative and in any event no later than [*] after receipt of such proposed publication or presentation or such shorter period as may be required by the publication or presentation. Sanofi agrees to allow a reasonable
period (not to exceed [*]) to permit filings for patent protection and to otherwise address issues of Confidential Information or related competitive harm to the reasonable satisfaction of DiCE. 

9.5.2    Except as expressly permitted by this Agreement, DiCE shall not and shall cause each of its Affiliates and
its and their licensees and sublicensees not to, make any publications or public disclosures regarding Collaboration Compounds or Collaboration Products or any Confidential Information of Sanofi without Sanofi’s prior written consent; provided,
DiCE may further disclose, without Sanofi consent, any information that Sanofi or its designees has previously publically disclosed. For clarity, DiCE may also make the disclosures described in Section 2.11. 

9.6    Return of Confidential Information. Upon the effective date of the termination of this Agreement for
any reason, either Party may request in writing and the non-requesting Party shall either (at the non-requesting Party’s election), with respect to Confidential
Information to which such non-requesting Party does not retain rights under the surviving provisions of this Agreement: (i) promptly destroy all copies of such Confidential Information in the possession
or control of the non-requesting Party and confirm such destruction in writing to the requesting Party; or (ii) promptly deliver to the requesting Party all copies of such Confidential Information in the
possession or control of the non-requesting Party. Notwithstanding the foregoing, the non-requesting Party shall be permitted to retain such Confidential Information
(x) to the extent necessary or useful for purposes of performing any continuing obligations or exercising any ongoing rights hereunder and, in any event, a single copy of such Confidential Information for archival purposes and (y) any
computer records or files containing such Confidential Information that have been created solely by such non-requesting Party’s automatic archiving and back-up
procedures, to the extent created and 

  
 -40- 

 
retained in a manner consistent with such non-requesting Party’s standard archiving and back-up procedures,
but not for any other uses or purposes. All Confidential Information shall continue to be subject to the terms of this Agreement for the period set forth in Section 9.1. 

9.7    Privileged Communications. [*]. 

ARTICLE 10 
 REPRESENTATIONS
AND WARRANTIES 
 10.1    Mutual Representations and Warranties. DiCE and Sanofi each represents and
warrants to the other, as of the Effective Date, that: 
 10.1.1    It is a corporation duly organized, validly
existing and in good standing under the laws of the jurisdiction of its organization and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement; 

10.1.2    The execution and delivery of this Agreement and the performance by it of the transactions contemplated
hereby have been duly authorized by all necessary corporate action and do not violate: (i) such Party’s charter documents, bylaws or other organizational documents; (ii) in any material respect, any agreement, instrument or
contractual obligation to which such Party is bound; (iii) any requirement of any Applicable Law; or (iv) any order, writ, judgment, injunction, decree, determination or award of any court or governmental agency presently in effect
applicable to such Party; 
 10.1.3    This Agreement is a legal, valid and binding obligation of such Party
enforceable against it in accordance with its terms and conditions, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of
specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity); and 

10.1.4    It is not under any obligation, contractual or otherwise, to any Person that conflicts with or is
inconsistent in any material respect with the terms of this Agreement or that would impede the diligent and complete fulfillment of its obligations hereunder. 

10.2    Additional Representations and Warranties of DiCE. DiCE further represents, warrants and covenants
to Sanofi, as of the Effective Date, as follows: 
 10.2.1    It has not previously granted, and during the
Agreement Term shall not knowingly make any commitment or grant any rights which are inconsistent in any material way with the rights and licenses granted herein, in each case other than non-exclusive licenses
granted to Third Party services providers to enable such services providers to perform the services for which they were contracted by DiCE or its Affiliates; 

10.2.2    To DiCE’s knowledge, there are no existing or threatened actions, suits or claims pending against it
with respect to the DPDCE Technology; 
 10.2.3    To DiCE’s knowledge, the practice by DiCE of the DPDCE
Technology in the Research Program shall not infringe any intellectual property rights of Third Parties. 

  
 -41- 

 10.2.4    To DiCE’s knowledge, no claim or litigation has
been brought or asserted by any Person alleging that (i) the DPDCE Patents are invalid or unenforceable or (ii) the conception, development, reduction to practice, disclosing, copying, making, assigning or licensing of the DPDCE Patents,
the DPDCE Patents or the DiCE Know-How existing as of the Effective Date as contemplated herein, violates, infringes, constitutes misappropriation or otherwise conflicts or interferes with or would violate,
infringe or otherwise conflict or interfere with, any intellectual property or proprietary right of any Person; 

10.2.5    There are no license or other agreements with Third Parties regarding any intellectual property rights
licensed by DiCE to Sanofi hereunder to which DiCE is a party, except the Stanford License; 
 10.2.6    Neither
DiCE nor any of its Affiliates has previously entered into any agreement, whether written or oral, assigning, transferring, licensing, conveying to a Third Party or otherwise encumbering its right, title or interest in or to the DPDCE Patents or the
DiCE Know-How (including by granting any covenant not to sue with respect thereto) or any Patent or other intellectual property or proprietary right or Information and Inventions that would be DPDCE Patents,
but for such assignment, transfer, license, conveyance or encumbrance; 
 10.2.7    DiCE has obtained from its
Affiliates the licenses and other rights necessary for DiCE to grant to Sanofi the rights and licenses provided herein and for Sanofi to perform its obligations hereunder; 

10.2.8    To DiCE’s knowledge, each of the DPDCE Patents properly identifies each and every inventor of the
claims thereof as determined in accordance with the laws of the jurisdiction in which such Existing Patent is issued or such application is pending; 

10.2.9    Each Person who has or has had any rights in or to any DPDCE Patents or any DiCE Know-How, has assigned and has executed an agreement assigning its entire right, title and interest in and to such Patents and DiCE Know-How to DiCE. All officers, employees,
agents and consultants of DiCE or any of its Affiliates who are inventors of or have otherwise contributed in a material manner to the creation or development of any Existing Patent or DiCE Know-How or who are
or shall be performing DiCE’s Development activities hereunder or who otherwise have access to any Confidential Information and Inventions of Sanofi (the “Inventor Personnel”), (i) in the case of current or former Inventor
Personnel, have executed and delivered and (ii) in the case of future Inventor Personnel, shall execute and deliver, to DiCE or such Affiliate an assignment or other agreement regarding the protection of proprietary information and the
assignment to DiCE or such Affiliate of any DiCE Patents, DiCE Know-How and any and all other Information and Inventions that relate to the Collaboration Compound or Collaboration Products, the current form of
which has been made available for review by Sanofi. 
 10.2.10    To DiCE’s knowledge, no current officer,
employee, agent or consultant of DiCE or any of its Affiliates is in violation of any term of any assignment or other agreement regarding the protection of Patents or other intellectual property or proprietary information of DiCE or such Affiliate
or of any employment contract or any other contractual obligation relating to the relationship of any such Person with DiCE; 

  
 -42- 

 10.2.11    All material works of authorship and all other
material materials subject to copyright protection included in DiCE Know-How are original and were either created by employees of DiCE or its Affiliates within the scope of their employment or are otherwise
works made for hire and all right, title and interest in and to such materials have been legally and fully assigned and transferred to DiCE or such Affiliate; 

10.2.12    To DiCE’s knowledge, the DiCE Know-How that DiCE has
determined, in the exercise of reasonable business discretion, to maintain as confidential, has been kept confidential or has been disclosed to Third Parties only under terms of confidentiality; 

10.2.13    The representations and warranties of DiCE in this Agreement and the information, documents and
materials furnished to Sanofi in connection with its period of diligence prior to the Effective Date, do not, taken as a whole, (i) contain any untrue statement of a material fact or (ii) omit to state any material fact necessary to make
the statements or facts contained therein, in light of the circumstances under which they were made, not misleading; 

10.2.14    DiCE has provided to Sanofi a copy of the Stanford License Agreement, and the Stanford License Agreement
is in full force and effect and has not been modified or amended; 
 10.2.15    Neither DiCE nor, to the
knowledge of DiCE, Stanford is in default with respect to any material obligation under, and neither such party has claimed or has grounds upon which to claim that the other party is in default with respect to any material obligation under, the
Stanford License Agreement; and 
 10.2.16    DiCE has not waived or allowed to lapse any of its material rights
under the Stanford License Agreement, and no such rights have lapsed or otherwise expired or been terminated; 

10.3    Additional Covenants of DiCE. DiCE hereby covenants, as of the Effective Date, as follows: 

10.3.1    During the period from the Effective Date through the end of the Agreement Term, DiCE shall obtain from
each of its Affiliates, sublicensees (other than Sublicensees), employees and agents, and from the employees and agents of its Affiliates, and agents, who have access to any Confidential Information of Sanofi, rights to any and all Information and
Inventions that relate to the Collaboration Compound or Collaboration Products and are generated pursuant to and during the time of such Person’s relationship with DiCE or its Affiliate, such that Sanofi shall, by virtue of this Agreement,
receive from DiCE, without payments beyond those required by this Agreement, the licenses and other rights granted to Sanofi hereunder (and such that the scope of such licenses and other rights are not limited in scope or exclusivity by a failure to
so obtain such rights from such Persons); 
 10.3.2    No transfer of property is being made and no obligation is
being incurred in connection with the transactions contemplated by this Agreement with the intent to hinder, delay or defraud any of DiCE’s current or future creditors. DiCE agrees that it shall not take or cause to be taken or omit to take any
action that could reasonably be expected to result in a determination 

  
 -43- 

 
pursuant to Applicable Law that any aspect of this transaction may be deemed a “fraudulent conveyance” or otherwise subject to claims of certain creditors of DiCE or any of its
Affiliates, or their respective trustees in any bankruptcy proceedings; 
 10.3.3    DiCE shall fulfill all of
its obligations under the Stanford License Agreement (including, without limitation, the payment of all amounts appropriately due thereunder) unless such failure is due to acts or omissions by Sanofi or its Affiliates or Sublicensees; 

10.3.4    DiCE shall not enter into any subsequent agreement with Stanford that modifies or amends the Stanford
License Agreement in any way that could adversely affect Sanofi’s rights in any material respect under this Agreement without Sanofi’s prior written consent, and DiCE shall provide Sanofi with a copy of all modifications to or amendments
of the Stanford License Agreement, regardless of whether Sanofi’s consent was required with respect (which may be redacted to remove any financial terms before provision to Sanofi); 

10.3.5    DiCE shall not terminate, nor take or fail to take any action that could reasonably be expected to
terminate, the Stanford License Agreement in whole or in part, directly or indirectly, without conferring first with Sanofi; 

10.3.6    DiCE shall promptly furnish Sanofi with copies of the portions of all written reports that DiCE furnishes
to Stanford with respect to any Collaboration Products(which reports DiCE may redact to remove information unrelated to Collaboration Products), which written reports shall be the Confidential Information of DiCE; and 

10.3.7    DiCE shall furnish Sanofi with copies of all written notices received by DiCE relating to any alleged
bona fide breach or default of any obligation by DiCE under the Stanford License Agreement within five (5) business days after DiCE’s receipt thereof and, if DiCE cannot or chooses not to cure or otherwise resolve any such alleged breach
or default and such alleged breach or default could reasonably be expected to give rise to Stanford exercising its rights to terminate he License Agreement, DiCE shall, to the extent Sanofi is capable of curing or otherwise resolving any such
alleged breach or default, allow Sanofi, in Sanofi’s sole discretion, to cure or otherwise resolve such alleged breach or default. 

10.4    Disclaimer of Warranties. 

10.4.1    Success of Research Program. Sanofi and DiCE specifically disclaim any representation or warranty
or guarantee that the Research Program shall be successful, in whole or in part. The failure of the Parties to successfully develop Collaboration Compounds or Collaboration Products with respect to any Sanofi Target shall not constitute a breach of
any representation or warranty or other obligation under this Agreement. 
 10.4.2    General. EXCEPT FOR
THE EXPRESS WARRANTIES SET FORTH IN SECTION 10.3, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE AND EACH PARTY SPECIFICALLY DISCLAIMS ANY
OTHER WARRANTIES, WHETHER WRITTEN OR ORAL OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A 

  
 -44- 

 
PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

 10.4.3    No Other Representations. Each Party confirms that it is not relying on any representations
or warranties of the other Party except as specifically set forth in this Agreement. 
 10.5    Anti-Bribery
and Anti-Corruption Compliance. With respect to the Exploitation of Collaboration Products, Sanofi represents and warrants to DiCE, as of the Effective Date, and covenants, as follows: 

10.5.1    It is licensed, registered, or qualified under Applicable Law to do business, and has obtained such
licenses, consents or authorizations or completed such registrations or made such notifications as may be necessary or required by Applicable Law; 

10.5.2    It has not taken and shall not, as of the Effective Date or at any time during the Term, take any action
directly or indirectly to offer, promise or pay, or authorize the offer or payment of, any money or anything of value in order to improperly or corruptly seek to influence any Government Official or any other person in order to gain an improper
advantage, and has not accepted, and shall not accept in the future such payment; 
 10.5.3    It complies with
Applicable Law where it operates, including Anti-Corruption Laws, accounting and record keeping laws, and laws relating to interactions with healthcare professionals or healthcare providers and Government Officials; and 

10.5.4    it is, as between the Parties, solely responsible to ensure it and its Affiliates compliance, in all
material respects, with all Applicable Laws. 
 10.6    Knowledge. As used in this Article 10,
“knowledge” shall mean actual knowledge after making reasonable inquiry and after exercising reasonable diligence. 
 ARTICLE 11

 INDEMNITY 

11.1    Indemnification of DiCE. Sanofi shall indemnify DiCE, its Affiliates and its and their respective
directors, officers, employees and agents and the Stanford Indemnitees, and defend and save each of them harmless, from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses)
(collectively, “Losses”) in connection with any and all suits, investigations, claims or demands of Third Parties (collectively, “Third Party Claims”) arising from or occurring as a result of: (i) the breach by
Sanofi of this Agreement; (ii) the gross negligence or willful misconduct on the part of Sanofi or its Affiliates or its or their respective directors, officers, employees or agents in performing its or their obligations under this Agreement;
(iii) any Third Party claims relating to the use or screening of any Sanofi Target in the Research Program, or [*]. In the event that any Losses arise from (A) on the one hand, acts or omissions described in clauses (i) and/or
(ii) of this Section 11.1 and (B) on the other hand, acts or omissions described in clauses (i) and/or (ii) of Section 

  
 -45- 

 
11.2, each Party shall indemnify the other on a comparative fault basis to the extent its acts or omissions gave rise to such liability. As used in this Section 11.1, Stanford Indemnitees
means Stanford and Stanford Hospitals and Clinics, and their respective trustees, officers, employees, students, agents, faculty, representatives and volunteers. 

11.2    Indemnification of Sanofi. DiCE shall indemnify Sanofi, and its Affiliates, Sublicensees and
Distributors and its and their respective directors, officers, employees and agents and defend and save each of them harmless, from and against any and all Losses in connection with any and all Third Party Claims arising from or occurring as a
result of: (i) the breach by DiCE of this Agreement; (ii) the gross negligence or willful misconduct on the part of DiCE or its Affiliates or its or their respective directors, officers, employees or agents in performing its obligations
under this Agreement; (iii) any Third Party claims relating to the use of any DPDCE Technology in the Research Program, or (iv) the Exploitation by DiCE or any of its Affiliates of any Terminated Products anywhere in the world at any time.
In the event that any Losses arise from (A) on the one hand, acts or omissions described in clauses (i) and/or (ii) of this Section 11.2 and (B) on the other hand, acts or omissions described in clauses (i) and/or
(ii) of Section 11.1, each Party shall indemnify the other on a comparative fault basis to the extent its acts or omissions gave rise to such liability. 

11.3    Indemnification Procedures. 

11.3.1    Notice of Claim. All indemnification claims in respect of a Party, its Affiliates and, in the case
of Sanofi, its or their Sublicensees and Distributors or its or their respective directors, officers, employees and agents shall be made solely by such Party to this Agreement (the “Indemnified Party”). The Indemnified Party shall
give the indemnifying Party prompt written notice (an “Indemnification Claim Notice”) of any Losses or discovery of fact upon which such indemnified Party intends to base a request for indemnification under this Article 11, but in
no event shall the indemnifying Party be liable for any Losses that result from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that
the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party Claims. 

11.3.2    Control of Defense. At its option, the indemnifying Party may assume the defense of any Third
Party Claim by giving written notice to the Indemnified Party within [*] after the indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of a Third Party Claim by the indemnifying Party shall not be
construed as an acknowledgment that the indemnifying Party is liable to indemnify the Indemnified Party in respect of the Third Party Claim, nor shall it constitute a waiver by the indemnifying Party of any defenses it may assert against the
Indemnified Party’s claim for indemnification. Upon assuming the defense of a Third Party Claim, the indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the indemnifying Party. In
the event the indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party shall immediately deliver to the indemnifying Party all original notices and documents (including court papers) received by the Indemnified Party in
connection with the Third Party Claim. Should the indemnifying Party assume the defense of a Third Party Claim, except as provided in 

  
 -46- 

 
Section 11.3.3, the indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis,
defense or settlement of the Third Party Claim unless specifically requested in writing by the indemnifying Party. In the event that it is ultimately determined that the indemnifying Party is not obligated to indemnify, defend or hold harmless the
Indemnified Party from and against the Third Party Claim, the Indemnified Party shall reimburse the indemnifying Party for any and all costs and expenses (including attorneys’ fees and costs of suit) and any Losses incurred by the indemnifying
Party in its defense of the Third Party Claim. 
 11.3.3    Right to Participate in Defense. Any
Indemnified Party shall be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the Indemnified
Party’s sole cost and expense unless (i) the employment thereof has been specifically authorized in writing by the indemnifying Party in writing, (ii) the indemnifying Party has failed to assume the defense and employ counsel in
accordance with Section 11.3.2 (in which case the Indemnified Party shall control the defense) or (iii) the interests of the indemnitee and the indemnifying Party with respect to such Third Party Claim are sufficiently adverse to prohibit
the representation by the same counsel of both Parties under Applicable Law, ethical rules or equitable principles. 

11.3.4    Settlement. With respect to any Losses relating solely to the payment of money damages in
connection with a Third Party Claim and that shall not result in the applicable indemnitee’s becoming subject to injunctive or other relief and as to which the indemnifying Party shall have acknowledged in writing the obligation to indemnify
the applicable indemnitee hereunder, the indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its sole
discretion, shall deem appropriate. With respect to all other Losses in connection with Third Party Claims, where the indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 11.3.2, the indemnifying Party
shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss; provided it obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably
withheld, conditioned or delayed). If the indemnifying Party does not assume and conduct the defense of a Third Party Claim as provided above, the Indemnified Party may defend against such Third Party Claim; provided that the Indemnified
Party shall not settle any Third Party Claim without the prior written consent of the indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed). 

11.3.5    Cooperation. Regardless of whether the indemnifying Party chooses to defend or prosecute any Third
Party Claim, the Indemnified Party shall and shall cause each indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery
proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the indemnifying Party to, and reasonable retention by the Indemnified
Party of, records and information that are reasonably relevant to such Third Party Claim and making Indemnified Parties and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any
material provided hereunder and the indemnifying Party shall reimburse the Indemnified Party for all its reasonable and verifiable out-of-pocket expenses in connection
therewith. 

  
 -47- 

 11.3.6    Expenses. Except as provided above, the costs
and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any claim shall be reimbursed on a Calendar Quarter basis by the indemnifying Party, without prejudice to the indemnifying Party’s
right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 

11.4    Special, Indirect and Other Losses. EXCEPT (I) IN THE EVENT OF THE WILLFUL MISCONDUCT OR FRAUD
OF A PARTY OR A PARTY’S BREACH OF ITS OBLIGATIONS UNDER ARTICLE 9 AND (II) TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 11, NEITHER
PARTY NOR ANY OF ITS AFFILIATES OR SUBLICENSEES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY CONSEQUENTIAL, INDIRECT, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES OR FOR LOSS OF PROFITS SUFFERED BY THE
OTHER PARTY. 
 11.5    Insurance. DiCE shall have and maintain for so long as DiCE is conducting
activities under the Research Program insurance covering its activities conducted in the Research Program. Sanofi shall have and maintain such types and amounts of insurance covering its Exploitation of the Collaboration Compounds and Collaboration
Products as is (i) normal and customary in the pharmaceutical industry generally for parties similarly situated and (ii) otherwise required by Applicable Law. Upon request by the other Party, each Party shall provide to the other Party
evidence of its insurance coverage. The Sanofi insurance policies shall be under an occurrence form, but if only a claims-made form is available, then Sanofi shall continue to maintain such insurance after the expiration or termination of this
Agreement for a period of [*]. Notwithstanding the foregoing, Sanofi may self-insure in whole or in part the insurance requirements described above. 

ARTICLE 12 
 TERM AND
TERMINATION 
 12.1    Term and Expiration. 

12.1.1    The term of this Agreement shall become effective as of the Effective Date and, unless earlier terminated
in accordance herewith, shall continue in force and effect until the later of the date of expiration of the last Royalty Term for the last Collaboration Product (such period, the “Agreement Term”). 

12.1.2    Following the expiration of the Royalty Term for a Collaboration Product in a particular country or
region (but not on any earlier termination thereof), the grants in Section 4.2 shall become exclusive, fully-paid, royalty-free, perpetual and irrevocable for such Collaboration Product in such country or region. 

  
 -48- 

 12.2    Termination by Either Party. Each Party shall have
the right to terminate this Agreement, upon notice to the other Party, in the event that: 
 12.2.1    The other
Party shall have: (i) voluntarily commenced any proceeding or filed any petition seeking relief under the bankruptcy, insolvency or other similar laws of any jurisdiction, (ii) applied for, or consented to, the appointment of a receiver,
trustee, custodian, sequestrator, conciliator, administrator or similar official for it or for all or substantially all of its property, (iii) filed an answer admitting the material allegations of a petition filed against or in respect of it in
any such proceeding, (iv) made a general assignment for the benefit of creditors of all or substantially all of its assets, (v) admitted in writing its inability to pay all or substantially all of its debts as they become due, or
(vi) taken corporate action for the purpose of effecting any of the foregoing; or 
 12.2.2    An
involuntary proceeding shall have been commenced, or any involuntary petition shall have been filed, in a court of competent jurisdiction seeking: (i) relief in respect of the other Party, or of its property, under the bankruptcy, insolvency or
similar laws of any jurisdiction, (ii) the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for such other Party or for all or substantially all of its property, or (iii) the winding-up or liquidation of such other Party; and, in each case, such proceeding or petition shall have continued undismissed for [*], or an order or decree approving or ordering any of the foregoing shall have
continued unstayed, unappealed and in effect for [*]. 
 12.3    Termination by Sanofi. 

12.3.1    For Breach of Material Obligations. Sanofi shall have the right to terminate this Agreement in its
entirety, upon notice to DiCE, in the event that DiCE defaults with respect to any of its material obligations under this Agreement and does not cure such default within [*] after the receipt of a notice from Sanofi specifying the nature of, and
requiring the remedy of, such default (or, if such default cannot be cured within such [*], if DiCE does not commence and diligently continue actions to cure same during such [*] period). Any termination pursuant to this Section 12.3.1 shall be
without prejudice to any of Sanofi’s other rights under this Agreement, and in addition to any other remedies available to it at law or in equity. 

12.3.2    Without Cause. Notwithstanding any other provision of this Agreement, Sanofi shall have the right
to terminate this Agreement in its entirety without cause during the Research Program Term by providing prior written notice to DiCE, which termination shall be effective upon the date that is [*] after the delivery of Sanofi’s notice of
termination; provided that Sanofi may not terminate this Agreement under this Section 12.3.2 prior to [*]. The Parties shall continue to have all rights and obligations under this Agreement until the termination is effective.
Without limiting the generality of the foregoing, if Sanofi delivers a notice of termination pursuant to this Section 12.3.2 on or after [*]. In addition, following the end of the Research Program Term, Sanofi may terminate this Agreement at
any time with [*] prior notice to DiCE. 
 12.3.3    Partial Termination. Sanofi may terminate this
Agreement with respect to a particular Sanofi Target (a “Terminated Target”), or Collaboration Product (a “Terminated Product”), or a particular country (a “Terminated Territory”) but not the
Agreement in its entirety with [*] written notice to DiCE. Following any such termination the provisions of this Agreement 

  
 -49- 

 
shall remain in effect with respect to the Terminated Territory, Terminated Target, or the Terminated Product(s) (to the extent they would survive and apply in the event the Agreement expires or
is terminated in its entirety) and all provisions not surviving in accordance with the foregoing shall terminate upon termination of this Agreement with respect to the Terminated Territory, Terminated Target, or Terminated Product and be of no
further force and effect (and for the avoidance of doubt all provisions of this Agreement shall remain in effect with respect to all countries in the Territory, all Sanofi Targets, and all Collaboration Products other than the Terminated Territory,
Terminated Targets and Terminated Products). 
 12.4    Termination by DiCE. DiCE shall have the right to
terminate this Agreement, upon notice to Sanofi, in the event that Sanofi defaults with respect to any of its obligations under this Agreement and does not cure such default within [*] after the receipt of a notice from DiCE specifying the nature
of, and requiring the remedy of, such default (or, if such default cannot be cured within such [*] period, if Sanofi does not commence and diligently continue actions to cure the same during such cure period; provided, however, the cure
period for any failure to pay any amount due under this Agreement shall be [*] rather than [*]. However, if any such default is limited to Sanofi’s obligations with respect to a particular Collaboration Product and/or a particular country in
the Territory, then any termination of this Agreement by DiCE pursuant to this Section 12.4 due to such default shall be limited to Sanofi’s rights under this Agreement with respect to such Collaboration Product and/or country and all of
Sanofi’s other rights and licenses hereunder shall survive such termination. Any termination pursuant to this Section 12.4 shall be without prejudice to any of DiCE’s other rights under this Agreement, and in addition to any other
remedies available to it by law or in equity. 
 12.5    Effect of Termination by Sanofi. 

12.5.1    Program Transfer. Upon a termination of this Agreement under Section 12.3.2 or 12.3.3 or 12.4
by DiCE, Sanofi shall, at Sanofi’s expense, and for the consideration set forth in Section 12.5.2: 

(i)    Transfer to DiCE [*] including, without limitation, [*], and execute all documents, reasonably necessary or
desirable to transfer any CTAs, INDs, BLAs, and other regulatory, in each case, solely to the extent related to the Terminated Products with respect to the Terminated Countries [*]; 

(ii)    [*] 

(iii)    To the extent Sanofi Controls any right, title and interest in any Product Trademarks under which any Terminated
Product has been or is being marketed or sold in the Territory or in the countries, Sanofi shall assign the same to DiCE. 

12.5.2    The foregoing provisions shall collectively be, the “Program Transfer”. 

12.5.3    Consideration. As consideration for any Program Transfer, DiCE shall pay Sanofi the following
amounts with regard to the applicable Collaboration Compound(s) and/or Collaboration Product(s) that become Terminated Products: 

  
 -50- 

 (i)    [*]. 

(ii)    [*]. 

12.5.4    Payments. Payment and reports of any amounts due under Section 12.5.2 shall be due and
payable by DiCE to Sanofi quarterly within [*] after the end of each Calendar Quarter in which such Net Sales reports are received by DiCE. In such case, defined terms which contemplate sales of Collaboration Products by Sanofi or its Affiliates or
Sublicensees, including without limitation, Section 5.3(c), Section 5.3(e) and Section 5.4 shall be interpreted for the purpose of this Section 12.5.3 to apply to sales of Terminated Products by DiCE, its Affiliates or
Sublicensees, mutatis mutandis. 
 12.6    Other Consequences. Upon termination of this Agreement,
all Sanofi Targets shall concurrently cease to be Sanofi Targets and DiCE shall be free to conduct research and development on any such Sanofi Targets, alone or with one or more Third Parties, as it deems appropriate, without any obligation to
Sanofi [*]. 
 12.7    Right to Sell Stock on Hand. Provided that Sanofi is not in material breach of any
obligation under this Agreement at the time of any termination of this Agreement, in whole or in part, Sanofi shall have the right for [*] thereafter to dispose of all Collaboration Product(s) then in its inventory and to complete manufacture of and
dispose of any work-in-progress then being manufactured, as though this Agreement had not terminated. Sanofi shall pay royalties thereon, in accordance with the
provisions of this Agreement, as though this Agreement had not terminated. 
 12.8    Accrued Rights, Surviving
Obligations. 
 12.8.1    Remedies. Except as otherwise expressly provided herein, termination of this
Agreement (either in its entirety or with respect to one or more country(ies)) in accordance with the provisions hereof shall not limit remedies that may otherwise be available in law or equity. 

12.8.2    Accrued Rights. Termination, relinquishment or expiration of this Agreement for any reason shall
be without prejudice to any rights which shall have accrued to the benefit of either Party prior to such termination, relinquishment or expiration. Such termination, relinquishment or expiration shall not relieve either Party from obligations which
are expressly indicated to survive termination or expiration of this Agreement. 
 12.8.3    Continuing
Obligations. Termination, relinquishment or expiration of this Agreement shall not terminate each Party’s obligation to pay all royalties, milestone payments and other monetary obligations that may have accrued hereunder prior to such
termination, and to provide reports as provided in Section 6.5.4. All of the Parties’ rights and obligations under Sections 2.3.6, 2.3.7, 2.7, 4.5, 5.7, 7.5, 7.6, 8.1, 8.2, 8.3, 8.4, 8.5 and 12.5 (in each instance, solely with respect to
any Patents issued or pending at such time), and Articles 9,11, 13 and 14 shall survive termination or expiration hereof. 

12.9    Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by Sanofi
or DiCE are and shall otherwise be deemed to be, for purposes of Section 

  
 -51- 

 
365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, licenses of right to “intellectual property” as defined under Section 101 of
the U.S. Bankruptcy Code. The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any
other country or jurisdiction. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction,
the Party hereto that is not a Party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in
the non-subject Party’s possession, shall be promptly delivered to it (i) upon any such commencement of a bankruptcy proceeding upon the non-subject
Party’s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under this Agreement or (ii) if not delivered under clause (i) above, following the rejection of this
Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party. 

ARTICLE 13 
 DISPUTE
RESOLUTION 
 13.1    Subject to Section 13.4, if a dispute arises between the Parties in connection with or
relating to this Agreement (a “Dispute”), then either Party shall have the right, upon notice to the other Party, to refer such Dispute to the Senior Executives for attempted resolution by good faith negotiations during the period
of [*] following the date of such referral. Any final decision mutually agreed to by the Senior Executives shall be conclusive and binding on the Parties. With respect to any unresolved Dispute as to a matter outside the jurisdiction or authority of
the JSC, either Party shall be free to institute binding arbitration in accordance with Section 13.2 upon written notice to the other Party (an “Arbitration Notice”) and seek such remedies as may be available. Notwithstanding
anything in this Agreement to the contrary, either Party shall be entitled to institute litigation in accordance with Section 13.3 or 13.5 immediately if litigation is necessary to prevent irreparable harm to that Party. For clarity, any
Dispute regarding the addition or substitution of a Sanofi Target shall be resolved by unanimous agreement of the JSC, or if the JSC is unable to reach unanimous agreement, then as provided in Section 3.3.6, the result shall be that no decision
of the JSC is reached and such deadlock of the JSC shall not be subject to further review under this Article 13. 

13.2    Upon receipt of an Arbitration Notice by a Party, the applicable Dispute shall be resolved by final and
binding arbitration before one (a) arbitrator who shall be a former judge of a court of federal jurisdiction (the “Arbitrator”). The Arbitrator shall be chosen promptly by mutual agreement of the Parties or the Chief Executive
of the San Francisco office of JAMS. The arbitration shall be administered by JAMS (or any successor entity thereto) in accordance with the then current Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited Procedures
contained therein (collectively, the “Rules”), except in the event of a conflict between the Rules and this Section 13.2, this Section 13.2 shall control (including with regard to any limitations of liability or forms of
relief). The arbitration shall be conducted in English and held in San Francisco, California. The Arbitrator shall, within [*] after the conclusion of the arbitration hearing, issue a written award and statement of decision describing the essential
findings and conclusions on which the award is based, including the calculation of 

  
 -52- 

 
any damages awarded. The decision or award rendered by the Arbitrator shall be final and non-appealable, and judgment may be entered upon it in accordance
with Applicable Law in the State of New York or any other court of competent jurisdiction. The Arbitrator shall be authorized to award compensatory damages, but shall not be authorized to reform, modify or materially change this Agreement. Each
Party shall bear its own counsel fees, costs, and disbursements arising out of the arbitration described in this Section 13.2, and shall pay an equal share of the fees and costs of the Arbitrator and all other general fees related to the
arbitration; provided, however, the Arbitrator shall be authorized to determine whether a Party is the prevailing Party, and if so, to award to that prevailing Party reimbursement for its reasonable counsel fees, costs and disbursements
(including expert witness fees and expenses, photocopy charges, or travel expenses), or the fees and costs of the Arbitrator. Unless the Parties otherwise agree in writing, during the period of time that any arbitration proceeding is pending under
this Agreement, the Parties shall continue to comply with all those terms and provisions of this Agreement that are not the subject of the pending arbitration proceeding. Nothing contained in this Agreement shall deny any Party the right to seek
injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing arbitration proceeding.
All arbitration proceedings and decisions of the Arbitrator under this Section 13.2 shall be deemed Confidential Information of both Parties under Article 13. The Parties intend that each award rendered by an Arbitrator hereunder shall be
entitled to recognition and enforcement under the United Nations Convention on the Recognition and Enforcement of Arbitral Awards (New York, 1958). 

13.3    Governing Law, Jurisdiction, Venue and Service. 

13.3.1    Governing Law. This Agreement shall be governed by and construed in accordance with the laws of
the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The Parties agree to exclude the
application to this Agreement of the United Nations Convention on Contracts for the International Sale of Goods. 

13.3.2    Jurisdiction. Subject to Section 13.3.3 and Section 13.4, the Parties hereby irrevocably
and unconditionally consent to the exclusive jurisdiction of the courts of the State of Delaware for any action arising out of or relating to this Agreement and agree not to commence any action, suit or proceeding (other than appeals therefrom)
related thereto except in such courts. Each Party hereby waives any defenses such Party may have with regard to venue before such courts, including without limitation any claim of forum non conveniens. Notwithstanding the above, any action regarding
the infringement or validity of a Patent may be brought before any court having jurisdiction over the Parties and such subject matter. 

13.3.3    Venue. Subject to Section 13.2, 13.3.2 and Section 13.4, the Parties further hereby
irrevocably and unconditionally waive any objection to the laying of venue of any action arising out of or relating to this Agreement in the courts of the State of Delaware and hereby further irrevocably and unconditionally waive and agree not to
plead or claim in any such court that any such action brought in any such court has been brought in an inconvenient forum. Notwithstanding the above, any action regarding the infringement of any patent may be brought before any court or other
governmental entity having jurisdiction over the Parties and such subject matter. 

  
 -53- 

 13.3.4    Service. Each Party further agrees that service
of any process, summons, notice or document by registered mail to its address set forth in Section 14.5.2 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such court. 

13.4    Equitable Relief. Each Party acknowledges and agrees that the restrictions set forth in Article 9
are reasonable and necessary to protect the legitimate interests of the other Party and that such other Party would not have entered into this Agreement in the absence of such restrictions and that any breach or threatened breach of any provision of
such Sections and Articles may result in irreparable injury to such other Party for which there will be no adequate remedy at law. In the event of a breach or threatened breach of any provision of such Sections and Articles, the non-breaching Party shall be authorized and entitled to seek from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, specific performance and an equitable accounting of all
earnings, profits and other benefits arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which such non-breaching Party may be entitled in law or
equity. Both Parties agree to waive any requirement that the other (i) post a bond or other security as a condition for obtaining any such relief and (ii) show irreparable harm, balancing of harms, consideration of the public interest or
inadequacy of monetary damages as a remedy. Nothing in this Section 13.4 is intended or should be construed, to limit either Party’s right to equitable relief or any other remedy for a breach of any other provision of this Agreement. 

ARTICLE 14 
 MISCELLANEOUS

 14.1    Force Majeure. Neither Party shall be held liable or responsible to the other Party or be
deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement (other than an obligation to make payments) when such failure or delay is caused by or results from events beyond
the reasonable control of the non-performing Party, including fires, floods, earthquakes, hurricanes, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorist
acts, insurrections, riots, civil commotion, strikes, lockouts or other labor disturbances (whether involving the workforce of the non-performing Party or of any other Person), acts of God or acts, omissions
or delays in acting by any governmental authority (except to the extent such omission or delay results from the breach by the non-performing Party or any of its Affiliates of its or their Development,
Manufacturing or Commercialization obligations or any other term or condition of this Agreement). The non-performing Party shall notify the other Party of such force majeure within [*] after such occurrence by
giving written notice to the other Party stating the nature of the event, its anticipated duration and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is
necessary and the non-performing Party shall use commercially reasonable efforts to remedy its inability to perform. 

14.2    Export Control. This Agreement is made subject to any restrictions concerning the export of products
or technical information from the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees that it shall not export, directly or indirectly, any technical information acquired from the other Party
under this 

  
 -54- 

 
Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first
obtaining the written consent to do so from the appropriate agency or other governmental entity in accordance with Applicable Law. 

14.3    Assignment and Change of Control. 

14.3.1    Except as expressly permitted in this Agreement, neither Party may assign this Agreement, delegate its
obligations under this Agreement, whether by operation of law or otherwise, in whole or in part, without the prior written consent of the other Party, except that each Party shall have the right, without such consent, to assign any or all of its
rights and delegate any or all of its obligations hereunder to any of its Affiliates or to any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or substantially all of its business to which this Agreement
relates; provided that the assigning or delegating Party shall provide written notice to the other Party within [*] after such assignment or delegation and shall remain primarily liable for the performance of its assignee or delegate.
Notwithstanding the foregoing, DiCE shall be free, without Sanofi’s consent, to assign or transfer to any Third Party selected by DiCE all or any portion of its interests in any payments due it from Sanofi hereunder, as provided in
Section 7.7. Any permitted successor of a Party or any permitted assignee of all of a Party’s rights under this Agreement that has also assumed all of such Party’s obligations hereunder in writing shall, upon any such succession or
assignment and assumption, be deemed to be a party to this Agreement as though named herein in substitution for the assigning Party, whereupon the assigning Party shall cease to be a party to this Agreement and shall cease to have any rights or
obligations under this Agreement. All validly assigned rights of a Party shall inure to the benefit of and be enforceable by, and all validly delegated obligations of such Party shall be binding on and be enforceable against, the permitted
successors and assigns of such Party. Any attempted assignment or delegation in violation of this Section 14.3.1 shall be void and of no effect. 

14.3.2    No later than [*] following the earlier of the first public announcement of the execution of any
transaction with respect to a Change of Control of DiCE or the closing date of such a transaction, DiCE shall notify Sanofi in writing and identify the counterparty to the transaction (the “Third Party Acquirer”). In such a case,
effective as of the later of (a) a notice from Sanofi pursuant to this Section 14.3.2 and (b) the closing of such a transaction, Sanofi may, in its sole discretion and by written notice to DiCE, except in the case of a Change of
Control transaction in which the Third Party Acquirer is a Non-Competitive Acquirer, require DiCE and the Third Party Acquirer and its Affiliates (“Third Party Acquirer Family”) to adopt
reasonable procedures, including firewalls, to prevent disclosure of Confidential Information of Sanofi and its Affiliates (including the Sanofi Know-How) and the Licensed
Know-How to the Third Party Acquirer Family (other than DiCE and its Affiliates) and to prevent the Third Party Acquirer Family (other than DiCE and its Affiliates) from involvement in the Development,
Commercialization and Manufacture of the Collaboration Products. In the case in which DiCE is acquired by a Third Party Acquirer, the rights to Information and Inventions controlled by the Third Party Acquirer Family immediately prior to the
closing of the Change of Control transaction shall be automatically excluded from the rights licensed or granted to the other Party under this Agreement. 

14.4    Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable
under any present or future law and if the rights or obligations of either Party 

  
 -55- 

 
under this Agreement shall not be materially and adversely affected thereby, (i) such provision shall be fully severable, (ii) this Agreement shall be construed and enforced as if such
illegal, invalid or unenforceable provision had never comprised a part hereof, (iii) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision
or by its severance herefrom and (iv) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal,
invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties. To the fullest extent permitted by Applicable Law, each Party hereby waives any provision of law that would render any provision hereof illegal, invalid
or unenforceable in any respect. 
 14.5    Notices. 

14.5.1    Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication
permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by facsimile transmission (with transmission confirmed) or by internationally
recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in Section 14.5.2 or to such other address as the Party to whom notice is to be given may have provided
to the other Party in accordance with this Section 14.5.1. Such Notice shall be deemed to have been given as of the date delivered by hand or transmitted by facsimile (with transmission confirmed) or on the second Business Day (at the place of
delivery) after deposit with an internationally recognized overnight delivery service. Any notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as practicable thereafter. This Section 14.5.1 is not intended to
govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement. 

14.5.2    Address for Notice. 

If to Sanofi, to: 

54 rue La Boétie 

75008 Paris 

France 

Attention: Legal Operations, Corporate Licenses 

Facsimile: +33.1.53.77.40.48 

with a copy (which shall not constitute notice) to: 

the Sanofi Alliance Manager 

If to DiCE: 

DiCE Molecules SV, LLC 

1455 Adams Way 

Suite 

Menlo Park, CA 

Attention: Chief Executive Officer 

  
 -56- 

 14.6    Entire Agreement; Amendments. This Agreement,
together with the Schedules attached hereto, sets forth and constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises and representations,
whether written or oral, with respect thereto, including that certain confidentiality agreement, dated as of November 13, 2014, are superseded hereby. No amendment, modification, release or discharge shall be binding upon the Parties unless in
writing and duly executed by authorized representatives of both Parties. In the event of any inconsistencies between this Agreement and any schedules or other attachments hereto, the terms of this Agreement shall control. 

14.7    Compliance with Laws. In exercising their rights under this license, the Parties shall fully comply
in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this license including, without limitation, those applicable
to the discovery, development, manufacture, distribution, import and export and sale of Collaboration Products pursuant to this Agreement. 

14.8    Patent Marking. Sanofi agrees to mark and have its Sublicensees mark all Collaboration Products sold
pursuant to this Agreement in accordance with the applicable statute or regulations relating to patent marking in the country or countries of manufacture and sale thereof. 

14.9    Construction. Sanofi and DiCE have each consulted counsel of their choice regarding this Agreement,
and each acknowledges and agrees that this Agreement shall not be deemed to have been drafted by one Party or another and shall be construed accordingly. 

14.10    English Language. This Agreement shall be written and executed in and all other communications
under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof and in the event of any conflict in interpretation between the English version and such
translation, the English version shall control. 
 14.11    Waiver and
Non-Exclusion of Remedies. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in
a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party hereto of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of
any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law
or otherwise available except as expressly set forth herein. 
 14.12    No Benefit to Third Parties.
Except as provided in Article 11, the covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns and they shall not be construed as conferring any rights on any
other Persons. Notwithstanding the above, Monetization Entities have the rights described in Section 7.7. 

  
 -57- 

 14.13    Further Assurances. Each Party shall duly execute
and deliver or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the
other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

14.14    Performance by Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a
Party, such Party agrees to cause its Affiliates to perform such obligations. 
 14.15    Relationship of the
Parties. It is expressly agreed that DiCE, on the one hand, and Sanofi, on the other hand, shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither
DiCE, on the one hand, nor Sanofi, on the other hand, shall have the authority to make any statements, representations or commitments of any kind, or to take any action that shall be binding on the other, without the prior written consent of the
other Party to do so. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such first Party. 

14.16    References. Unless otherwise specified, (i) references in this Agreement to any Article,
Section or Schedule shall mean references to such Article, Section or Schedule of this Agreement, (ii) references in any Section to any clause are references to such clause of such Section and (iii) references to any agreement, instrument
or other document in this Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently amended, replaced or supplemented from time to time, as so amended, replaced or supplemented and in effect at the
relevant time of reference thereto. 
 14.17    Construction. Except where the context otherwise requires,
wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). Whenever this Agreement refers to a number
of days, unless otherwise specified, such number refers to calendar days. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any
provision contained in this Agreement. The term “including,” “include,” or “includes” as used herein shall mean including, without limiting the generality of any description preceding such term. The language of this
Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party hereto. 

14.18    Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile, PDF format via email or other electronically transmitted signatures and such signatures shall be deemed
to bind each Party hereto as if they were original signatures. 
 [SIGNATURE PAGE FOLLOWS.] 

  
 -58- 

 THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date
first written above. 
  

									
	AVENTIS INC.	  		  	DICE MOLECULES SV, LLC
					
	By:	  	 /s/ Chan H. Lee
	  		  	By:	  	 /s/ J. Kevin Judice

	Name:	  	 Chan H. Lee
	  		  	Name:	  	 J. Kevin Judice

	Title:	  	 Vice President
	  		  	Title	  	 Chief Executive Officer

 Schedule 1.27 

DiCE Patents 
 as of the
Effective Date 
 [*] 
 [*]

 Active Target List and Status 
  

					
	Target Name	  	Status	  	 [*]

Multiplier

	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]
	[*]	  	[*]	  	[*]EX-10.10

 Exhibit 10.10 

LOAN AND SECURITY AGREEMENT 

THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of April 13, 2021 (the “Effective
Date”) by and among (a) SILICON VALLEY BANK, a California corporation with a loan production office located at 505 Howard Street, 3rd Floor, San Francisco, California 94103
(“Bank”), and (b) (i) DICE MOLECULES SV, INC., a Delaware corporation (“SV”) and (ii) DICE ALPHA, INC., a Delaware corporation (“Alpha”; together with SV, individually and
collectively, jointly and severally, the “Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows: 

1. ACCOUNTING AND OTHER TERMS 

Accounting terms not defined in this Agreement shall be construed following GAAP. Calculations and determinations must be made following GAAP.
Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in Section 13. All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such
terms are defined therein. 
 2. LOAN AND TERMS OF PAYMENT 

2.1 Promise to Pay. Borrower hereby unconditionally promises to pay Bank the outstanding principal amount of all Credit
Extensions and accrued and unpaid interest thereon as and when due in accordance with this Agreement. 
 2.1.1 Term Loan Advances.

 (a) Availability. Subject to the terms and conditions of this Agreement, during Draw Period A, upon Borrower’s request, Bank
shall make term loan advances (each, a “Term A Loan Advance”, and collectively, the “Term A Loan Advances”) available to Borrower in an aggregate original principal amount not to exceed Ten Million Dollars
($10,000,000.00); provided that the initial Term A Loan Advance in an amount of at least Two Million Five Hundred Thousand Dollars ($2,500,000.00) shall be made on or about the Effective Date. Subject to the terms and conditions of this Agreement,
during Draw Period B, upon Borrower’s request, Bank shall term loan advances (each, a “Term B Loan Advance”, and collectively, the “Term B Loan Advances”) available to Borrower in an aggregate original
principal amount not to exceed Two Million Five Hundred Thousand Dollars ($2,500,000.00). Subject to the terms and conditions of this Agreement, during Draw Period C, upon Borrower’s request, Bank shall term loan advances (each, a “Term
C Loan Advance”, and collectively, the “Term C Loan Advances”) available to Borrower in an aggregate original principal amount not to exceed Five Million Dollars ($5,000,000.00). The Term A Loan Advance, the Term B Loan
Advance, and the Term C Loan Advance are each hereinafter referred to singly as a “Term Loan Advance” and collectively as the “Term Loan Advances”. Each Term Loan Advance shall be in an amount of at least One
Million Dollars ($1,000,000.00). After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed. 
 (b) Interest
Period. Commencing on the first (1st) Payment Date of the month following the month in which the Funding Date of the applicable Term Loan Advance occurs, and continuing on each Payment Date
thereafter, Borrower shall make monthly payments of interest in arrears on the principal amount of each Term Loan Advance at the rate set forth in Section 2.2(a). 

(c) Repayment. Commencing on the Term Loan Amortization Date and continuing on each Payment Date thereafter, Borrower shall repay the
Term Loan Advances in (i) consecutive equal monthly installments of principal based on the Repayment Schedule, plus (ii) monthly payments of accrued interest at the rate set forth in Section 2.2(a). All outstanding principal and
accrued and unpaid interest with respect to the Term Loan Advances, and all other outstanding Obligations with respect to the Term Loan Advances, are due and payable in full on the Term Loan Maturity Date. 

 (d) Mandatory Prepayment Upon an Acceleration. If the Term Loan Advances are
accelerated by Bank following the occurrence and during the continuance of an Event of Default, Borrower shall immediately pay to Bank an amount equal to the sum of: (i) all outstanding principal plus accrued and unpaid interest, plus
(ii) the Prepayment Fee (if any), (iii) the Final Payment, and (iv) all other sums, if any, that shall have become due and payable, including interest at the Default Rate with respect to any past due amounts. 

(e) Permitted Prepayment of Term Loan Advances. Borrower shall have the option to prepay all, but not less than all, of the Term Loan
Advances advanced by Bank under this Agreement, provided Borrower (i) provides written notice to Bank of its election to prepay the Term Loan Advances at least ten (10) days prior to such prepayment, and (ii) pays, on the date of such
prepayment (A) all outstanding principal plus accrued and unpaid interest, (B) the Prepayment Fee (if any), (C) the Final Payment, and (D) all other sums, if any, that shall have become due and payable, including interest at the
Default Rate with respect to any past due amounts. 
 2.2 Payment of Interest on the Credit Extensions. 

(a) Interest Rate. Subject to Section 2.2(b), the principal amount outstanding under each Term Loan Advance shall accrue interest
at a floating per annum rate equal to the greater of (i) one and three- quarters of one percent (1.75%) above the Prime Rate and (ii) five percent (5.0%), which interest, in each case, shall be payable monthly in accordance with
Section 2.2(d) below. 
 (b) Default Rate. Immediately upon the occurrence and during the continuance of an Event of Default,
Obligations shall bear interest at a rate per annum which is five percent (5.0%) above the rate that is otherwise applicable thereto (the “Default Rate”) unless Bank otherwise elects from time to time in its sole discretion to
impose a smaller increase. Fees and expenses which are required to be paid by Borrower pursuant to the Loan Documents (including, without limitation, Bank Expenses) but are not paid when due shall bear interest until paid at a rate equal to the
highest rate applicable to the Obligations. Payment or acceptance of the increased interest rate provided in this Section 2.2(b) is not a permitted alternative to timely payment and shall not constitute a waiver of any Event of Default or
otherwise prejudice or limit any rights or remedies of Bank. 
 (c) Adjustment to Interest Rate. Changes to the interest rate of any
Credit Extension based on changes to the Prime Rate shall be effective on the effective date of any change to the Prime Rate and to the extent of any such change. 

(d) Payment; Interest Computation. Interest is payable monthly on the Payment Date and shall be computed on the basis of a 360-day year for the actual number of days elapsed. In computing interest, (i) all payments received after 12:00 p.m. Pacific time on any day shall be deemed received at the opening of business on the next
Business Day, and (ii) the date of the making of any Credit Extension shall be included and the date of payment shall be excluded; provided, however, that if any Credit Extension is repaid on the same day on which it is made, such day shall be
included in computing interest on such Credit Extension. 
 2.3 Fees. Borrower shall pay to Bank: 

(a) Prepayment Fee. The Prepayment Fee (if any), when due hereunder; 

(b) Final Payment. The Final Payment, when due hereunder; and 

(c) Bank Expenses. All Bank Expenses (including reasonable attorneys’ fees and expenses for documentation and negotiation of this
Agreement) incurred through and after the Effective Date, when due (or, if no stated due date, upon demand by Bank). 
 Unless otherwise
provided in this Agreement or in a separate writing by Bank, Borrower shall not be entitled to any credit, rebate, or repayment of any fees earned by Bank pursuant to this Agreement notwithstanding any termination of this Agreement or the suspension
or termination of Bank’s obligation to make loans and advances hereunder. Bank may deduct amounts owing by Borrower under the clauses of this Section 2.3 pursuant to the terms of Section 2.4(c). Bank shall provide Borrower written
notice of deductions made from the Designated Deposit Account pursuant to the terms of the clauses of this Section 2.3. 

  
 -2- 

 2.4 Payments; Application of Payments; Debit of Accounts. 

(a) All payments to be made by Borrower under any Loan Document shall be made in immediately available funds in Dollars, without setoff or
counterclaim, before 12:00 p.m. Pacific time on the date when due. Payments of principal and/or interest received after 12:00 p.m. Pacific time are considered received at the opening of business on the next Business Day. When a payment is due on a
day that is not a Business Day, the payment shall be due the next Business Day, and additional fees or interest, as applicable, shall continue to accrue until paid. 

(b) Bank has the exclusive right to determine the order and manner in which all payments with respect to the Obligations may be applied.
Borrower shall have no right to specify the order or the accounts to which Bank shall allocate or apply any payments required to be made by Borrower to Bank or otherwise received by Bank under this Agreement when any such allocation or application
is not specified elsewhere in this Agreement. 
 (c) Bank may debit the Designated Deposit Account (or to the extent sufficient funds are not
present in the Designated Deposit Account at the time of such debit or if an Event of Default has occurred and is continuing, any other account of Borrower maintained with Bank), for principal and interest payments or any other amounts Borrower owes
Bank when due. These debits shall not constitute a set-off. 
 2.5 Withholding.
Payments received by Bank from Borrower under this Agreement will be made free and clear of and without deduction for any and all present or future taxes, levies, imposts, duties, deductions, withholdings, assessments, fees or other charges
imposed by any Governmental Authority (including any interest, additions to tax or penalties applicable thereto). Specifically, however, if at any time any Governmental Authority, applicable law, regulation or international agreement requires
Borrower to make any withholding or deduction from any such payment or other sum payable hereunder to Bank, Borrower hereby covenants and agrees that the amount due from Borrower with respect to such payment or other sum payable hereunder will be
increased to the extent necessary to ensure that, after the making of such required withholding or deduction, Bank receives a net sum equal to the sum which it would have received had no withholding or deduction been required, and Borrower shall pay
the full amount withheld or deducted to the relevant Governmental Authority. Borrower will, upon request, furnish Bank with proof reasonably satisfactory to Bank indicating that Borrower has made such withholding payment; provided, however, that
Borrower need not make any withholding payment if the amount or validity of such withholding payment is contested in good faith by appropriate and timely proceedings and as to which payment in full is bonded or reserved against by Borrower. The
agreements and obligations of Borrower contained in this Section 2.5 shall survive the termination of this Agreement. 
 3.
CONDITIONS OF LOANS 
 3.1 Conditions Precedent to Initial Credit Extension. Bank’s obligation to make the
initial Credit Extension is subject to the condition precedent that Bank shall have received, in form and substance satisfactory to Bank, such documents, and completion of such other matters, as Bank may reasonably deem necessary or appropriate,
including, without limitation: 
 (a) duly executed signatures to the Loan Documents; 

(b) duly executed signatures to the Warrant; 

(c) duly executed signatures to the Control Agreement (SAM Securities Account Control Agreement); 

(d) the Operating Documents and long-form good standing certificates of each Borrower and Guarantor certified by the Secretary of State of
Delaware and the State of California, each as of a date no earlier than thirty (30) days prior to the Effective Date; 

  
 -3- 

 (e) a secretary’s corporate borrowing certificate of each Borrower with respect to such
Borrower’s Operating Documents, incumbency, specimen signatures and resolutions authorizing the execution and delivery of this Agreement and the other Loan Documents; 

(f) a limited liability company certificate to guaranty of Guarantor with respect to such Guarantor’s Operating Documents, incumbency,
specimen signatures and resolutions authorizing the execution and delivery of this Agreement and the other Loan Documents; 
 (g) duly
executed signatures to the completed Borrowing Resolutions for each Borrower and Guarantor; 
 (h) certified copies, dated as of a recent
date, of financing statement searches, as Bank may request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such financing statements either constitute Permitted Liens or have been or, in
connection with the initial Credit Extension, will be terminated or released; 
 (i) the Perfection Certificate of each Borrower and
Guarantor, together with the duly executed signatures thereto; 
 (j) duly executed signatures to the Guaranty; 

(k) duly executed signatures to the Security Agreement; and 

(l) payment of the fees and Bank Expenses then due as specified in Section 2.3 hereof. 

3.2 Conditions Precedent to all Credit Extensions. Bank’s obligations to make each Credit Extension, including the initial
Credit Extension, is subject to the following conditions precedent: 
 (a) except as otherwise provided in Section 3.4, timely receipt
of an executed Payment/Advance Form; 
 (b) the representations and warranties in this Agreement shall be true, accurate, and complete in all
material respects on the date of the Payment/Advance Form and on the Funding Date of each Credit Extension, taking into account updates thereof subsequent to the Effective Date to the extent permitted by notice to Bank by one or more specific
provisions of this Agreement; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that
those representations and warranties expressly referring to a specific date or time period shall be true, accurate and complete in all material respects as of such date or with respect to such time period, and no Event of Default shall have occurred
and be continuing or result from the Credit Extension. Each Credit Extension is Borrower’s representation and warranty on that date that the representations and warranties in this Agreement remain true, accurate, and complete in all material
respects, taking into account updates thereof subsequent to the Effective Date to the extent permitted by notice to the Bank by one or more specific provisions of this Agreement; provided, however, that such materiality qualifier shall not be
applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date or time period shall
be true, accurate and complete in all material respects as of such date or with respect to such time period; and 
 (c) Bank determines to
its reasonable satisfaction that there has not been any material impairment in the general affairs, management, results of operation, financial condition or the prospect of repayment of the Obligations, or any material adverse deviation by Borrower
from the most recent business plan of Borrower presented to and accepted by Bank. 
 If any event, condition, circumstances or other factor
(collectively, “Circumstances”) exists or does not exist whose existence or non-existence serves as justification under Section 3.1 or this Section 3.2 for Bank’s refusal to
make a requested Credit Extension, the existence or non-existence of such Circumstances shall not in and of itself constitute an Event of Default under Section 8 unless it independently constitutes an
Event of Default pursuant to another provision of this Agreement. 

  
 -4- 

 3.3 Covenant to Deliver. Borrower agrees to deliver to Bank each item required
to be delivered to Bank under this Agreement as a condition precedent to any Credit Extension. Borrower expressly agrees that a Credit Extension made prior to the receipt by Bank of any such item shall not constitute a waiver by Bank of
Borrower’s obligation to deliver such item, and the making of any Credit Extension in the absence of a required item shall be in Bank’s sole discretion. 

3.4 Procedures for Borrowing. Subject to the prior satisfaction of all other applicable conditions to the making of a Credit
Extension set forth in this Agreement, to obtain a Credit Extension, Borrower shall notify Bank (which notice shall be irrevocable) by electronic mail, facsimile, or telephone by 12:00 p.m. Pacific time at least two (2) Business Days prior to
the proposed Funding Date of the Credit Extension. Together with any such electronic or facsimile notification, Borrower shall deliver to Bank by electronic mail or facsimile a completed Payment/Advance Form executed by an Authorized Signer. Bank
may rely on any telephone notice given by a person whom Bank reasonably believes is an Authorized Signer. Bank shall credit the Credit Extensions to the Designated Deposit Account. Bank may make Credit Extensions under this Agreement based on
instructions from an Authorized Signer or without instructions if the Credit Extensions are necessary to meet Obligations which have become due. 

4. CREATION OF SECURITY INTEREST 

4.1 Grant of Security Interest. Borrower hereby grants Bank, to secure the payment and performance in full of all of the
Obligations, a continuing security interest in, and pledges to Bank, the Collateral, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof. 

Borrower acknowledges that it previously has entered, and/or may in the future enter, into Bank Services Agreements with Bank. Regardless of
the terms of any Bank Services Agreement, Borrower agrees that any amounts Borrower owes Bank thereunder shall be deemed to be Obligations hereunder and that it is the intent of Borrower and Bank to have all such Obligations secured by the first
priority perfected security interest in the Collateral granted herein (subject only to Permitted Liens that are permitted pursuant to the terms of this Agreement to have superior priority to Bank’s Lien in this Agreement). 

If this Agreement is terminated, Bank’s Lien in the Collateral shall continue until the Obligations (other than inchoate indemnity
obligations) are repaid in full in cash. Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations) and at such time as Bank’s obligation to make Credit Extensions has terminated, Bank shall, at the sole cost
and expense of Borrower, release its Liens in the Collateral and all rights therein shall revert to Borrower and shall take such actions as may be reasonably requested by Borrower to evidence such repayment and release (including delivery of a
payoff letter and filing of UCC-3 termination statements (or authorizing Borrower to file such UCC-3 termination statements)). In the event (x) all Obligations
(other than inchoate indemnity obligations), except for Bank Services, are satisfied in full, and (y) this Agreement is terminated, Bank shall terminate the security interest granted herein upon Borrower providing cash collateral acceptable to
Bank in its good faith business judgment for Bank Services, if any. In the event such Bank Services consist of outstanding Letters of Credit, Borrower shall provide to Bank cash collateral in an amount equal to (x) if such Letters of Credit are
denominated in Dollars, then at least one hundred five percent (105.0%); and (y) if such Letters of Credit are denominated in a Foreign Currency, then at least one hundred ten percent (110.0%), of the Dollar Equivalent of the face amount of all
such Letters of Credit plus, in each case, all interest, fees, and costs due or to become due in connection therewith (as estimated by Bank in its good faith business judgment), to secure all of the Obligations relating to such Letters of Credit.

 4.2 Priority of Security Interest. Borrower represents, warrants, and covenants, assuming the filing by Bank of a UCC
financing statement with the Secretary of State of Delaware covering the Collateral, and solely with respect to any type of Collateral for which the receipt of a Control Agreement by Bank is necessary in order to perfect Bank’s security
interest, Bank’s receipt of a Control Agreement, that the security interest granted herein is and shall at all times continue to be a first priority perfected security interest in the Collateral (subject only to Permitted Liens that are
permitted pursuant to the terms of this Agreement to have superior priority to Bank’s Lien 

  
 -5- 

 
under this Agreement). If Borrower shall acquire a commercial tort claim, Borrower shall promptly notify Bank in a writing signed by Borrower of the general details thereof and grant to Bank in
such writing a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Bank. 

4.3 Authorization to File Financing Statements. Borrower hereby authorizes Bank to file financing statements, without notice to
Borrower, with all appropriate jurisdictions to perfect or protect Bank’s interest or rights hereunder, including a notice that any disposition of the Collateral, by either Borrower or any other Person, shall be deemed to violate the rights of
Bank under the Code. Such financing statements may indicate the Collateral as “all assets of the Debtor” or words of similar effect, or as being of an equal or lesser scope, or with greater detail, all in Bank’s discretion. 

5. REPRESENTATIONS AND WARRANTIES 

Borrower represents and warrants as follows: 

5.1 Due Organization, Authorization; Power and Authority. Borrower is duly existing and in good standing as a Registered
Organization in its jurisdiction of formation and is qualified and licensed to do business and is in good standing in any jurisdiction in which the conduct of its business or its ownership of property requires that it be qualified except where the
failure to do so could not reasonably be expected to have a material adverse effect on Borrower’s business. In connection with this Agreement, each Borrower has delivered to Bank a completed certificate signed by such Borrower and Guarantor,
entitled “Perfection Certificate” (collectively, the “Perfection Certificate”). Each Borrower represents and warrants to Bank that (a) such Borrower’s exact legal name is that indicated on the Perfection
Certificate and on the signature page hereof; (b) such Borrower is an organization of the type and is organized in the jurisdiction set forth in the Perfection Certificate; (c) the Perfection Certificate accurately sets forth such
Borrower’s organizational identification number or accurately states that such Borrower has none; (d) the Perfection Certificate accurately sets forth such Borrower’s place of business, or, if more than one, its chief executive office
as well as such Borrower’s mailing address (if different than its chief executive office); (e) such Borrower (and each of its predecessors) has not, in the past five (5) years, changed its jurisdiction of formation, organizational
structure or type, or any organizational number assigned by its jurisdiction (other than the conversion by Parent from a Delaware corporation to a Delaware limited liability company as set forth on the Perfection Certificate, and any conversion by
Parent from a Delaware limited liability company to a Delaware corporation after the date hereof); and (f) all other information set forth on the Perfection Certificate pertaining to such Borrower and each of its Subsidiaries is accurate and
complete in all material respects (it being understood and agreed that such Borrower may from time to time update certain information in the Perfection Certificate after the Effective Date to the extent permitted by one or more specific provisions
in this Agreement and provided that the Perfection Certificate shall be deemed to be updated to reflect the information provided in any notice that is required or permitted to be delivered (and is actually delivered) by Borrower to Bank). If any
Borrower is not now a Registered Organization but later becomes one, each Borrower shall promptly notify Bank of such occurrence and provide Bank with such Borrower’s organizational identification number. 

The execution, delivery and performance by Borrower of the Loan Documents to which it is a party have been duly authorized, and do not
(i) conflict with any of Borrower’s organizational documents, (ii) contravene, conflict with, constitute a default under or violate any material Requirement of Law, (iii) contravene, conflict or violate any applicable order,
writ, judgment, injunction, decree, determination or award of any Governmental Authority by which Borrower or any of its Subsidiaries or any of their property or assets may be bound or affected, (iv) require any action by, filing, registration, or
qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental Approvals which have already been obtained and are in full force and effect (or are being obtained pursuant to Section 6.1(b))) or
(v) conflict with, contravene, constitute a default or breach under, or result in or permit the termination or acceleration of, any material agreement by which Borrower is bound. Borrower is not in default under any agreement to which it is a
party or by which it is bound in which the default could reasonably be expected to have a material adverse effect on Borrower’s business. 

  
 -6- 

 5.2 Collateral. Borrower has good title to, rights in, and the power to
transfer each item of the Collateral upon which it purports to grant a Lien hereunder, free and clear of any and all Liens except Permitted Liens. Borrower has no Collateral Accounts at or with any bank or financial institution other than Bank or
Bank’s Affiliates except for the Collateral Accounts described in the Perfection Certificate delivered to Bank in connection herewith and which Borrower has taken such actions as are necessary to give Bank a perfected security interest therein,
pursuant to the terms of Section 6.6(b). The Accounts are bona fide, existing obligations of the Account Debtors. 
 The Collateral is
not in the possession of any third party bailee (such as a warehouse) except as otherwise provided in the Perfection Certificate. None of the components of the Collateral shall be maintained at locations other than as provided in the Perfection
Certificate or as permitted pursuant to Section 7.2. 
 All Inventory is in all material respects of good and marketable quality, free
from material defects. 
 Borrower is the sole owner of the Intellectual Property which it owns or purports to own except for
(a) non-exclusive licenses granted to its customers in the ordinary course of business, (b) over-the-counter software that is commercially available to the
public, and (c) material Intellectual Property licensed to Borrower and noted on the Perfection Certificate. Each Patent which it owns or purports to own and which is material to Borrower’s business is, to Borrower’s knowledge, valid
and enforceable, and no part of the Intellectual Property which Borrower owns or purports to own and which is material to Borrower’s business has been judged invalid or unenforceable, in whole or in part. To the best of Borrower’s
knowledge, no claim has been made that any part of the Intellectual Property violates the rights of any third party except to the extent such claim would not reasonably be expected to have a material adverse effect on Borrower’s business. 

Except as noted on the Perfection Certificate, Borrower is not a party to, nor is it bound by, any Restricted License. 

5.3 Litigation. There are no actions or proceedings pending or, to the knowledge of any Responsible Officer, threatened in
writing by or against Borrower or any of its Subsidiaries that could reasonably be expected to result in damages or costs to Borrower or any of its Subsidiaries in an amount more than, individually or in the aggregate, Two Hundred Fifty Thousand
Dollars ($250,000.00). 
 5.4 Financial Statements; Financial Condition. All consolidated financial statements for Borrower and
any of its Subsidiaries delivered to Bank by submission to the Financial Statement Repository or otherwise submitted to Bank fairly present in all material respects Borrower’s consolidated financial condition and Borrower’s consolidated
results of operations. There has not been any material deterioration in Borrower’s consolidated financial condition since the date of the most recent financial statements submitted to the Financial Statement Repository or otherwise submitted to
Bank. 
 5.5 Solvency. The fair salable value of Borrower’s consolidated assets (including goodwill minus disposition
costs) exceeds the fair value of Borrower’s liabilities; Borrower is not left with unreasonably small capital after the transactions in this Agreement; and Borrower is able to pay its debts (including trade debts) as they mature. 

5.6 Regulatory Compliance. Borrower is not an “investment company” or a company “controlled” by an
“investment company” under the Investment Company Act of 1940, as amended. Borrower is not engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of
Governors). Borrower (a) has complied in all material respects with all Requirements of Law, and (b) has not violated any Requirements of Law the violation of which could reasonably be expected to have a material adverse effect on its business.
None of Borrower’s or any of its Subsidiaries’ properties or assets has been used by Borrower or any Subsidiary or, to the best of Borrower’s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting
any hazardous substance other than legally. Borrower and each of its Subsidiaries have obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are
necessary to continue their respective businesses as currently conducted. 
 5.7 Subsidiaries; Investments. Borrower does not
own any stock, partnership, or other ownership interest or other equity securities except for equity securities of Borrower’s Subsidiaries and Permitted Investments. 

  
 -7- 

 5.8 Tax Returns and Payments; Pension Contributions. Borrower has timely filed
all required tax returns and reports, and Borrower has timely paid all foreign, federal, state and local taxes, assessments, deposits and contributions owed by Borrower except (a) to the extent such taxes are being contested in good faith by
appropriate proceedings promptly instituted and diligently conducted, so long as such reserve or other appropriate provision, if any, as shall be required in conformity with GAAP shall have been made therefor, or (b) if such taxes, assessments,
deposits and contributions do not, individually or in the aggregate, exceed Fifty Thousand Dollars ($50,000.00). 
 To the extent Borrower
defers payment of any contested taxes, Borrower shall (i) notify Bank in writing of the commencement of, and any material development in, the proceedings, and (ii) post bonds or take any other steps required to prevent the Governmental
Authority levying such contested taxes from obtaining a Lien upon any of the Collateral that is other than a Permitted Lien. Borrower is unaware of any claims or adjustments proposed for any of Borrower’s prior tax years which could reasonably
be expected to result in additional taxes becoming due and payable by Borrower in excess of Fifty Thousand Dollars ($50,000.00). Borrower has paid all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in
accordance with their terms, and Borrower has not withdrawn from participation in, and has not permitted partial or complete termination of, or permitted the occurrence of any other event with respect to, any such plan which could reasonably be
expected to result in any liability of Borrower, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency. 

5.9 Use of Proceeds. Borrower shall use the proceeds of the Credit Extensions as working capital and to fund its general business
requirements and not for personal, family, household or agricultural purposes. 
 5.10 Full Disclosure. No written
representation, warranty or other statement of Borrower in any report, certificate or written statement submitted to the Financial Statement Repository, as of the date such representation, warranty, or other statement was made, taken together with
all such written reports, written certificates or written statements submitted to the Financial Statement Repository, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained in
the reports, certificates or written statements not misleading (it being recognized by Bank that the projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts and that actual results
during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results). 
 5.11
Definition of “Knowledge.” For purposes of the Loan Documents, whenever a representation or warranty is made to Borrower’s knowledge or awareness, to the “best of” Borrower’s knowledge, or with a similar
qualification, knowledge or awareness means the actual knowledge, after reasonable investigation, of any Responsible Officer. 
 6.
AFFIRMATIVE COVENANTS 
 Borrower shall do all of the following: 

6.1 Government Compliance. 

(a) Maintain its and all its Subsidiaries’ legal existence and good standing in their respective jurisdictions of formation and maintain
qualification in each jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on Borrower’s business or operations. Borrower shall comply, and have each Subsidiary comply with all laws,
ordinances and regulations to which it is subject, where the failure to so comply would reasonably be expected to have a material adverse effect on Borrower’s business or operations. 

(b) Obtain all of the Governmental Approvals necessary for the performance by Borrower of its obligations under the Loan Documents to which it
is a party and the grant of a security interest to Bank in all of its property. Borrower shall promptly provide copies of any such obtained Governmental Approvals to Bank. 

  
 -8- 

 6.2 Financial Statements, Reports, Certificates. Provide Bank with the
following by submitting to the Financial Statement Repository or otherwise submitting to Bank: 
 (a) Monthly Financial Statements. As
soon as available, but no later than thirty (30) days after the last day of each month, a company prepared consolidated and consolidating balance sheet, income statement, and cash flow statement covering Parent’s and each of its
Subsidiary’s consolidated operations for such month certified by a Responsible Officer and in a form of presentation reasonably acceptable to Bank (the “Monthly Financial Statements”); 

(b) Monthly Compliance Statement. Within thirty (30) days after the last day of each month and together with the Monthly Financial
Statements, a duly completed Compliance Statement, confirming that, as of the end of such month, Borrower was in full compliance with all of the terms and conditions of this Agreement, and setting forth calculations showing compliance with the
financial covenants (if any) set forth in this Agreement and such other information as Bank may reasonably request; 
 (c) [Reserved];

 (d) [Reserved]; 
 (e)
Other Statements. Within ten (10) days of delivery, copies of all statements, reports and notices made available to Borrower’s security holders or to any holders of Subordinated Debt; 

(f) SEC Filings. In the event that Borrower and/or Guarantor becomes subject to the reporting requirements under the Exchange Act within
ten (10) days of filing, copies of all periodic and other reports, proxy statements and other materials filed by Borrower and/or any Guarantor with the SEC, any Governmental Authority succeeding to any or all of the functions of the SEC or with
any national securities exchange, or distributed to its shareholders, as the case may be. Documents required to be delivered pursuant to the terms hereof (to the extent any such documents are included in materials otherwise filed with the SEC) may
be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower posts such documents, or provides a link thereto, on Borrower’s website on the internet at Borrower’s website address;
provided, however, Borrower shall promptly notify Bank in writing (which may be by electronic mail) of the posting of any such documents; 

(g) Beneficial Ownership Information. Prompt written notice of any changes to the beneficial ownership information set out in
Section 14 of the Perfection Certificate. Borrower understands and acknowledges that Bank relies on such true, accurate and up-to-date beneficial ownership
information to meet Bank’s regulatory obligations to obtain, verify and record information about the beneficial owners of its legal entity customers; 

(h) Legal Action Notice. A prompt report of any legal actions pending or threatened in writing against Borrower or any of its
Subsidiaries that could reasonably be expected to result in damages or costs to Borrower or any of its Subsidiaries of, individually or in the aggregate, Two Hundred Fifty Thousand Dollars ($250,000.00) or more; and 

(i) Other Financial Information. Other financial information reasonably requested by Bank. 

Any submission by Borrower of a Compliance Statement or any other financial statement submitted to the Financial Statement Repository pursuant to this
Section 6.2 or otherwise submitted to Bank shall be deemed to be a representation by Borrower that (a) as of the date of such Compliance Statement or other financial statement, the information and calculations set forth therein are true,
accurate and correct, (b) as of the end of the compliance period set forth in such submission, Borrower is in complete compliance with all required covenants except as noted in such Compliance Statement or other financial statement, as
applicable; (c) as of the date of such submission, no Events of Default have occurred or are continuing; (d) all representations and warranties other than any representations or warranties that are made as of a specific date in Article 5
remain true and correct in all material respects as of the date of such submission except as noted in such Compliance Statement or other financial 

  
 -9- 

 
statement, as applicable; (e) as of the date of such submission, Borrower and each of its Subsidiaries has timely filed all required tax returns and reports, and Borrower has timely paid all
foreign, federal, state and local taxes, assessments, deposits and contributions owed by Borrower except as otherwise permitted pursuant to the terms of Section 5.8; and (f) as of the date of such submission, no Liens have been levied or
claims made against Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Bank. 

6.3 Inventory; Returns. Keep all Inventory in good and marketable condition, free from material defects. Returns and allowances
between Borrower and its Account Debtors shall follow Borrower’s customary practices as they exist at the Effective Date. Borrower must promptly notify Bank of all returns, recoveries, disputes and claims that involve more than One Hundred
Thousand Dollars ($100,000.00). 
 6.4 Taxes; Pensions. Timely file, and require each of its Subsidiaries to timely file, all
required tax returns and reports and timely pay, and require each of its Subsidiaries to timely pay, all foreign, federal, state and local taxes, assessments, deposits and contributions owed by Borrower and each of its Subsidiaries, except for
(a) deferred payment of any taxes contested pursuant to the terms of Section 5.8 hereof, and (b) taxes, assessments, deposits and contributions which do not, individually or in the aggregate, exceed Fifty Thousand Dollars
($50,000.00), and shall deliver to Bank, on demand, appropriate certificates attesting to such payments, and pay all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms. 

6.5 Insurance. 
 (a) Keep
its business and the Collateral insured for risks and in amounts standard for companies in Borrower’s industry and location and as Bank may reasonably request. Insurance policies shall be in a form, with financially sound and reputable
insurance companies that are not Affiliates of Borrower, and in amounts that are reasonably satisfactory to Bank. All property policies shall have a lender’s loss payable endorsement showing Bank as lender loss payee. All liability policies
shall show, or have endorsements showing, Bank as an additional insured. Bank shall be named as lender loss payee and/or additional insured with respect to any such insurance providing coverage in respect of any Collateral. 

(b) Ensure that proceeds payable under any property policy are, at Bank’s option, payable to Bank on account of the Obligations.
Notwithstanding the foregoing, (a) so long as no Event of Default has occurred and is continuing, Borrower shall have the option of applying the proceeds of any casualty policy up to Two Hundred Fifty Thousand Dollars ($250,000.00) with respect
to any loss, but not exceeding Two Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate for all losses under all casualty policies in any one (1) year, toward the replacement or repair of destroyed or damaged property; provided that
any such replaced or repaired property (i) shall be of equal or like value as the replaced or repaired Collateral and (ii) shall be deemed Collateral in which Bank has been granted a first priority security interest, and (b) after the
occurrence and during the continuance of an Event of Default, all proceeds payable under such casualty policy shall, at the option of Bank, be payable to Bank on account of the Obligations. 

(c) At Bank’s request, Borrower shall deliver certified copies of insurance policies and evidence of all premium payments. Each provider
of any such insurance required under this Section 6.5 shall agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to Bank, that it will give Bank thirty (30) days prior written notice before
any such policy or policies shall be materially altered or canceled. If Borrower fails to obtain insurance as required under this Section 6.5 or to pay any amount or furnish any required proof of payment to third persons and Bank, Bank may make
all or part of such payment or obtain such insurance policies required in this Section 6.5, and take any action under the policies Bank deems prudent. 

6.6 Operating Accounts. 

(a) Maintain all of its and all of its Subsidiaries’ operating accounts and all excess cash with Bank and Bank’s Affiliates. In
addition to the foregoing, Borrower shall conduct all of its primary banking with Bank and Bank’s Affiliates, including, without limitation, letters of credit and business credit cards. Any Guarantor shall maintain all of its operating accounts
and all excess cash with Bank and Bank’s Affiliates. 

  
 -10- 

 (b) Provide Bank five (5) days prior written notice before establishing any Collateral
Account at or with any bank or financial institution other than Bank or Bank’s Affiliates. For each Collateral Account that Borrower at any time maintains, Borrower shall cause the applicable bank or financial institution (other than Bank) at
or with which any Collateral Account is maintained to execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect Bank’s Lien in such Collateral Account in accordance with the terms
hereunder which Control Agreement may not be terminated without the prior written consent of Bank. The provisions of the previous sentence shall not apply to deposit accounts exclusively used for payroll, payroll taxes and other employee wage and
benefit payments to or for the benefit of Borrower’s employees and identified to Bank by Borrower as such. 
 6.7 Protection of
Intellectual Property Rights. 
 (a) (i) Use commercially reasonable efforts to protect, defend and maintain the validity and
enforceability of its Intellectual Property which is material to Borrower’s business (other than Intellectual Property which Borrower does not own and which it licenses from one or more third parties); (ii) promptly advise Bank in writing of
material infringements or any other event that could reasonably be expected to materially and adversely affect the value of its Intellectual Property which is material to Borrower’s business; and (iii) not allow any Intellectual Property
material to Borrower’s business to be abandoned, forfeited or dedicated to the public without Bank’s written consent. 
 (b)
Provide written notice to Bank within fifteen (15) days of entering or becoming bound by any Restricted License (other than over-the-counter software that is
commercially available to the public). Borrower shall take such commercially reasonable steps as Bank reasonably requests to obtain the consent of, or waiver by, any person whose consent or waiver is necessary for (i) any Restricted License to
be deemed Collateral and for Bank to have a security interest in it that might otherwise be restricted or prohibited by law or by the terms of any such Restricted License, whether now existing or entered into in the future, and (ii) Bank to
have the ability in the event of a liquidation of any Collateral to dispose of such Collateral in accordance with Bank’s rights and remedies under this Agreement and the other Loan Documents. 

6.8 Litigation Cooperation. From the date hereof and continuing through the termination of this Agreement, make available to
Bank, without expense to Bank, Borrower and its officers, employees and agents and Borrower’s books and records, to the extent that Bank may deem them reasonably necessary to prosecute or defend any third-party suit or proceeding instituted by
or against Bank with respect to any Collateral or relating to Borrower. 
 6.9 Access to Collateral; Books and Records. Allow
Bank, or its agents, at reasonable times, on five (5) Business Days’ notice (provided no notice is required if an Event of Default has occurred and is continuing), to inspect the Collateral and audit and copy Borrower’s Books. Such
inspections or audits shall be conducted no more often than once every twelve (12) months unless an Event of Default has occurred and is continuing in which case such inspections and audits shall occur as often as Bank shall determine is
necessary. The foregoing inspections and audits shall be at Borrower’s expense, and the charge therefor shall be One Thousand Dollars ($1,000.00) per person per day (or such higher amount as shall represent Bank’s then-current standard
charge for the same), plus reasonable out-of-pocket expenses. In the event Borrower and Bank schedule an audit more than eight (8) days in advance, and Borrower
cancels or seeks to reschedule the audit with less than eight (8) days written notice to Bank, then (without limiting any of Bank’s rights or remedies), Borrower shall pay Bank a fee of Two Thousand Dollars ($2,000.00) plus any out-of-pocket expenses incurred by Bank to compensate Bank for the anticipated costs and expenses of the cancellation or rescheduling. 

6.10 Further Assurances. Execute any further instruments and take further action as Bank reasonably requests to perfect or
continue Bank’s Lien in the Collateral or to effect the purposes of this Agreement. Deliver to Bank, within five (5) days after the same are sent or received, copies of all correspondence, reports, documents and other filings with any
Governmental Authority regarding compliance with or maintenance of Governmental Approvals or Requirements of Law or that could reasonably be expected to have a material effect on any of the Governmental Approvals or otherwise on the operations of
Borrower or any of its Subsidiaries. 

  
 -11- 

 6.11 Conversion by Parent. Upon the conversion by Parent from a Delaware
limited liability company to a Delaware corporation, Borrower shall (a) cause Parent to provide to Bank a joinder to this Agreement to become a co-borrower hereunder, together with such appropriate
financing statements and/or Control Agreements, all in form and substance satisfactory to Bank (including being sufficient to grant Bank a first priority Lien (subject to Permitted Liens) in and to the assets of such new Delaware corporation) (upon
which the Guaranty and Security Agreement shall terminate), (b) provide to Bank appropriate certificates and financing statements, in form and substance satisfactory to Bank; and (c) provide to Bank all other documentation in form and substance
reasonably satisfactory to Bank, which in its opinion is appropriate with respect to the execution and delivery of the applicable documentation referred to above. Any document, agreement, or instrument executed or issued pursuant to this
Section 6.11 shall be a Loan Document. 
 6.12 Post-Closing Deliverables. Borrower shall deliver to Bank within sixty
(60) days after the Effective Date, a landlord’s consent in favor of Bank for Borrower’s leased location at 279 E. Grand Avenue, Suite 300, Lobby B, South San Francisco, CA 94080, by the landlord thereof, together with the duly
executed signatures thereto. 
 7. NEGATIVE COVENANTS 

Borrower shall not do any of the following without Bank’s prior written consent: 

7.1 Dispositions. Convey, sell, lease, transfer, assign, or otherwise dispose of (including, without limitation, pursuant to a
Division) (collectively, “Transfer”), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, except for Transfers (a) of Inventory in the ordinary course of business; (b) of worn- out,
surplus or obsolete Equipment that is, in the reasonable judgment of Borrower, no longer economically practicable to maintain or useful in the ordinary course of business of Borrower; (c) consisting of Permitted Liens and Permitted Investments;
(d) consisting of Borrower’s use or transfer of money or Cash Equivalents in a manner that is not prohibited by the terms of this Agreement or the other Loan Documents; (e) of non-exclusive
licenses for the use of the property of Borrower or its Subsidiaries in the ordinary course of business; (f) of Intellectual Property that is no longer material to Borrower’s business, subject to Section 6.7(a) hereof; and
(g) consisting of any leases or subleases of real property by Borrower not constituting Indebtedness and not entered into as part of a sale leaseback transaction. 

7.2 Changes in Business, Management, Control, or Business Locations. (a) Engage in or permit any of its Subsidiaries to
engage in any business other than the businesses currently engaged in by Borrower and such Subsidiary, as applicable, or reasonably related thereto; (b) liquidate or dissolve (provided that, nothing herein shall prohibit any Subsidiary that is
not a Borrower from liquidating or dissolving (provided further that any such assets are transferred to Borrower or another Subsidiary)); (c) fail to provide notice to Bank of any Key Person departing from or ceasing to be employed by Borrower
within ten (10) Business Days after such Key Person’s departure from Borrower; or (d) permit or suffer any Change in Control (other than the conversion by Parent from a Delaware limited liability company to a Delaware corporation,
subject to Section 6.11 hereof). 
 Borrower shall not, without at least fifteen (15) days prior written notice to Bank:
(1) add any new offices or business locations, including warehouses (unless such new offices or business locations contain less than Two Hundred Fifty Thousand Dollars ($250,000.00) in Borrower’s assets or property) or deliver any portion
of the Collateral valued, individually or in the aggregate, in excess of Two Hundred Fifty Thousand Dollars ($250,000.00) to a bailee at a location other than to a bailee and at a location already disclosed in the Perfection Certificate,
(2) change its jurisdiction of organization, (3) change its organizational structure or type, (4) change its legal name, or (5) change any organizational number (if any) assigned by its jurisdiction of organization. If Borrower adds
any new offices or business locations, including warehouses, containing in excess of Two Hundred Fifty Thousand Dollars ($250,000.00) of Borrower’s assets or property, then Borrower will promptly use commercially reasonable efforts to cause
such landlord of any such new offices or business locations, including warehouses, to execute and deliver a landlord consent in form and substance reasonably satisfactory to Bank. If Borrower delivers any portion of the Collateral valued,
individually or in the aggregate, in excess of Two Hundred Fifty Thousand Dollars ($250,000.00) to a bailee, and Bank and such bailee are not already parties to a bailee agreement governing both the Collateral and the location to which Borrower
delivered the Collateral, then Borrower will promptly use commercially reasonable efforts to cause such bailee to execute and deliver a bailee agreement in form and substance reasonably satisfactory to Bank. 

  
 -12- 

 7.3 Mergers or Acquisitions. Merge or consolidate, or permit any of its
Subsidiaries to merge or consolidate, with any other Person, or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person (including, without limitation, by the formation of
any Subsidiary or pursuant to a Division). A Subsidiary may merge or consolidate into another Subsidiary or into Borrower. Nothing herein shall restrict the conversion by Parent from a Delaware limited liability company to a Delaware corporation,
subject to Section 6.11 hereof. 
 7.4 Indebtedness. Create, incur, assume, or be liable for any Indebtedness, or permit
any Subsidiary to do so, other than Permitted Indebtedness. 
 7.5 Encumbrance. Create, incur, allow, or suffer any Lien on any
of its property, or assign or convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, permit any Collateral not to be subject to the first priority security
interest granted herein, or enter into any agreement, document, instrument or other arrangement (except with or in favor of Bank) with any Person which directly or indirectly prohibits or has the effect of prohibiting Borrower or any Subsidiary from
assigning, mortgaging, pledging, granting a security interest in or upon, or encumbering any of Borrower’s or any Subsidiary’s Intellectual Property, except as is otherwise permitted in Section 7.1 hereof and the definition of
Permitted Liens herein. 
 7.6 Maintenance of Collateral Accounts. Maintain any Collateral Account except pursuant to the terms
of Section 6.6(b) hereof. 
 7.7 Distributions; Investments. (a) Pay any dividends or make any distribution or
payment or redeem, retire or purchase any capital stock provided that Borrower may (i) pay dividends and make distributions to Parent, including, without limitation, for the purpose of enabling Parent to make and pay Permitted Tax Payments,
(ii) convert any of its convertible securities into other securities pursuant to the terms of such convertible securities or otherwise in exchange thereof (including pursuant to “net exercise” or “net share settlement” of options
and warrants), (iii) make cash payments in lieu of the issuance of fractional shares of capital stock upon conversion of convertible securities, stock splits, stock combinations or business combinations so long as an Event of Default does not exist
at the time of any such payment and would not exist after giving effect to any such payment provided that the aggregate amount of all such payments does not exceed Twenty-Five Thousand Dollars ($25,000.00) in any twelve (12) month period,
(iv) pay dividends solely in common stock; and (v) repurchase the equity interests of former directors, employees or consultants pursuant to the terms of equity incentive plans, restricted stock agreements, stock repurchase agreements or
similar agreements so long as an Event of Default does not exist at the time of any such repurchase and would not exist after giving effect to any such repurchase, provided that the aggregate amount of all such repurchases does not exceed One
Hundred Thousand Dollars ($100,000.00) in any twelve (12) month period; or (b) directly or indirectly make any Investment (including, without limitation, by the formation of any Subsidiary) other than Permitted Investments, or permit any
of its Subsidiaries to do so. 
 7.8 Transactions with Affiliates. Directly or indirectly enter into or permit to exist any
material transaction with any Affiliate of Borrower, except for (a) transactions that are in the ordinary course of Borrower’s business, upon fair and reasonable terms that are no less favorable to Borrower than would be obtained in an
arm’s length transaction with a non-affiliated Person, (b) sales of equity securities in bona fide venture financing transactions that are not prohibited by Section 7.2, (c) the incurrence of
Subordinated Debt, (d) transactions of the type described in and permitted pursuant to Section 7.7 hereof, and (e) commercially reasonable and customary compensation or other incentive arrangements approved by the Board. 

7.9 Subordinated Debt. (a) Make or permit any payment on any Subordinated Debt, except under the terms of the
subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject, or (b) amend any provision in any document relating to the Subordinated Debt which would increase the amount thereof, provide for earlier or
greater principal, interest, or other payments thereon, or adversely affect the subordination thereof to Obligations owed to Bank. 

  
 -13- 

 7.10 Compliance. Become an “investment company” or a company
controlled by an “investment company”, under the Investment Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of
Governors of the Federal Reserve System), or use the proceeds of any Credit Extension for that purpose; fail to (a) meet the minimum funding requirements of ERISA, (b) prevent a Reportable Event or Prohibited Transaction, as defined in
ERISA, from occurring, or (c) comply with the Federal Fair Labor Standards Act, the failure of any of the conditions described in clauses (a) through (c) which could reasonably be expected to have a material adverse effect on
Borrower’s business; or violate any other law or regulation, if the violation could reasonably be expected to have a material adverse effect on Borrower’s business, or permit any of its Subsidiaries to do so; withdraw or permit any
Subsidiary to withdraw from participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred compensation plan which could reasonably be
expected to result in any liability of Borrower, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency. 

8. EVENTS OF DEFAULT 

Any one of the following shall constitute an event of default (an “Event of Default”) under this Agreement: 

8.1 Payment Default. Borrower fails to (a) make any payment of principal or interest on any Credit Extension when due, or
(b) pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day cure period shall not apply to payments due on the Term Loan Maturity Date). During the cure period,
the failure to make or pay any payment specified under clause (b) hereunder is not an Event of Default (but no Credit Extension will be made during the cure period); 

8.2 Covenant Default. 
 (a)
Borrower fails or neglects to perform any obligation in Sections 6.2, 6.4, 6.5, 6.6, 6.7(b) 6.9, 6.11, or 6.12 or violates any covenant in Section 7; or 

(b) Borrower fails or neglects to perform, keep, or observe any other term, provision, condition, covenant or agreement contained in this
Agreement or any Loan Documents, and as to any default (other than those specified in this Section 8) under such other term, provision, condition, covenant or agreement that can be cured, has failed to cure the default within ten (10) days
after the occurrence thereof; provided, however, that if the default cannot by its nature be cured within the ten (10) day period or cannot after diligent attempts by Borrower be cured within such ten (10) day period, and such default is
likely to be cured within a reasonable time, then Borrower shall have an additional period (which shall not in any case exceed thirty (30) days) to attempt to cure such default, and within such reasonable time period the failure to cure the
default shall not be deemed an Event of Default (but no Credit Extensions shall be made during such cure period). Cure periods provided under this section shall not apply, among other things, to financial covenants or any other covenants set forth
in clause (a) above; 
 8.3 Material Adverse Change. A Material Adverse Change occurs; 

8.4 Attachment; Levy; Restraint on Business. 

(a) (i) The service of process seeking to attach, by trustee or similar process, any funds of Borrower or of any entity under the control of
Borrower (including a Subsidiary), or (ii) a notice of lien or levy is filed against any of Borrower’s assets by any Governmental Authority, and the same under subclauses (i) and (ii) hereof are not, within ten (10) days after
the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise); provided, however, no Credit Extensions shall be made during any ten (10) day cure period; or 

(b) (i) any material portion of Borrower’s assets is attached, seized, levied on, or comes into possession of a trustee or receiver, or
(ii) any court order enjoins, restrains, or prevents Borrower from conducting all or any material part of its business; 

  
 -14- 

 8.5 Insolvency. (a) Borrower is unable to pay its debts (including trade
debts) as they become due or otherwise becomes insolvent; (b) Borrower begins an Insolvency Proceeding; or (c) an Insolvency Proceeding is begun against Borrower and is not dismissed or stayed within thirty (30) days (but no Credit
Extensions shall be made while any of the conditions described in clause (a) exist and/or until any Insolvency Proceeding is dismissed); 

8.6 Other Agreements. There is, under any agreement to which Borrower or any Guarantor is a party with a third party or parties,
(a) any default resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount individually or in the aggregate in excess of Two Hundred Fifty Thousand Dollars
($250,000.00); or (b) any breach or default by Borrower or Guarantor, the result of which could reasonably be expected to have a material adverse effect on Borrower’s or any Guarantor’s business; 

8.7 Judgments; Penalties. One or more fines, penalties or final judgments, orders or decrees for the payment of money in an
amount, individually or in the aggregate, of at least Two Hundred Fifty Thousand Dollars ($250,000.00) (not covered by independent third-party insurance as to which liability has been accepted by such insurance carrier) shall be rendered against
Borrower by any Governmental Authority, and the same are not, within ten (10) days after the entry, assessment or issuance thereof, discharged, satisfied, or paid, or after execution thereof, stayed or bonded pending appeal, or such judgments
are not discharged prior to the expiration of any such stay (provided that no Credit Extensions will be made prior to the satisfaction, payment, discharge, stay, or bonding of such fine, penalty, judgment, order or decree); 

8.8 Misrepresentations. Borrower or any Person acting for Borrower makes any representation, warranty, or other statement now or
later in this Agreement, any Loan Document or in any writing delivered to Bank or to induce Bank to enter this Agreement or any Loan Document, and such representation, warranty, or other statement is incorrect in any material respect when made; 

8.9 Subordinated Debt. Any document, instrument, or agreement evidencing any Subordinated Debt shall for any reason be revoked or
invalidated or otherwise cease to be in full force and effect, any Person shall be in breach thereof or contest in any manner the validity or enforceability thereof or deny that it has any further liability or obligation thereunder, or the
Obligations shall for any reason be subordinated or shall not have the priority contemplated by this Agreement; 
 8.10 Guaranty.
(a) Any guaranty of any Obligations terminates or ceases for any reason to be in full force and effect; (b) any Guarantor does not perform any obligation or covenant under any guaranty of the Obligations; (c) any circumstance
described in Sections 8.3, 8.4, 8.5, 8.6, 8.7, or 8.8 of this Agreement occurs with respect to any Guarantor, (d) the death, liquidation, winding up, or termination of existence of any Guarantor; or (e) 

(i) a material impairment in the perfection or priority of Bank’s Lien in the collateral provided by Guarantor or in the value of such
collateral or (ii) a material adverse change in the general affairs, management, results of operation, condition (financial or otherwise) or the prospect of repayment of the Obligations occurs with respect to any Guarantor; or 

8.11 Governmental Approvals. Any Governmental Approval shall have been (a) revoked, rescinded, suspended, modified in an
adverse manner or not renewed in the ordinary course for a full term or (b) subject to any decision by a Governmental Authority that designates a hearing with respect to any applications for renewal of any of such Governmental Approval or that
could result in the Governmental Authority taking any of the actions described in clause (a) above, and such decision or such revocation, rescission, suspension, modification or non- renewal (i) causes, or could reasonably be expected to
cause, a Material Adverse Change, or (ii) adversely affects the legal qualifications of Borrower or any of its Subsidiaries to hold such Governmental Approval in any applicable jurisdiction and such revocation, rescission, suspension,
modification or non-renewal could reasonably be expected to affect the status of or legal qualifications of Borrower or any of its Subsidiaries to hold any Governmental Approval in any other jurisdiction. 

  
 -15- 

 9. BANK’S RIGHTS AND REMEDIES 

9.1 Rights and Remedies. Upon the occurrence and during the continuance of an Event of Default, Bank may, without notice or
demand, do any or all of the following: 
 (a) declare all Obligations immediately due and payable (but if an Event of Default described in
Section 8.5 occurs all Obligations are immediately due and payable without any action by Bank); 
 (b) stop advancing money or extending
credit for Borrower’s benefit under this Agreement or under any other agreement between Borrower and Bank; 
 (c) demand that Borrower
(i) deposit cash with Bank in an amount equal to at least (x) one hundred five percent (105.0%) of the Dollar Equivalent of the aggregate face amount of all Letters of Credit denominated in Dollars remaining undrawn, and (y) one
hundred ten percent (110.0%) of the Dollar Equivalent of the aggregate face amount of all Letters of Credit denominated in a Foreign Currency remaining undrawn (plus, in each case, all interest, fees, and costs due or to become due in connection
therewith (as estimated by Bank in its good faith business judgment)), to secure all of the Obligations relating to such Letters of Credit, as collateral security for the repayment of any future drawings under such Letters of Credit, and Borrower
shall forthwith deposit and pay such amounts, and (ii) pay in advance all letter of credit fees scheduled to be paid or payable over the remaining term of any Letters of Credit; 

(d) terminate any FX Contracts; 

(e) verify the amount of, demand payment of and performance under, and collect any Accounts and General Intangibles, settle or adjust disputes
and claims directly with Account Debtors for amounts on terms and in any order that Bank considers advisable, and notify any Person owing Borrower money of Bank’s security interest in such funds; 

(f) make any payments and do any acts it considers necessary or reasonable to protect the Collateral and/or its security interest in the
Collateral. Borrower shall assemble the Collateral if Bank requests and make it available as Bank designates. Bank may enter premises where the Collateral is located, take and maintain possession of any part of the Collateral, and pay, purchase,
contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred. Borrower grants Bank a license to enter and occupy any of its premises, without charge, to exercise any of Bank’s
rights or remedies; 
 (g) apply to the Obligations (i) any balances and deposits of Borrower it holds, or (ii) any amount held by
Bank owing to or for the credit or the account of Borrower; 
 (h) ship, reclaim, recover, store, finish, maintain, repair, prepare for sale,
advertise for sale, and sell the Collateral. Bank is hereby granted a non-exclusive, royalty-free license or other right to use, without charge, Borrower’s labels, Patents, Copyrights, mask works, rights
of use of any name, trade secrets, trade names, Trademarks, and advertising matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral and, in connection with
Bank’s exercise of its rights under this Section, Borrower’s rights under all licenses and all franchise agreements inure to Bank’s benefit; 

(i) place a “hold” on any account maintained with Bank and/or deliver a notice of exclusive control, any entitlement order, or other
directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral; 
 (j) demand and
receive possession of Borrower’s Books; and 
 (k) exercise all rights and remedies available to Bank under the Loan Documents or at law
or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof). 
 9.2
Power of Attorney. Borrower hereby irrevocably appoints Bank as its lawful attorney-in-fact, exercisable upon the occurrence and during the continuance of an
Event of Default, to: (a) endorse Borrower’s name on any checks or other forms of payment or security; (b) sign Borrower’s name on any invoice or bill of lading for any Account or drafts against Account Debtors; (c) settle and
adjust disputes and claims about the Accounts directly with Account Debtors, for amounts and on terms Bank determines reasonable; (d) make, settle, and adjust 

  
 -16- 

 
all claims under Borrower’s insurance policies; (e) pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the Collateral, or any judgment
based thereon, or otherwise take any action to terminate or discharge the same; and (f) transfer the Collateral into the name of Bank or a third party as the Code permits. Borrower hereby appoints Bank as its lawful attorney-in-fact to sign Borrower’s name on any documents necessary to perfect or continue the perfection of Bank’s security interest in the Collateral regardless of
whether an Event of Default has occurred until all Obligations have been satisfied in full and Bank is under no further obligation to make Credit Extensions hereunder. Bank’s foregoing appointment as Borrower’s attorney in fact, and all of
Bank’s rights and powers, coupled with an interest, are irrevocable until all Obligations have been fully repaid and performed and Bank’s obligation to provide Credit Extensions terminates. 

9.3 Protective Payments. If Borrower fails to obtain the insurance called for by Section 6.5 or fails to pay any premium
thereon or fails to pay any other amount which Borrower is obligated to pay under this Agreement or any other Loan Document or which may be required to preserve the Collateral, Bank may obtain such insurance or make such payment, and all amounts so
paid by Bank are Bank Expenses and immediately due and payable, bearing interest at the then highest rate applicable to the Obligations, and secured by the Collateral. Bank will make reasonable efforts to provide Borrower with notice of Bank
obtaining such insurance at the time it is obtained or within a reasonable time thereafter. No payments by Bank are deemed an agreement to make similar payments in the future or Bank’s waiver of any Event of Default. 

9.4 Application of Payments and Proceeds Upon Default. If an Event of Default has occurred and is continuing, Bank shall have the
right to apply in any order any funds in its possession, whether from Borrower account balances, payments, proceeds realized as the result of any collection of Accounts or other disposition of the Collateral, or otherwise, to the Obligations. Bank
shall pay any surplus to Borrower by credit to the Designated Deposit Account or to other Persons legally entitled thereto; Borrower shall remain liable to Bank for any deficiency. If Bank, directly or indirectly, enters into a deferred payment or
other credit transaction with any purchaser at any sale of Collateral, Bank shall have the option, exercisable at any time, of either reducing the Obligations by the principal amount of the purchase price or deferring the reduction of the
Obligations until the actual receipt by Bank of cash therefor. 
 9.5 Bank’s Liability for Collateral. So long as Bank
complies with reasonable banking practices regarding the safekeeping of the Collateral in the possession or under the control of Bank, Bank shall not be liable or responsible for: (a) the safekeeping of the Collateral; (b) any loss or
damage to the Collateral; (c) any diminution in the value of the Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or other Person. Borrower bears all risk of loss, damage or destruction of the Collateral. 

9.6 No Waiver; Remedies Cumulative. Bank’s failure, at any time or times, to require strict performance by Borrower of any
provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Bank thereafter to demand strict performance and compliance herewith or therewith. No waiver hereunder shall be effective unless signed by the
party granting the waiver and then is only effective for the specific instance and purpose for which it is given. Bank’s rights and remedies under this Agreement and the other Loan Documents are cumulative. Bank has all rights and remedies
provided under the Code, by law, or in equity. Bank’s exercise of one right or remedy is not an election and shall not preclude Bank from exercising any other remedy under this Agreement or other remedy available at law or in equity, and
Bank’s waiver of any Event of Default is not a continuing waiver. Bank’s delay in exercising any remedy is not a waiver, election, or acquiescence. 

9.7 Demand Waiver. Borrower waives demand, notice of default or dishonor, notice of payment and nonpayment, notice of any
default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Bank on which Borrower is liable. 

9.8 Borrower Liability. Either Borrower may, acting singly, request Advances hereunder. Each Borrower hereby appoints the other
as agent for the other for all purposes hereunder, including with respect to requesting Advances hereunder. Each Borrower hereunder shall be jointly and severally obligated to repay all Advances made hereunder, regardless of which Borrower actually
receives said Advance, as if each Borrower hereunder directly received all Advances. Each Borrower waives (a) any suretyship defenses available to it under the Code or any other applicable law, and (b) any right to require Bank to:
(i) proceed against any Borrower or any 

  
 -17- 

 
other person; (ii) proceed against or exhaust any security; or (iii) pursue any other remedy. Bank may exercise or not exercise any right or remedy it has against any Borrower or any
security it holds (including the right to foreclose by judicial or non-judicial sale) without affecting any Borrower’s liability. Notwithstanding any other provision of this Agreement or other related
document, each Borrower irrevocably waives all rights that it may have at law or in equity (including, without limitation, any law subrogating Borrower to the rights of Bank under this Agreement) to seek contribution, indemnification or any other
form of reimbursement from any other Borrower, or any other Person now or hereafter primarily or secondarily liable for any of the Obligations, for any payment made by Borrower with respect to the Obligations in connection with this Agreement or
otherwise and all rights that it might have to benefit from, or to participate in, any security for the Obligations as a result of any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise. Any
agreement providing for indemnification, reimbursement or any other arrangement prohibited under this Section shall be null and void. If any payment is made to a Borrower in contravention of this Section, such Borrower shall hold such payment in
trust for Bank and such payment shall be promptly delivered to Bank for application to the Obligations, whether matured or unmatured. 

10. NOTICES 
 All
notices, consents, requests, approvals, demands, or other communication by any party to this Agreement or any other Loan Document must be in writing and shall be deemed to have been validly served, given, or delivered: (a) upon the earlier of
actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage prepaid; (b) upon transmission, when sent by electronic mail or facsimile
transmission; (c) one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid; or (d) when delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent
to the address, facsimile number, or email address indicated below. Bank or Borrower may change its mailing or electronic mail address or facsimile number by giving the other party written notice thereof in accordance with the terms of this
Section 10. 
  

			
	 If to Borrower:
	  	DiCE Molecules SV, Inc.
		  	 DiCE Alpha, Inc.
 279 E. Grand Avenue, Suite
300
 South San Francisco, CA 94080

		  	Attn:
                                         
                                       
		  	Email:
                                         
                                     
		
	 with a copy to:
	  	 Fenwick & West LLC
 555 California
Street
 San Francisco, CA 94104

		  	Attn: Matthew Rossiter
		  	Email: mrossiter@fenwick.com
		
	 If to Bank:
	  	Silicon Valley Bank
		  	 505 Howard Street, 3rd Floor

San Francisco, California 94103
 Attn: Peter
Sletteland

		  	Email: PSletteland@svb.com
		
	 with a copy to:
	  	 Morrison & Foerster LLP
 200 Clarendon
Street

		  	Boston, Massachusetts 02116
		  	 Attn: David A. Ephraim, Esquire
 Email:
DEphraim@mofo.com

  
 -18- 

 11. CHOICE OF LAW, VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE 

Except as otherwise expressly provided in any of the Loan Documents, California law governs the Loan Documents without regard to principles of
conflicts of law. Borrower and Bank each submit to the exclusive jurisdiction of the State and Federal courts in Santa Clara County, California; provided, however, that nothing in this Agreement shall be deemed to operate to preclude Bank from
bringing suit or taking other legal action in any other jurisdiction to realize on the Collateral or any other security for the Obligations, or to enforce a judgment or other court order in favor of Bank. Borrower expressly submits and consents in
advance to such jurisdiction in any action or suit commenced in any such court, and Borrower hereby waives any objection that it may have based upon lack of personal jurisdiction, improper venue, or forum non conveniens and hereby consents to the
granting of such legal or equitable relief as is deemed appropriate by such court. Borrower hereby waives personal service of the summons, complaints, and other process issued in such action or suit and agrees that service of such summons,
complaints, and other process may be made by registered or certified mail addressed to Borrower at the address set forth in, or subsequently provided by Borrower in accordance with, Section 10 of this Agreement and that service so made shall be
deemed completed upon the earlier to occur of Borrower’s actual receipt thereof or three (3) days after deposit in the U.S. mails, proper postage prepaid. 

TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER AND BANK EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION
ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR BOTH PARTIES TO ENTER INTO THIS AGREEMENT. EACH
PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL. 
 WITHOUT INTENDING IN ANY WAY TO LIMIT THE PARTIES’ AGREEMENT TO WAIVE THEIR
RESPECTIVE RIGHT TO A TRIAL BY JURY, if the above waiver of the right to a trial by jury is not enforceable, the parties hereto agree that any and all disputes or controversies of any nature between them arising at any time shall be decided by a
reference to a private judge, mutually selected by the parties (or, if they cannot agree, by the Presiding Judge of the Santa Clara County, California Superior Court) appointed in accordance with California Code of Civil Procedure Section 638
(or pursuant to comparable provisions of federal law if the dispute falls within the exclusive jurisdiction of the federal courts), sitting without a jury, in Santa Clara County, California; and the parties hereby submit to the jurisdiction of such
court. The reference proceedings shall be conducted pursuant to and in accordance with the provisions of California Code of Civil Procedure Sections 638 through 645.1, inclusive. The private judge shall have the power, among others, to grant
provisional relief, including without limitation, entering temporary restraining orders, issuing preliminary and permanent injunctions and appointing receivers. All such proceedings shall be closed to the public and confidential and all records
relating thereto shall be permanently sealed. If during the course of any dispute, a party desires to seek provisional relief, but a judge has not been appointed at that point pursuant to the judicial reference procedures, then such party may apply
to the Santa Clara County, California Superior Court for such relief. The proceeding before the private judge shall be conducted in the same manner as it would be before a court under the rules of evidence applicable to judicial proceedings. The
parties shall be entitled to discovery which shall be conducted in the same manner as it would be before a court under the rules of discovery applicable to judicial proceedings. The private judge shall oversee discovery and may enforce all discovery
rules and orders applicable to judicial proceedings in the same manner as a trial court judge. The parties agree that the selected or appointed private judge shall have the power to decide all issues in the action or proceeding, whether of fact or
of law, and shall report a statement of decision thereon pursuant to California Code of Civil Procedure Section 644(a). Nothing in this paragraph shall limit the right of any party at any time to exercise self-help remedies, foreclose against
collateral, or obtain provisional remedies. The private judge shall also determine all issues relating to the applicability, interpretation, and enforceability of this paragraph. 

This Section 11 shall survive the termination of this Agreement. 

12. GENERAL PROVISIONS 

12.1 Termination Prior to Term Loan Maturity Date; Survival. All covenants, representations and warranties made in this Agreement
shall continue in full force until this Agreement has terminated pursuant to its terms and all Obligations have been satisfied. So long as Borrower has satisfied the Obligations (other than inchoate indemnity obligations and, any other obligations
which, by their terms, are to survive the termination of this Agreement, and any Obligations under Bank Services Agreements that are cash collateralized in accordance with 

  
 -19- 

 
Section 4.1 of this Agreement), this Agreement may be terminated prior to the Term Loan Maturity Date by Borrower, effective three (3) Business Days after written notice of termination
is given to Bank. Those obligations that are expressly specified in this Agreement as surviving this Agreement’s termination shall continue to survive notwithstanding this Agreement’s termination. 

12.2 Successors and Assigns. This Agreement binds and is for the benefit of the successors and permitted assigns of each party.
Borrower may not assign this Agreement or any rights or obligations under it without Bank’s prior written consent (which may be granted or withheld in Bank’s discretion). Bank has the right, without the consent of or notice to Borrower, to
sell, transfer, assign, negotiate, or grant participation in all or any part of, or any interest in, Bank’s obligations, rights, and benefits under this Agreement and the other Loan Documents (other than the Warrant, as to which assignment,
transfer and other such actions are governed by the terms thereof). 
 12.3 Indemnification. Borrower agrees to indemnify,
defend and hold Bank and its directors, officers, employees, agents, attorneys, or any other Person affiliated with or representing Bank (each, an “Indemnified Person”) harmless against: (i) all obligations, demands, claims,
and liabilities (collectively, “Claims”) claimed or asserted by any other party in connection with the transactions contemplated by the Loan Documents; and (ii) all losses or expenses (including Bank Expenses) in any way
suffered, incurred, or paid by such Indemnified Person as a result of, following from, consequential to, or arising from transactions between Bank and Borrower (including reasonable attorneys’ fees and expenses), except for Claims and/or losses
directly caused by such Indemnified Person’s gross negligence or willful misconduct. 
 This Section 12.3 shall survive until all
statutes of limitation with respect to the Claims, losses, and expenses for which indemnity is given shall have run. 
 12.4 Time
of Essence. Time is of the essence for the performance of all Obligations in this Agreement. 
 12.5 Severability of
Provisions. Each provision of this Agreement is severable from every other provision in determining the enforceability of any provision. 

12.6 Correction of Loan Documents. Bank may correct patent errors and fill in any blanks in the Loan Documents consistent with
the agreement of the parties so long as Bank provides Borrower with written notice of such correction and allows Borrower at least ten (10) days to object to such correction. In the event of such objection, such correction shall not be made
except by an amendment signed by both Bank and Borrower. 
 12.7 Amendments in Writing; Waiver; Integration. No purported
amendment or modification of any Loan Document, or waiver, discharge or termination of any obligation under any Loan Document, shall be enforceable or admissible unless, and only to the extent, expressly set forth in a writing signed by the party
against which enforcement or admission is sought. Without limiting the generality of the foregoing, no oral promise or statement, nor any action, inaction, delay, failure to require performance or course of conduct shall operate as, or evidence, an
amendment, supplement or waiver or have any other effect on any Loan Document. Any waiver granted shall be limited to the specific circumstance expressly described in it, and shall not apply to any subsequent or other circumstance, whether similar
or dissimilar, or give rise to, or evidence, any obligation or commitment to grant any further waiver. The Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements,
understandings, representations, warranties, and negotiations between the parties about the subject matter of the Loan Documents merge into the Loan Documents. 

12.8 Counterparts. This Agreement may be executed in any number of counterparts and by different parties on separate
counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement. 
 12.9
Confidentiality. In handling any confidential information, Bank shall exercise the same degree of care that it exercises for its own proprietary information, but disclosure of information may be made: (a) to Bank’s Subsidiaries or
Affiliates (such Subsidiaries and Affiliates, together with Bank, collectively, “Bank Entities”); (b) 

  
 -20- 

 
to prospective transferees or purchasers of any interest in the Credit Extensions (provided, however, that any prospective transferee or purchaser shall have entered into an agreement containing
provisions substantially the same as those in this Section 12.9); (c) as required by law, regulation, subpoena, or other order; (d) to Bank’s regulators or as otherwise required in connection with Bank’s examination or audit;
(e) as Bank considers appropriate in exercising remedies under the Loan Documents; and (f) to third-party service providers of Bank so long as such service providers have executed a confidentiality agreement with Bank with terms no less
restrictive than those contained herein. Confidential information does not include information that is either: (i) in the public domain or in Bank’s possession when disclosed to Bank, or becomes part of the public domain (other than as a
result of its disclosure by Bank in violation of this Agreement) after disclosure to Bank; or (ii) disclosed to Bank by a third party, if Bank does not know that the third party is prohibited from disclosing the information. 

Bank Entities may use anonymous forms of confidential information for aggregate datasets, for analyses or reporting, and for any other uses
not expressly prohibited in writing by Borrower. The provisions of the immediately preceding sentence shall survive termination of this Agreement. 

12.10 Right of Set Off. Borrower hereby grants to Bank, a lien, security interest and right of set off as security for all
Obligations to Bank, whether now existing or hereafter arising upon and against all deposits, credits, collateral and property, now or hereafter in the possession, custody, safekeeping or control of Bank or any entity under the control of Bank
(including a Bank subsidiary) or in transit to any of them. At any time after the occurrence and during the continuance of an Event of Default, without demand or notice, Bank may set off the same or any part thereof and apply the same to any
liability or obligation of Borrower even though unmatured and regardless of the adequacy of any other collateral securing the Obligations. ANY AND ALL RIGHTS TO REQUIRE BANK TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL
WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF BORROWER ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED. 

12.11 Electronic Execution of Documents. The words “execution,” “signed,” “signature” and words of
like import in any Loan Document shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity and enforceability as a manually executed signature or the use
of a paper-based recordkeeping systems, as the case may be, to the extent and as provided for in any applicable law, including, without limitation, any state law based on the Uniform Electronic Transactions Act. 

12.12 Attorneys’ Fees, Costs and Expenses. In any action or proceeding between Borrower and Bank arising out of or relating
to the Loan Documents, the prevailing party shall be entitled to recover its reasonable attorneys’ fees and other costs and expenses incurred, in addition to any other relief to which it may be entitled. 

12.13 Captions. The headings used in this Agreement are for convenience only and shall not affect the interpretation of this
Agreement. 
 12.14 Construction of Agreement. The parties mutually acknowledge that they and their attorneys have participated
in the preparation and negotiation of this Agreement. In cases of uncertainty this Agreement shall be construed without regard to which of the parties caused the uncertainty to exist. 

12.15 Relationship. The relationship of the parties to this Agreement is determined solely by the provisions of this Agreement.
The parties do not intend to create any agency, partnership, joint venture, trust, fiduciary or other relationship with duties or incidents different from those of parties to an arm’s-length contract.

 12.16 Third Parties. Nothing in this Agreement, whether express or implied, is intended to: (a) confer any benefits,
rights or remedies under or by reason of this Agreement on any persons other than the express parties to it and their respective permitted successors and assigns; (b) relieve or discharge the obligation or liability of any person not an express
party to this Agreement; or (c) give any person not an express party to this Agreement any right of subrogation or action against any party to this Agreement. 

  
 -21- 

 13. DEFINITIONS 

13.1 Definitions. As used in the Loan Documents, the word “shall” is mandatory, the word “may” is permissive,
the word “or” is not exclusive, the words “includes” and “including” are not limiting, the singular includes the plural, and numbers denoting amounts that are set off in brackets are negative. As used in this Agreement,
the following capitalized terms have the following meanings: 
 “Account” is any “account” as defined in the Code
with such additions to such term as may hereafter be made, and includes, without limitation, all accounts receivable and other sums owing to Borrower. 

“Account Debtor” is any “account debtor” as defined in the Code with such additions to such term as may hereafter
be made. 
 “Affiliate” is, with respect to any Person, each other Person that owns or controls directly or indirectly the
Person, any Person that controls or is controlled by or is under common control with the Person, and each of that Person’s senior executive officers, directors, partners and, for any Person that is a limited liability company, that
Person’s managers and members. 
 “Agreement” is defined in the preamble hereof. 

“Alpha” is defined in the preamble hereof. 

“Authorized Signer” is any individual listed in Borrower’s Borrowing Resolutions who is authorized to execute the Loan
Documents, including any Credit Extension request, on behalf of Borrower. 
 “Bank” is defined in the preamble hereof. 

“Bank Entities” is defined in Section 12.9. 

“Bank Expenses” are all audit fees and expenses, costs, and expenses (including reasonable and documented attorneys’
fees and documented expenses) for preparing, amending, negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred
with respect to Borrower or any Guarantor. 
 “Bank Services” are any products, credit services, and/or financial
accommodations previously, now, or hereafter provided to Borrower or any of its Subsidiaries by Bank or any Bank Affiliate, including, without limitation, any letters of credit, cash management services (including, without limitation, merchant
services, direct deposit of payroll, business credit cards, and check cashing services), interest rate swap arrangements, and foreign exchange services as any such products or services may be identified in Bank’s various agreements related
thereto (each, a “Bank Services Agreement”). 
 “Bank Services Agreement” is defined in the definition of
Bank Services. 
 “Board” means Parent’s and/or Borrower’s board of directors. 

“Borrower” is defined in the preamble hereof. 

“Borrower’s Books” are all Borrower’s books and records including ledgers, federal and state tax returns, records
regarding Borrower’s assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information. 

“Borrowing Resolutions” are, with respect to any Person, those resolutions adopted by such Person’s board of directors (and, if required
under the terms of such Person’s Operating Documents, stockholders) and delivered by such Person to Bank approving the Loan Documents to which such Person is a party and the transactions contemplated thereby, together with a certificate
executed by its secretary on behalf of such Person certifying (a) such Person has the authority to execute, deliver, and perform its obligations under each of the Loan Documents to which it is a party, (b) that set forth as a part of or
attached as an exhibit to such certificate is a true, 

  
 -22- 

 
correct, and complete copy of the resolutions then in full force and effect authorizing and ratifying the execution, delivery, and performance by such Person of the Loan Documents to which it is
a party, (c) the name(s) of the Person(s) authorized to execute the Loan Documents, including any Credit Extension request, on behalf of such Person, together with a sample of the true signature(s) of such Person(s), and (d) that Bank may
conclusively rely on such certificate unless and until such Person shall have delivered to Bank a further certificate canceling or amending such prior certificate. 

“Business Day” is any day that is not a Saturday, Sunday or a day on which Bank is closed, except that if any determination
of a “Business Day” shall relate to an FX Contract, the term “Business Day” shall mean a day on which dealings are carried on in the country of settlement of the Foreign Currency. 

“Cash Equivalents” means (a) marketable direct obligations issued or unconditionally guaranteed by the United States or
any agency or any State thereof having maturities of not more than one (1) year from the date of acquisition; (b) commercial paper maturing no more than one (1) year after its creation and having the highest rating from either
Standard & Poor’s Ratings Group or Moody’s Investors Service, Inc.; (c) Bank’s certificates of deposit issued maturing no more than one (1) year after issue; and (d) money market funds at least ninety-five percent
(95.0%) of the assets of which constitute Cash Equivalents of the kinds described in clauses (a) through (c) of this definition. 

“Change in Control” means (a) at any time, any “person” or “group” (as such terms are used in
Sections 13(d) and 14(d) of the Exchange Act) shall become, or obtain rights (whether by means of warrants, options or otherwise) to become, the “beneficial owner” (as defined in Rules 13(d)-3 and 13(d)-5 under the Exchange Act), directly or indirectly, of forty-nine percent (49.0%) or more of the ordinary voting power for the election of directors of Borrower (determined on a fully diluted basis) other than
by the sale of Borrower’s equity securities in a public offering or to venture capital or private equity investors so long as Borrower identifies to Bank the venture capital or private equity investors at least seven (7) Business Days
prior to the closing of the transaction and provides to Bank a description of the material terms of the transaction; (b) during any period of twelve (12) consecutive months, a majority of the members of the board of directors or other
equivalent governing body of Borrower cease to be composed of individuals (i) who were members of that board or equivalent governing body on the first day of such period, (ii) whose election or nomination to that board or equivalent
governing body was approved by individuals referred to in clause (i) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body or (iii) whose election or nomination to that
board or other equivalent governing body was approved by individuals referred to in clauses (i) and (ii) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body; or
(c) at any time, Borrower shall cease to own and control, of record and beneficially, directly or indirectly, one hundred percent (100.0%) of each class of outstanding capital stock of each Subsidiary of Borrower free and clear of all Liens
(except Liens created by this Agreement and Permitted Liens). 
 “Claims” is defined in Section 12.3. 

“Code” is the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of
California; provided, that, to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently in different Articles or Divisions of the Code, the definition of such term contained in Article
or Division 9 shall govern; provided further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies with respect to, Bank’s Lien on any Collateral is governed by
the Uniform Commercial Code in effect in a jurisdiction other than the State of California, the term “Code” shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the
provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions. 

“Collateral” is any and all properties, rights and assets of Borrower described on Exhibit A. 

“Collateral Account” is any Deposit Account, Securities Account, or Commodity Account. 

“Commodity Account” is any “commodity account” as defined in the Code with such additions to such term as may
hereafter be made. 

  
 -23- 

 “Compliance Statement” is that certain certificate in the form attached
hereto as Exhibit B. 
 “Contingent Obligation” is, for any Person, any direct or indirect liability, contingent or
not, of that Person for (a) any indebtedness, lease, dividend, letter of credit or other obligation of another such as an obligation, in each case, directly or indirectly guaranteed, endorsed, co-made,
discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable; (b) any obligations for undrawn letters of credit for the account of that Person; and (c) all obligations from any interest rate,
currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; but “Contingent
Obligation” does not include endorsements in the ordinary course of business. The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not
determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement. 

“Control Agreement” is any control agreement entered into among the depository institution at which Borrower maintains a
Deposit Account or the securities intermediary or commodity intermediary at which Borrower maintains a Securities Account or a Commodity Account, Borrower, and Bank pursuant to which Bank obtains control (within the meaning of the Code) over such
Deposit Account, Securities Account, or Commodity Account. 
 “Copyrights” are any and all copyright rights, copyright
applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret. 

“Credit Extension” is any Term Loan Advance or any other extension of credit by Bank for Borrower’s benefit. 

“Default Rate” is defined in Section 2.2(b). 

“Deposit Account” is any “deposit account” as defined in the Code with such additions to such term as may hereafter
be made. 
 “Designated Deposit Account” is the account number ending [***] (last three digits) maintained by Borrower with
Bank (provided, however, if no such account number is included, then the Designated Deposit Account shall be any deposit account of Borrower maintained with Bank as chosen by Bank). 

“Division” means, in reference to any Person which is an entity, the division of such Person into two (2) or more
separate Persons, with the dividing Person either continuing or terminating its existence as part of such division, including, without limitation, as contemplated under Section 18-217 of the Delaware
Limited Liability Company Act for limited liability companies formed under Delaware law, or any analogous action taken pursuant to any other applicable law with respect to any corporation, limited liability company, partnership or other entity. 

“Dollars,” “dollars” or use of the sign “$” means only lawful money of the United
States and not any other currency, regardless of whether that currency uses the “$” sign to denote its currency or may be readily converted into lawful money of the United States. 

“Dollar Equivalent” is, at any time, (a) with respect to any amount denominated in Dollars, such amount, and
(b) with respect to any amount denominated in a Foreign Currency, the equivalent amount therefor in Dollars as determined by Bank at such time on the basis of the then-prevailing rate of exchange in San Francisco, California, for sales of the
Foreign Currency for transfer to the country issuing such Foreign Currency. 
 “Draw Period A” is the period of time
commencing upon the Effective Date and continuing through the earlier to occur of (a) December 31, 2021, or (b) an Event of Default that has occurred and is continuing hereunder. 

  
 -24- 

 “Draw Period B” is the period of time commencing upon the occurrence of
Performance Milestone 1 and continuing through the earlier to occur of (a) March 31, 2022, or (b) an Event of Default that has occurred and is continuing hereunder. 

“Draw Period C” is the period of time commencing upon the occurrence of Performance Milestone 1 and Performance Milestone 2
and continuing through the earlier to occur of (a) June 30, 2022, or (b) an Event of Default that has occurred and is continuing hereunder. 

“Effective Date” is defined in the preamble hereof. 

“Equipment” is all “equipment” as defined in the Code with such additions to such term as may hereafter be made,
and includes without limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing. 

“ERISA” is the Employee Retirement Income Security Act of 1974, and its regulations. “Event of Default” is
defined in Section 8. 
 “Exchange Act” is the Securities Exchange Act of 1934, as amended. 

“Final Payment” is a payment (in addition to and not in substitution for the regular monthly payments of principal plus
accrued interest) equal to the aggregate original principal amount of the Term Loan Advances extended by the Bank to Borrower hereunder multiplied by five and three-quarters of one percent (5.75%) due on the earliest to occur of (a) the Term
Loan Maturity Date, (b) the payment in full of the Term Loan Advances, (c) as required by Section 2.1.1(d) or Section 2.1.1(e), or (d) the termination of this Agreement. 

“Financial Statement Repository” is LifeScienceReporting@svb.com or such other means of collecting information approved and
designated by Bank after providing notice thereof to Borrower from time to time. 
 “Foreign Currency” means lawful money
of a country other than the United States. 
 “Funding Date” is any date on which a Credit Extension is made to or for the
account of Borrower which shall be a Business Day. 
 “FX Contract” is any foreign exchange contract by and between
Borrower and Bank under which Borrower commits to purchase from or sell to Bank a specific amount of Foreign Currency on a specified date. 

“GAAP” is generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles
Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant segment of the
accounting profession, which are applicable to the circumstances as of the date of determination. 
 “General Intangibles”
is all “general intangibles” as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made, and includes without limitation, all Intellectual Property, claims, income and other tax refunds,
security and other deposits, payment intangibles, contract rights, options to purchase or sell real or personal property, rights in all litigation presently or hereafter pending (whether in contract, tort or otherwise), insurance policies (including
without limitation key man, property damage, and business interruption insurance), payments of insurance and rights to payment of any kind. 

“Governmental Approval” is any consent, authorization, approval, order, license, franchise, permit, certificate,
accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority. 

  
 -25- 

 “Governmental Authority” is any nation or government, any state or other
political subdivision thereof, any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government,
any securities exchange and any self-regulatory organization. 
 “Guarantor” is (a) Parent, and (b) any other
Person providing a Guaranty in favor of Bank. 
 “Guaranty” is (a) that certain Unconditional Guaranty by and between
Parent and Bank dated as of the Effective Date and (b) any other guarantee of all or any part of the Obligations, as the same may from time to time be amended, restated, modified or otherwise supplemented. 

“Indebtedness” is (a) indebtedness for borrowed money or the deferred price of property or services, such as
reimbursement and other obligations for surety bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease obligations, and (d) Contingent Obligations. 

“Indemnified Person” is defined in Section 12.3. 

“Insolvency Proceeding” is any proceeding by or against any Person under the United States Bankruptcy Code, or any other
bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief. 

“Intellectual Property” means, with respect to any Person, all of such Person’s right, title, and interest in and to the
following: 
 (a) its Copyrights, Trademarks and Patents; 

(b) any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know-how, and operating manuals; 
 (c) any and all source code; 

(d) any and all design rights which may be available to such Person; 

(e) any and all claims for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the
obligation, to sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above; and 
 (f)
all amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents. 
 “Interest-Only Extension Event”
means delivery by Borrower to Bank, on or prior to June 30, 2022, of evidence satisfactory to Bank in its sole but reasonable discretion, that Borrower has received (a) positive phase 1(c) data (Proof of Concept in Psoriasis) for its IL-17 program that is sufficient initiate a Phase 2 study, or (b) at least Eighty-Five Million Dollars ($85,000,000.00) in net cash proceeds as a result of an Initial Public Offering. 

“Inventory” is all “inventory” as defined in the Code in effect on the date hereof with such additions to such term
as may hereafter be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such inventory as is temporarily out of
Borrower’s custody or possession or in transit and including any returned goods and any documents of title representing any of the above. 

“Investment” is any beneficial ownership interest in any Person (including stock, partnership interest or other securities),
and any loan, advance or capital contribution to any Person. 

  
 -26- 

 “Key Person” is the Parent’s (a) Chief Executive Officer, who is
Kevin Judice as of the Effective Date, and (b) Chief Financial Officer, who is Scott Robertson as of the Effective Date. 

“Letter of Credit” is a standby or commercial letter of credit issued by Bank upon request of Borrower based upon an
application, guarantee, indemnity, or similar agreement. 
 “Lien” is a claim, mortgage, deed of trust, levy, charge,
pledge, security interest or other encumbrance of any kind, whether voluntarily incurred or arising by operation of law or otherwise against any property. 

“Loan Documents” are, collectively, this Agreement and any schedules, exhibits, certificates, notices, and any other
documents related to this Agreement, the Warrant, the Perfection Certificate, the Guaranty, the Security Agreement, any Control Agreement, any Bank Services Agreement, any subordination agreement, any note, or notes or guaranties executed by
Borrower or any Guarantor, and any other present or future agreement by Borrower and/or any Guarantor with or for the benefit of Bank in connection with this Agreement or Bank Services, all as amended, restated, or otherwise modified. 

“Material Adverse Change” is (a) a material impairment in the perfection or priority of Bank’s Lien in the
Collateral or in the value of such Collateral; (b) a material adverse change in the business, operations, or condition (financial or otherwise) of Borrower; or (c) a material impairment of the prospect of repayment of any portion of the
Obligations when due. In determining whether a “Material Adverse Change” has occurred under clause (b) or (c) above, Bank’s primary, though not sole, consideration will be whether Borrower has or will have sufficient cash
resources to repay the Obligations as and when due. Bank recognizes that, as a pre-profit company, Borrower’s cash resources will decline over time, and Borrower will periodically require additional
infusions of equity capital. The clear intention of Borrower’s investors to continue to fund Borrower in the amounts and timeframe necessary, in Bank’s judgment, to enable Borrower to satisfy the Obligations as they become due and payable
is the most significant criterion Bank shall consider in making any such determination. 
 “Monthly Financial Statements”
is defined in Section 6.2(a). 
 “Obligations” are Borrower’s obligations to pay when due any debts, principal,
interest, fees, Bank Expenses, the Prepayment Fee, the Final Payment, and other amounts Borrower owes Bank now or later, whether under this Agreement, the other Loan Documents (other than the Warrant), or otherwise, including, without limitation,
all obligations relating to Bank Services and any interest accruing after Insolvency Proceedings begin and debts, liabilities, or obligations of Borrower assigned to Bank, and to perform Borrower’s duties under the Loan Documents (other than
the Warrant). 
 “Operating Documents” are, for any Person, such Person’s formation documents, as certified by the
Secretary of State (or equivalent agency) of such Person’s jurisdiction of organization on a date that is no earlier than thirty (30) days prior to the Effective Date, and, (a) if such Person is a corporation, its bylaws in current
form, (b) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c) if such Person is a partnership, its partnership agreement (or similar agreement), each of the foregoing with all
current amendments or modifications thereto. 
 “Parent” means DiCE Molecules Holdings, LLC, a Delaware limited liability
company. 
 “Parent LLC Agreement” means the Parent’s Fourth Amended and Restated Limited Liability Company Agreement,
as amended, restated, supplemented or otherwise modified from time to time. 
 “Patents” means all patents, patent
applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the
same. 
 “Payment/Advance Form” is that certain form attached hereto as Exhibit C. 

“Payment Date” is the first (1st) calendar day of each month. 

  
 -27- 

 “Perfection Certificate” is defined in Section 5.1. 

“Performance Milestone 1” means delivery by Borrower to Bank, on or prior to March 31, 2022, of evidence satisfactory to
Bank in its sole but reasonable discretion, that Borrower has filed an IND or CTA for its IL- 17 program. 
 “Performance Milestone
2” means delivery by Borrower to Bank, on or prior to June 30, 2022, of evidence satisfactory to Bank in its sole but reasonable discretion, that Borrower has achieved positive phase 1(a) data for its
IL-17 program that is sufficient to access the second tranche of its Series C equity financing round. 

“Permitted Indebtedness” is: 

(a) Borrower’s Indebtedness to Bank under this Agreement and the other Loan Documents; 

(b) Indebtedness existing on the Effective Date and shown on the Perfection Certificate; 

(c) Subordinated Debt; 
 (d)
unsecured Indebtedness to trade creditors incurred in the ordinary course of business; 
 (e) Indebtedness incurred as a result of endorsing
negotiable instruments received in the ordinary course of business; 
 (f) Indebtedness secured by Liens permitted under clauses (a) and
(c) of the definition of Permitted Liens hereunder; 
 (g) Indebtedness constituting Investments described in clauses (c) or (d) of the
definition of “Permitted Investments” and intercompany Indebtedness owed to Parent; 
 (h) other unsecured Indebtedness not
otherwise permitted by Section 7.4 not exceeding Two Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate outstanding at any time; and 

(i) extensions, refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness (a) through (h) above,
provided that the principal amount thereof is not increased or the terms thereof are not modified to impose more burdensome terms upon Borrower or its Subsidiary, as the case may be. 

“Permitted Investments” are: 

(a) Investments (including, without limitation, Subsidiaries) existing on the Effective Date and shown on the Perfection Certificate; and 

(b) Investments consisting of Cash Equivalents and (ii) any Investments permitted by Borrower’s investment policy, as amended from
time to time, provided that such investment policy (and any such amendment thereto) has been approved in writing by Bank; 
 (c) Investments
by Borrower in a Subsidiary that is not a secured guarantor or co-borrower for ordinary, necessary and current operating expenses, in an amount not to exceed One Hundred Thousand Dollars ($100,000.00) in the
aggregate in any fiscal year, provided that, an Event of Default does not exist at the time of any such Investment and would not exist after giving effect to any such Investment; 

(d) Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary
course of business; 
 (e) Investments accepted in connection with Transfers permitted by Section 7.1; 

  
 -28- 

 (f) Investments consisting of (i) travel advances and employee relocation loans and
other employee loans and advances in the ordinary course of business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee stock purchase plans or
agreements approved by the Board; 
 (g) Investments (including debt obligations) received in connection with the bankruptcy or
reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business; 

(h) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not
Affiliates, in the ordinary course of business; provided that this paragraph (h) shall not apply to Investments of Borrower in any Subsidiary; 

(i) non-cash Investments in joint ventures, strategic alliances, licensing (consisting of non-
exclusive licenses and licenses that could not result in a legal transfer of title of the licensed property that may be exclusive in respects other than territory and that may be exclusive as to territory only as to discreet geographical areas
outside of the United States) and similar arrangements in the ordinary course of Borrower’s business or customary in Borrower’s industry, and which do not require Borrower to assume or otherwise become liable for the obligations of any
third party not directly related to or arising out of such arrangement or require Borrower to transfer ownership of assets to such joint venture or other entity; and 

(j) other Investments not otherwise permitted by Section 7.7 not exceeding Two Hundred Fifty Thousand Dollars ($250,000.00) in the
aggregate outstanding at any time. 
 “Permitted Liens” are: 

(a) Liens existing on the Effective Date and shown on the Perfection Certificate or arising under this Agreement and the other Loan Documents;

 (b) Liens for taxes, fees, assessments or other government charges or levies, either (i) not due and payable or (ii) being
contested in good faith and for which Borrower maintains adequate reserves on its Books, provided that no notice of any such Lien has been filed or recorded under the Internal Revenue Code of 1986, as amended, and the Treasury Regulations
adopted thereunder; 
 (c) purchase money Liens or capital leases (i) on Equipment acquired or held by Borrower incurred for financing
the acquisition of the Equipment securing no more than Two Million Five Hundred Thousand Dollars ($2,500,000.00) in the aggregate amount outstanding, or (ii) existing on Equipment when acquired, if the Lien is confined to the property
and improvements and the proceeds of the Equipment; 
 (d) Liens incurred in the extension, renewal or refinancing of the indebtedness
secured by Liens described in (a) through (c), but any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness may not increase; 

(e) Liens of carriers, warehousemen, suppliers, or other Persons that are possessory in nature arising in the ordinary course of business so
long as such Liens secure liabilities in the aggregate amount not to exceed Two Hundred Fifty Thousand Dollars ($250,000.00) and which are not delinquent or remain payable without penalty or which are being contested in good faith and by appropriate
proceedings which proceedings have the effect of preventing the forfeiture or sale of the property subject thereto; 
 (f) Liens to secure
payment of workers’ compensation, employment insurance, old-age pensions, social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA); 

  
 -29- 

 (g) deposits to secure the performance of bids, trade contracts, leases, statutory
obligations, surety and appeal bonds, performance bonds, and other obligations of a like nature, in each case, in the ordinary course of business not representing an obligation for borrowed money; 

(h) leases or subleases of real property granted in the ordinary course of Borrower’s business (or, if referring to another Person, in the
ordinary course of such Person’s business), and leases, subleases, non- exclusive licenses or sublicenses of personal property (other than Intellectual Property) granted in the ordinary course of Borrower’s business (or, if referring to
another Person, in the ordinary course of such Person’s business), if the leases, subleases, licenses and sublicenses do not prohibit granting Bank a security interest therein; 

(i) Liens arising from attachments or judgments, orders, or decrees in circumstances not constituting an Event of Default under Sections 8.4
and 8.7; 
 (j) Liens securing Subordinated Debt so long as (i) such Liens are subordinated to Bank’s Liens on terms acceptable to
Bank, and (ii) such Liens do not cover any property not subject to Bank’s Liens; 
 (k)
non-exclusive license of Intellectual Property granted to third parties in the ordinary course of business, and licenses of Intellectual Property that could not result in a legal transfer of title of the
licensed property that may be exclusive in respects other than territory and that may be exclusive as to territory only as to discreet geographical areas outside of the United States. 

“Permitted Tax Payments” means, with respect to any taxable year in which Parent is treated as a partnership or disregarded
entity for U.S. federal income tax purposes, the declaration and payment of cash dividends and making of cash distributions to Parent’s members pursuant to the Parent LLC Agreement with respect to the taxable income of Parent and its
Subsidiaries. 
 “Person” is any individual, sole proprietorship, partnership, limited liability company, joint venture,
company, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency. 

“Prepayment Fee” shall be an additional fee, payable to Bank, with respect to the Term Loan Advances, in an amount equal to:

 (a) for a prepayment of the Term Loan Advances made on or prior to the second (2nd
anniversary of the Effective Date, two percent (2.0%) of the then outstanding principal amount of such Term Loan Advances immediately prior to such prepayment; and 

(b) for a prepayment of the Term Loan Advances made after the second (2nd) anniversary of
the Effective Date, but prior to the Term Loan Maturity Date, one percent (1.0%) of the then outstanding principal amount of such Term Loan Advances immediately prior to such prepayment. 

Notwithstanding the foregoing, provided no Event of Default has occurred and is continuing, the Prepayment Fee shall be waived by Bank, if
Bank closes on the refinance and redocumentation of this Agreement (in its sole and absolute discretion) prior to the Term Loan Maturity Date. 

“Prime Rate” is the rate of interest per annum from time to time published in the money rates section of The Wall Street
Journal or any successor publication thereto as the “prime rate” then in effect; provided that, in the event such rate of interest is less than zero, such rate shall be deemed to be zero for purposes of this Agreement and provided further
that if such rate of interest, as set forth from time to time in the money rates section of The Wall Street Journal, becomes unavailable for any reason as determined by Bank, the “Prime Rate” shall mean the rate of interest per annum
announced by Bank as its prime rate in effect at its principal office in the State of California (such Bank announced Prime Rate not being intended to be the lowest rate of interest charged by Bank in connection with extensions of credit to
debtors); provided that, in the event such rate of interest is less than zero, such rate shall be deemed to be zero for purposes of this Agreement. 

  
 -30- 

 “Registered Organization” is any “registered organization” as
defined in the Code with such additions to such term as may hereafter be made. 
 “Repayment Schedule” means the period of
time equal to thirty-two (32) consecutive calendar months, which shall be reduced to a period of time equal to twenty-one (21) consecutive months upon the
occurrence of the Interest-Only Extension Event. 
 “Requirement of Law” is as to any Person, the organizational or
governing documents of such Person, and any law (statutory or common), treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its
property or to which such Person or any of its property is subject. 
 “Responsible Officer” is any of the Chief Executive
Officer, President, Chief Financial Officer and Controller of Borrower. 
 “Restricted License” is any material license or
other material agreement with respect to which Borrower is the licensee (a) that prohibits or otherwise restricts Borrower from granting a security interest in Borrower’s interest in such license or agreement or any other property, or
(b) for which a default under or termination of could reasonably be expected to interfere with the Bank’s right to sell any Collateral. 

“SEC” shall mean the Securities and Exchange Commission, any successor thereto, and any analogous Governmental Authority.

 “Securities Account” is any “securities account” as defined in the Code with such additions to such term as
may hereafter be made. 
 “Subordinated Debt” is indebtedness incurred by Borrower subordinated to all of Borrower’s
now or hereafter indebtedness to Bank (pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Bank entered into between Bank and the other creditor), on terms acceptable to Bank. 

“Subsidiary” is, as to any Person, a corporation, partnership, limited liability company or other entity of which shares of
stock or other ownership interests having ordinary voting power (other than stock or such other ownership interests having such power only by reason of the happening of a contingency) to elect a majority of the board of directors or other managers
of such corporation, partnership or other entity are at the time owned, or the management of which is otherwise controlled, directly or indirectly through one or more intermediaries, or both, by such Person. Unless the context otherwise requires,
each reference to a Subsidiary herein shall be a reference to a Subsidiary of Borrower or Guarantor. 
 “SV” is defined in
the preamble hereof. 
 “Term A Loan Advance” and “Term A Loan Advances” are each defined in
Section 2.1.1(a). 
 “Term B Loan Advance” and “Term B Loan Advances” are each defined in
Section 2.1.1(a). 
 “Term C Loan Advance” and “Term C Loan Advances” are each defined in
Section 2.1.1(a). 
 “Term Loan Advance” and “Term Loan Advances” are each defined in
Section 2.1.1(a). 
 “Term Loan Amortization Date” means July 1, 2022, which shall be extended until June 1,
2023 upon the occurrence of the Interest-Only Extension Event. 
 “Term Loan Maturity Date” is February 1, 2025. 

  
 -31- 

 “Trademarks” means any trademark and servicemark rights, whether registered
or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks. 

“Transfer” is defined in Section 7.1. 

“Warrant” is that certain warrant to purchase stock by and between Parent and Bank dated as of the Effective Date, as may be
amended, modified, supplemented and/or restated from time to time. 
 [Signature page follows.] 

  
 -32- 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as
of the Effective Date. 
  

			
	BORROWER:
	
	DICE MOLECULES SV, INC.
		
	By	 	 /s/ Scott Robertson

	Name: Scott Robertson
	 Title: Chief Financial Officer
  

DICE ALPHA, INC.

		
	By	 	 /s/ Scott Robertson

	Name: Scott Robertson
	Title: Chief Financial Officer
	
	BANK:
	
	SILICON VALLEY BANK
		
	By	 	 /s/ Peter Sletteland

	 Name: Peter Sletteland
 Title: Vice
President

 Signature Page to Loan and Security Agreement 

 EXHIBIT A – COLLATERAL DESCRIPTION 

The Collateral consists of all of Borrower’s right, title and interest in and to the following personal property: 

All goods, Accounts (including health-care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license
agreements, franchise agreements, General Intangibles (except as provided below), commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts, certificates
of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired,
wherever located; and 
 all Borrower’s Books relating to the foregoing, and any and all claims, rights and interests in any of the
above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing. 

Notwithstanding the foregoing, the Collateral does not include (a) any property to the extent that such grant of security interest is
prohibited by any Requirement of Law of a Governmental Authority or constitutes a breach or default under or results in the termination of or requires any consent not obtained under, any contract, license, agreement, instrument or other document
evidencing or giving rise to such property, except to the extent that such Requirement of Law or the term in such contract, license, agreement, instrument or other document providing for such prohibition, breach, default or termination or requiring
such consent is ineffective under Section 9-406, 9-407, 9-408 or 9-409 of the Code
(or any successor provision or provisions) of any relevant jurisdiction or any other applicable law (including the Bankruptcy Code) or principles of equity; provided, however, that such security interest shall attach immediately at such time as such
Requirement of Law is not effective or applicable, or such prohibition, breach, default or termination is no longer applicable or is waived, and to the extent severable, shall attach immediately to any portion of the Collateral that does not result
in such consequences; (b) any interest of Borrower as a lessee or sublessee under a real property lease; (c) any interest of Borrower as a lessee under an Equipment lease if Borrower is prohibited by the terms of such lease from granting a
security interest in such lease or under which such an assignment or Lien would cause a default to occur under such lease (but only to the extent such restriction on assignment is enforceable under applicable law), provided, however, that
upon termination of such prohibition, such interest shall immediately become Collateral without any action by Borrower or Bank; or (d) any Intellectual Property; provided, however, the Collateral shall include all Accounts and all proceeds of
Intellectual Property. If a judicial authority (including a U.S. Bankruptcy Court) would hold that a security interest in the underlying Intellectual Property is necessary to have a security interest in such Accounts and such property that are
proceeds of Intellectual Property, then the Collateral shall automatically, and effective as of the Effective Date, include the Intellectual Property to the extent necessary to permit perfection of Bank’s security interest in such Accounts and
such other property of Borrower that are proceeds of the Intellectual Property. 
 Pursuant to the terms of a certain negative pledge
arrangement with Bank, Borrower has agreed not to encumber any of its Intellectual Property without Bank’s prior written consent. 

 EXHIBIT B 

COMPLIANCE STATEMENT 
  

							
	TO:	  	SILICON VALLEY BANK	  	Date:	  	                                      
                      
	FROM:	  	DICE MOLECULES SV, INC. (“SV”)
		  	DICE ALPHA, INC. (“ALPHA”, together with “SV”, individually and collectively, jointly and severally, “Borrower”)
		  	DICE MOLECULES HOLDINGS, LLC (“Parent”)

 Under the terms and conditions of the Loan and Security Agreement between Borrower and Bank (the
“Agreement”), Borrower is in complete compliance for the period ending with all required covenants except as noted below. Attached are the required documents evidencing such compliance, setting forth calculations prepared in accordance
with GAAP consistently applied from one period to the next except as explained in an accompanying letter or footnotes. Capitalized terms used but not otherwise defined herein shall have the meanings given them in the Agreement. 

Please indicate compliance status by circling Yes/No under “Complies” column. 

 

					
	 Reporting Covenants
	  	 Required
	  	 Complies

	Monthly financial statements	  	Monthly within 30 days	  	Yes No
	Compliance Statement	  	Monthly within 30 days	  	Yes No
	10-Q, 10-K and 8-K	  	Within 10 days after filing with SEC	  	Yes No

 Other Matters 
  

					
	Have there been any amendments of or other changes to the capitalization table of Parent or Borrower and to the Operating Documents of Parent, Borrower or any of its Subsidiaries?	  	Yes	  	No
	If yes, provide copies of any such amendments or changes with this Compliance Statement.	  		  	

 The following are the exceptions with respect to the statements above: (If no exceptions exist, state “No
exceptions to note.”) 
  
   

 

 EXHIBIT C – LOAN PAYMENT/ADVANCE REQUEST FORM 

DEADLINE FOR SAME DAY PROCESSING IS
NOON PACIFIC TIME 
  

			
	Fax To:	  	Date:
                                         
               

  

			
	LOAN PAYMENT:
                                         
       DICE MOLECULES SV, INC. AND DICE ALPHA, INC.
	 	 
	From Account #
                                         
                                   	  	To Account #
                                         
                                   
	 (Deposit Account #)
	  	 (Loan Account #)

	 	 
	Principal $
                                         
                                         
   	  	and/or Interest $
                                         
                               
	Authorized Signature:
                                         
                          	  	Phone Number:
                                         
                                
	Print Name/Title:
                                         
                                 	  	 
	 	  	 

  

			
	LOAN ADVANCE:	  	 
	Complete Outgoing Wire Request section below if all or a portion of the funds from this loan advance are
for an outgoing wire.
	From Account #
                                         
                                   	  	To Account #
                                         
                                   
	 (Loan Account #)
	  	 (Deposit Account #)

	Amount of Credit Extension $
                                         
             	  	 
	All Borrower’s representations and warranties in the Loan and Security Agreement are true, correct and
complete in all material respects on the date of the request for a Credit Extension; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by
materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date:
	 	 
	Authorized Signature:
                                         
                           	  	Phone Number:
                                         
                                
	Print Name/Title:
                                         
                                  	  	 
	 	  	 

  

			
	OUTGOING WIRE REQUEST:	  	 
	Complete only if all or a portion of funds from the loan advance above is to be wired.
	Deadline for same day processing is noon, Pacific Time	  	 
	 	 
	Beneficiary Name:
                                         
                               	  	Amount of Wire: $
                                         
                           
	Beneficiary Bank:
                                         
                                	  	Account Number:
                                         
                              
	City and State:
                                         
                                      	  	 
	Beneficiary Bank Transit (ABA) #:
                                         
     	  	Beneficiary Bank Code (Swift, Sort, Chip, etc.):
                      
	 	  	 (For International Wire Only)

	Intermediary Bank:
                                         
                               	  	Transit (ABA) #:
                                         
                               
	For Further Credit to:
                                         
                                         
                                         
                                         
              
	Special Instruction:
                                         
                                         
                                         
                                         
                 
	 
	By signing below, I (we) acknowledge and agree that my (our) funds transfer request shall be processed in
accordance with and subject to the terms and conditions set forth in the agreements(s) covering funds transfer service(s), which agreements(s) were previously received and executed by me (us).
	 	 
	Authorized Signature:
                                         
                           	  	2nd Signature (if required):
                                         
               
	Print Name/Title:
                                         
                                   	  	Print Name/Title:
                                         
                             
	Telephone #:
                                         
                                         
  	  	Telephone #:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]